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Abstract
Inflammatory bowel disease (IBD) is an illness of chronic intestinal inflammation
comprised of Crohn's disease (CD) and ulcerative colitis (UC). Specialists rely heavily
on drugs that target a dysregulated immune system. There is a staggering degree of
variation in drug response in CD. Our understanding of drug metabolism and response in
IBD is limited. Gaining new insights into IBD-specific modifications of drug
metabolism may allow for improved drug efficacy and reduced toxicity.
Cytochrome P450 (CYP) 3A4 is the most relevant determinant of drug
metabolism and exposure for medications prescribed today. CYP3A4 is highly expressed
in the liver, but is also important to intestinal drug metabolism. Little is known about
CYP3A4 activity in disease states. We tested the hypothesis that CD affects the activity,
expression and regulation of CYP3A4.
Acute, non-hepatic inflammatory states are reported to reduce hepatic CYP3A4
activity. Using midazolam pharmacokinetics and the cholesterol metabolite, 4βhydroxycholesterol as in vivo probes of CYP3A4 activity, we were able to demonstrate
and confirm that CYP3A4 activity is lower in CD. Conversely, we were unable to show,
using in vitro modeling, that differences in CYP3A4 activity were due to differential
nuclear receptor-signaling in CD.
CYP3A4 plays a key role in hepatic and intestinal first-pass metabolism, likely in
concert with the xenobiotic exporter, P-glycoprotein (P-gp). The intestinal and colonic
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expression of CYP3A4 in CD has not been well characterized. Using an immunobloting
technique, we were able to demonstrate that the intestinal and colonic expression of
CYP3A4 are reduced in CD.
Lastly, nuclear receptors such as FXR and PXR are important regulators of
CYP3A4. Both are down-regulated in IBD. This may have important consequences for
drug response in IBD. We confirm that a novel single nucleotide polymorphism in FXR
results in a reduction in its downstream products in vivo and reveal a link between genetic
variation in FXR and outcomes of CD severity, such as risk and time to surgery,
particularly relevant to women affected by CD.
Ultimately, these studies demonstrate the impact of CD on drug metabolism
pathways and offer insight into the overlap between CD pathogenesis and drug
metabolism.

Keywords
Crohn's disease, inflammatory bowel disease, drug metabolism, nuclear receptor,
farnesoid X receptor, pregnane X receptor, cytochrome P450 3A4, pharmacokinetics,
single nucleotide polymorphism; biomarker
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INTRODUCTION
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1.1

Inflammatory bowel disease
Inflammatory bowel disease (IBD) is an illness of chronic intestinal inflammation

that follows a remitting and relapsing course. It is comprised of two distinct entities:
Crohn's disease (CD) and ulcerative colitis (UC). Classically, CD involves the full
thickness of the bowel wall and follows a discontinuous path along the gut's full length
from mouth to anus. UC is characterized by continuous and superficial mucosal
inflammation confined to the colon and rectum (Table 1.1). The pathogenesis of IBD has
not been fully elucidated. The most widely held hypothesis suggests that there is an
overly aggressive immune response to luminal microbial antigens and other adjuvants
that occurs in genetically susceptible individuals facilitated by certain environmental
factors 1.
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Table 1.1: A comparison of Crohn's disease and ulcerative colitis (adapted from
Sleisenger & Fordtran's Gastrointestinal and Liver Disease 10th Edition)1
Feature
Age of onset (years)
Pattern of disease
Inflammatory lesion
Depth of injury
Presence of diarrhea
Presence of
hematochezia
Presence of
abdominal pain
Complications
Extra-intestinal
manifestations

Crohn's Disease
15-30
Small intestine, large
intestine, rarely stomach
Skip lesions/ulcers;
cobble-stoning
Transmural
Common
Less frequent

Ulcerative colitis
15-30
Large intestine

Mild to severe

Mild to severe

Fistulae, abscesses,
strictures
Anemia, ankylosing
spondylitis, pyoderma
gangrenosum,
cholelithiasis, vitamin
deficiency

Hemorrhage, toxic
megacolon
Anemia, ankylosing
spondylitis, pyoderma
gangrenosum , primary
sclerosing cholangitis

Continuous erythema
and friability
Mucosal
Common
Frequent
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1.1.1 Intestinal Immunity
The intestinal immune system is complex. Firstly, it consists of the innate
immune system that offers an initial rapid response to foreign antigen via immune cells
bearing pattern-recognition receptors. Secondly, there is the adaptive immune system
that provides "immunologic memory" via antigen-specific recognition2. The intestinal
epithelium acts as another layer of defense. It is a physical barrier between foreign and
host microbiota and the lymphoid tissue of the gut and host circulation, preventing
continuous stimulation of the mucosal immune system 3. Under normal conditions, the
lamina propria beneath the intestinal epithelium hosts a complex network of immune
cells. These cells preserve the balance between the need for immune tolerance of luminal
microbiota with the need to defend against foreign pathogens and the disproportionate
entry of microbiota1, 2. In a healthy individual, tight junctions seal the spaces between
adjacent epithelial cells, while interspersed goblet cells and paneth cells provide mucous
and antimicrobial proteins, giving additional defense 4. In IBD, disruption of the mucus
layer, loss of epithelial tight junctions and increased intestinal permeability all serve to
increase the intestinal immune system's exposure to bacteria allowing the dissemination
of an immune response via its innate and adaptive arms 5-7. There is also a shift in
production from anti-inflammatory proteins to pro-inflammatory cytokines. Activation
of the nuclear transcription factor nuclear factor κB (NFκB) plays a role in this shift 8.
NFκB refers to a family of nuclear transcription factors consisting of p65, c-Rel,
RelB, p50 and p52 that activate the transcription of target genes. In the unstimulated cell,
NFκB proteins remain within the cell's cytoplasm. Activation of NFκB proteins leads to
their release from bound inhibitors and translocation to the nucleus to exert a regulatory
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effect. Regulation of NFkB activity occurs via two pathways: one mediated by the
inhibitor IκBα/β/ε, which aids in the retention of NFκB proteins within the cytoplasm,
and the other mediated by the activating kinases IKKα/β, which when stimulated by
specific cytokines led to the degradation of co-repressors and the activation of NFκB
proteins 9. Genes regulated by NFκB include: 1) inflammatory and immunoregulatory
genes 2) cell cycle regulating genes 3) anti-apoptotic genes 4) negative regulators of
NFκB. Activation of NFκB can be mediated via bacterial wall products such as
lipopolysaccharides as well as interleukin (IL)-1, tumor necrosis factor (TNF)-α and
some viruses. NFκB activity has been observed in the mononuclear cells (macrophages
and lymphocytes) of the lamina propria as well as in the epithelial cells of the inflamed
gut. A key function of the NFκB pathway is the up-regulation of pro-inflammatory
cytokines including, TNF-α, IL-1, IL-6, IL-12, IL-23, and inducible nitric oxide synthase
(iNOS), all important in the dissemination of the immune response10. Unchecked NFκB
activity is a key component of the dysregulated inflammatory response seen in IBD11-14.
IBD medications such as prednisone, methotrexate and anti-TNF-α exert their effects
partly by targeting the NFκB pathway.

1.1.2 Barrier Function
Defects in the epithelial barrier are well-documented in UC and CD 7, 15, 16.
Intestinal permeability is regulated by changes in the cell cytoskeleton and tight
junctions17. A number of factors likely play a role in epithelial barrier dysfunction.
Inflammatory cytokines such as TNFα, interferon (INF)-γ and IL-13 are involved in the
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initiation and perpetuation of the dysregulated immune response in IBD 2. These
cytokines have also been implicated in the disruption of the epithelial barrier function 3.
This provides a plausible reason as to why inflammatory cytokines have been the target
of pharmacological therapy in IBD.

1.1.3 The Intestinal Microbiome and Inflammatory Bowel Disease
In the healthy individual, the composition of the gastrointestinal (GI) microbiome
is unique and consists of hundreds to thousands of species of bacteria, the majority of
which can be categorized into four phyla: Firmicutes, Bacteroidetes, Proteobacteria, and
Actinobacteria18-22. Gut bacteria are closely intertwined with many human biological
processes and modulate the processing of many nutrients and drugs, including lipids and
amino acids23. Factors such as age and diet are known to influence the composition of
the gut microbiome24. For example, a study by Wu et.al. (2011) showed that long-term
diet was strongly associated with the composition of the gut microbiota, while
Yatsunenko et.al. (2012) convincingly demonstrated a similar association with age25, 26.
Disease state has also been linked to alterations in the bacterial composition of the gut.
Multiple studies demonstrate that diversity in the intestinal microbiota is reduced in IBD
compared to non-IBD controls27, 28. There is loss of members of multiple genera
including Bacteroides species, Clostridia species, Eubacterium species, and
Lactobacillus species29, 30. Moreover, microbiota varies with disease activity and
distribution 31, 32. Willing et.al. (2010)32 showed that the microbiota in inactive CD was
different than that of non-IBD controls, while there was little difference between the
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microbiota in inactive UC in comparison to non-IBD controls. Whether this loss of
diversity is a consequence or a precipitator of disease is unknown. It is speculated by
some that alterations in the gut microbial profile play a role in the pathogenesis and
phenotype of IBD33. This is supported by the increased detection of invasive Escherichia
(E.) coli in inflamed ileal samples from patients with active CD34, 35. Other pathogens
have been associated with disease-onset; however, no causal link has been clearly
identified33. Additional evidence supporting the IBD-gut bacteria hypothesis is the
modest benefit seen with the use of antibiotics, such as ciprofloxacin and metronidazole
in CD colitis36. Furthermore, many of the genetic defects associated with IBD are found
in genes such as NOD2 and ATG16L1 which are important for innate immunity and the
ability to sense and clear intracellular bacteria33. Lastly, many strains of geneticallysusceptible mice predisposed to the development of a spontaneous immune-mediated
colitis, such as the multi-drug resistance protein (MDR)-1 or IL-10 knock out murine
models, fail to develop such colitis when maintained under germ-free conditions37, 38.

1.1.4 Other Environmental Factors
In addition to the influence of the gut microbiome, other factors within the
environment likely influence an individual's susceptibility to IBD. Cigarette smoking is
repeatedly shown to be protective against the development of UC, but conversely
increases the risk of CD in Western populations39, 40. In Western countries, childhood
antibiotic exposure increases the risk of both UC and CD, while breastfeeding appears to
be protective39. In two large administrative database studies, oral contraceptives were
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shown to increase the risk and severity of CD41, 42. Similarly, low plasma concentrations
of vitamin D increases CD risk, while appendectomy is protective against the
development of UC43, 44. The mechanisms by which these factors impact disease
susceptibility are not well-defined.
Another important consideration is the influence of diet. There is a rising
incidence of CD and UC in nations not previously affected by IBD. This may be
attributable to improvements in health care technologies and accessibility; however, it has
been hypothesized that the "westernization" of food products has contributed to this
epidemiologic shift. In a review by Kaplan and Ng (2017), it is discussed that "The
increasing incidence of IBD in Europe and the United States since the 1950s, and in Asia
in the early 1990s, coincided with the introduction and promotion of packaged food and
fast food chains, as well as increased use of antibiotics in human beings and livestock."45
In North America, there has been an expansion in the production of specialty starches and
high fructose corn syrup. This has necessitated the development of additives and novel
methods for processing these products to ensure their shelf-life. Interestingly, this has
coincided with significant increases in CD and UC cases46. In support of this, murine
models have linked dietary additives such as sweeteners and emulsifiers to the
development of intestinal inflammation47, 48.

1.1.5 The Genetic Landscape of Inflammatory Bowel Disease
IBD is a polygenic disease: 241 risk loci within the human genome are associated
with its onset49. These associations tend to be weak, with odds ratios less than 2 and
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explain only a small portion of an individual's risk for developing the disease50. This is
somewhat discordant with the high rates of heritability amongst individuals with affected
family members as well as what has been reported in studies of monozygotic twins51.
Variation in the NOD2 gene was the first and most consistently replicated
susceptibility locus in CD49, 52-54. NOD2 codes for the nucleotide oligomerization domain
2 (NOD2) protein, an intracellular protein found in epithelial cells, paneth cells, dendritic
cells, and endothelial cells as well as macrophages55. NOD2 contains a leucine-rich
repeat region that acts as a receptor for bacterial muramyl dipeptide and allows the
intracellular detection of bacteria by the innate immune system and the activation of the
NFκB pathway56. Three single nucleotide polymorphism (SNP)s within the leucine-rich
receptor have been documented as conferring an increased risk of CD as high as two-fold
in heterozygous carriers and twenty-fold in homozygous carriers49. Interestingly, despite
these findings, the role of NOD2 in IBD pathogenesis is unclear. Thirty percent of
individuals of Caucasian ancestry carry one of the risk SNPs and the majority do not
develop CD. Moreover, NOD2 deficient mice do not develop a spontaneous colitis,
despite increased presence of intestinal bacteria57. Taken together, it would appear that
defects in NOD2 are insufficient to cause CD.
Other risk loci associated with the onset of IBD include genes implicated in innate
immune pathways such as CARD9, FCGR2A, and ATG16L158. Genetic variation in
various aspects of the adaptive immune system including SNPs in IL10 (T-cell tolerance)
and IL23R (T-cell differentiation) also contribute to the genetic landscape of IBD and
confer an increased risk of disease susceptibility58.
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The predictive value of genetics in IBD has also become of interest as a tool for
determining a patient's response to their IBD medications, for example, azathioprine
(AZA). Variation in the TPMT gene, a determinant of AZA metabolism and
bioavailability is associated with an increased risk of AZA-induced myelotoxicity.
Individuals homozygous for a reduced function variant have preferential formation of 6thioguanine which can result in life-threatening bone marrow suppression 59. The utility
of pre-emptive TPMT genotyping is widely accepted. Canadian, American and British
Gastroenterology Society guidelines, all advocate for pre-emptive TPMT genotyping
prior to the introduction of thiopurine-based therapies in IBD 60-63. Variation in other
genes such as HLA-DQA1 and HLA-DRB1 as well as NUDT15 are associated with an
increased risk of AZA-induced pancreatitis (homozygous variant carriers, odds ratio
15.83) and myelotoxicity (homozygous variant carriers, odds ratio 16.2) respectively64-67.
These data highlight the role of genetic variation in IBD pathogenesis as well as in drug
response.

1.1.6 Clinical Presentation, Diagnosis and Biomarkers
The clinical manifestations of CD and UC are largely determined by the intestinal
distribution of the disease. Early in the disease course, both conditions are remitting and
relapsing, with periods of activity punctuated by debilitating symptoms of abdominal
pain, diarrhea with or without hematochezia, and weight loss as well as biochemical and
endoscopic findings of inflammation. Patients may also develop extra-intestinal
manifestations of IBD such as inflammatory arthropathy, dermatological or ocular
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abnormalities or disorders of the hepatopancreatobiliary system. This can affect
approximately 25-40% of patients68-70. As the disease progresses over time, permanent
damage to the intestinal structure may result, leading to an irreversible impairment of
intestinal function, significant morbidity and long-term disability. Disease severity is
marked by the need for and time to surgery, failure of multiple medical therapies, need
for hospitalization and the presence of complications such as fistulae or strictures 71, 72.
The need for surgical intervention is relatively common amongst individuals affected by
CD. A recent systematic review and meta-analysis highlighted that the risk of surgery 1,
5, and 10 years after a diagnosis of CD is 16.3% (95% CI,11.4%–23.2%), 33.3% (95%
CI, 26.3%–42.1%), and 46.6% (95% CI, 37.7%–57.7%), respectively73. The risk of
surgery 1, 5, and 10 years after a diagnosis of UC is 4.9% (95% CI, 3.8%–6.3%), 11.6%
(95% CI, 9.3%–14.4%), and 15.6% (95% CI, 12.5%–19.6%), respectively73.
Endoscopic depiction of mucosal inflammation by ileocolonoscopy is the gold
standard test for diagnosis of CD in combination with histological evidence of chronicity.
Similarly, endoscopic re-evaluation of the colon including the terminal ileum is needed to
assess drug response. Clinical and endoscopic scoring systems such as the HarveyBradshaw Index, the Crohn's Disease Activity Index, or the Simple Endoscopic Score for
CD are used to evaluate CD activity to allow clinicians to appropriately titrate
treatment74-76 (Table 1.2). More recently, deep remission defined as histological
mucosal healing, has become the coveted endpoint for clinical trials and real-world
practice77, 78.
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Table 1.2: Clinical indices for the evaluation of disease activity in Crohn's disease
Size of ulcer 0-3
The simple
endoscopic score
for Crohn's
disease

Ulcerated surface 0-3

Daperno et.al.
Gastrointestinal
Endoscopy 2004

Affected surface 0-3
Presence of narrowings 0-3
Number of liquid stools
Abdominal pain 0-3

Best et.al.
Gastroenterology
1976

General well-being 0-4
Crohn's disease
activity index*

Presence of complications
Taking lomotil
Presence of an abdominal mass 0-5

Crohn's
disease

Hematocrit <0.42 women; <0.47
men
% deviation from standard weight
Number of liquid stools
Abdominal pain 0-3
Harvey-Bradshaw
Index

General well-being 0-4
Presence of complications
Presence of an abdominal mass 0-5

*An additional weighting factor is applied to each variable to determine the final score

Bradshaw Lancet
1980
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Ileocolonoscopy is an invasive, and sometimes arduous test that may be associated with
complications such as bleeding, perforation and rarely death79. Given this, biomarkers of
disease may also aid clinicians in the diagnosis and quantification of disease as well as in
predicting the risk for complications. Such biomarkers include, but are not limited, to Creactive protein (CRP), erythrocyte sedimentation rate (ESR), fecal leukocyte markers
(fecal calprotectin) and antibodies against Saccharomyces cerevisiae (ASCA) and
perinuclear antineutrophil cytoplasmic proteins (ANCA)80-83. Unfortunately, these
biomarkers are not without their own respective limitations: CRP and ESR often lack
specificity for intestinal inflammation, while fecal calprotectin and serologic antibodies
lack accessibility through non-tertiary and quaternary care centres and whose diagnostic
accuracy may be confounded by other factors80, 81. Therefore, the role of biomarkers in
clinical practice has not been consistently defined.

1.1.7 The Therapeutic Landscape
CD and UC are largely incurable. Affected individuals are often committed to
long-term drug therapy with immunosuppressive agents. Current treatments include the
monoclonal antibodies known as biologics. These drugs target various proteins involved
in the dissemination of the inflammatory response, such as TNF-α, a variety of
interleukins (IL-12, IL-23) and gut integrin complexes. Other treatments include
immunosuppressants, such as methotrexate and AZA, and anti-inflammatories such as the
5-aminosalicylate (5-ASA) compounds and glucocorticoids, (prednisone or budesonide)
84, 85

. Despite their different immune targets, these therapies all focus on suppressing the
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host intestinal immune response and serve to dampen the effect of inflammatory proteins
(IL-6, IL-1, TNF-α, IFN-γ) released by effector cells (cytotoxic and helper T cells) on the
intestinal mucosa.
The 5-ASA agents are largely ineffective in CD and are used predominantly for
the management of UC. A systematic review evaluating the efficacy of oral 5-ASA for
the maintenance of remission in CD found no evidence that 5-ASA agents were superior
to placebo86. It is hypothesized that the effect of the 5-ASA agents is limited to the
mucosal surface of the intestine and are unlikely to benefit a trans-mural disease such as
CD. 5-ASA compounds are metabolized by the ubiquitously expressed-Nacetyltransferase (NAT) 187, 88. They are also metabolized by NAT2, though its
intestinal expression is far less than what is seen in the liver. 5-ASAs are poorly absorbed
and are largely excreted in the stool. Their mechanism of action is poorly described.
Glucocorticoid agents such as prednisone and budesonide are highly effective for
the induction of remission in CD, though the original evidence for glucocorticoids in IBD
was derived from a UC cohort89-91. The utility of these drugs in CD are highlighted by
their frequent and pervasive use: by their 10th anniversary of disease, more than two
thirds of patients will have been exposed to a glucocorticoid, with more than 20%
receiving greater than 3000mg within their first 5 years of diagnosis92. Glucocorticoids
diminish the inflammatory response via several pathways: they suppress the cytokinemediated activation of T-cells, and antigen-presenting cells (APCs) including
macrophages; they stabilize the liposomal membrane of neutrophils and prevent the
release of catabolic enzymes; they inhibit phospholipase A2 and decrease the release of
histamine, prostaglandins, leukotrienes and other pro-inflammatory chemicals; and they

15

promote vasoconstriction and reduce capillary permeability93. Both budesonide and
prednisone are rapidly metabolized by cytochrome P450 (CYP) 3A494-96. CYP3A4
converts prednisone to its active metabolite, prednisolone. Prednisone has a significant
systemic anti-inflammatory effect97. Conversely, budesonide undergoes substantial firstpass metabolism mediated by hepatic and intestinal CYP3A498. Budesonide, thus, has a
greater local anti-inflammatory effect at the intestinal level compared to its systemic
effect.
In the event that patients require prolonged or recurrent glucocorticoid exposure,
clinicians have the opportunity to transition patients to one of two immunomodulators,
AZA or methotrexate. AZA antagonizes purine metabolism and inhibits DNA synthesis.
It has a limited benefit for the maintenance of remission in CD as well as a modest
steroid-sparing effect99, 100. Similarly, methotrexate, a competitive inhibitor of
dihydrofolate reductase, is effective for the maintenance of remission in CD and is used
as a means for withdrawing patients from glucocorticoids101,102.
Lastly, the monoclonal antibodies known as biologics have revolutionized the
management of CD and UC. Biologics impair the function of the target molecule by
inducing apoptosis of the target-expressing cell or by modulating the signaling pathway.
In Canada, there are currently four biologic agents approved for the management of CD:
infliximab, adalimumab, vedolizumab and ustekinumab.
Infliximab, the first biologic to be approved for the management of CD in
Canada, is a chimeric human-murine monoclonal antibody directed against the proinflammatory cytokine, TNF-α. The efficacy of infliximab in CD was demonstrated in
two landmark trials known as ACCENT 1 and ACCENT 2103, 104. Its sister drug,

16

adalimumab, is a humanized monoclonal directed against TNF-α that is delivered via
subcutaneous route. The CHARM trial highlighted the benefit of long-term treatment
with adalimumab in CD patients who responded to loading doses105. Newer agents
vedolizumab and ustekinumab target alternate pathways in CD. Vedolizumab binds to
the α4β7 integrin expressed on T-lymphocytes and inhibits their interaction with the
mucosal addressin cell adhesion molecule-1 (MAdCAM-1) on endothelial cells within
the gut, ultimately, preventing the trafficking of lymphocytes to the intestinal tissues106.
The GEMINI 2 randomized-controlled studies were the basis of approval for
vedolizumab in CD107. The Health Canada approval of ustekinumab for CD is based on
three pivotal studies (UNITI-1, UNITI-2 and IM-UNITI)108, 109. These studies included
more than 1,300 CD patients who were either new to, experienced with, or failed biologic
therapy. Ustekinumab targets and binds the shared p40 subunit of interleukin-12 and
interleukin-23, two pro-inflammatory cytokines produced by APCs involved in
perpetuating the inflammatory response and suppressing regulatory T-cells110.
Of note, the metabolism of the biologics is very different from the processes
applied to small molecule drugs. Small molecules such as the glucocorticoids or
immunomodulators are typically eliminated by hepatic metabolism or renal or biliary
excretion. As monoclonal antibodies, the biologics are captured from the vascular space
by endocytosis and subjected to proteolysis within the lysosome or salvaged by the
neonatal Fc receptor (to which they owe their long half-life)111.

1.1.8 Limitations of Treatment
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Overall, CD patients are exposed to a heavy burden of medications over the
course of their disease. Inter-individual responses to commonly used IBD medications
vary significantly and rates of resistance, loss of response, and adverse drug reaction
(ADR) remain high, despite a long history of use 101-103, 112, 113.

1.1.8.1

Adverse Drug Risks

The glucocorticoids, immunomodulators and biologics are associated with a
number of adverse drug risks that in some cases are distinct and in others, overlapping.
The glucocorticoids are associated with defects in bone metabolism as well as can
negatively affect the cardiovascular, endocrine, psychiatric and immunologic systems114.
The immunomodulators like AZA are associated with hepato- and myelotoxicity, an
increased risk of malignancy, infection and malaise61, 115. The biologics may carry an
increased risk of malignancy and infection as well as neurologic impairment and
worsening of any underlying cardiovascular disease116, 117.

1.1.8.2

Variability of Drug Response

Currently, there is a lack of predictably to drug response in CD. As an example,
the corticosteroids have been used in the management of CD and UC for more than 70
years118. Data derived from Olmstead County administrative databases revealed that
within 30 days of treatment with a corticosteroid, 60% of CD patients will have a
complete response to therapy, while 25% will have only a partial response and 15% will
have no response118. Similarly, in clinical trials, we see that rates of non-response are as
high as 30% and 50% for budesonide and prednisone respectively91, 119. Many groups
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have attempted to uncover predictors of glucocorticoid response, but no predictor has
made it to large-scale clinical practice120, 121.
Likewise, response rates to biologic agents vary significantly between patients.
Ben-Horin et.al. (2014) summarized rates of biologic resistance seen in clinical trials as
well as what was reported in select "real-world" case series. The authors found that
approximately 40% of clinical trial subjects and 20% of "real-world" patients were
resistant to the effects of infliximab or adalimumab122. In a recent editorial by JeanFrancois Colombel, an international expert in IBD management, the author identified the
crux of the IBD therapeutic paradigm: "One of the biggest challenges we are now facing
[in the management of IBD] is the search for biomarkers predicting efficacy or failure of
biologics and small molecule drugs in the hope of personalized therapy." The lack of
predictability in drug response suggests a fundamental gap in our knowledge on how IBD
impacts drug metabolism and exposure to large and small molecule drugs. Gaining new
insight into CD-specific modifications of drug metabolism and response may allow for
improved drug efficacy and reduced drug toxicity as well a better understanding of
disease pathogenesis.

1.1.8.3

The Effect of Inflammation on Drug Metabolism

The effect of inflammation on the CYP enzymes is well-established. In vitro
studies, in vivo murine models and pharmacokinetic analysis in human subjects in an
acute inflammatory state demonstrate that the expression and activity of CYP enzymes
are down-regulated123. Mechanisms of down-regulation have been suggested including
inflammation-induced oxidative stress, the effect of inflammatory cytokines (TNF-α, IL-
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1, IL-6) or changes in the activation of NRs such as PXR123. This has not been studied in
any significant way in the setting of IBD or specifically in CD. One small study
conducted by Sanaee et.al. (2011) evaluated the impact of CD on a patient's systemic
exposure to the CYP3A4 substrate verapamil. The authors reported higher verapamil
plasma concentrations in the CD cohort versus healthy controls. Plasma concentrations
increased with increasing disease activity124. This suggests a dampening effect of CD on
CYP3A4 activity and emphasizes the paucity of available data pertaining to CD-related
changes in drug metabolism.

1.2

Cytochrome P450
Drug metabolism is often divided into three phases: phase 1 metabolism

characterized by reactions such as oxidation, reduction or hydrolysis that increase the
hydrophilicity of a compound; phase 2 metabolism characterized by conjugation
reactions that prepare compounds for excretion; and phase 3, where the products of phase
1 or 2 metabolism are recognized by membrane-bound transporters and are transported to
the extracellular space125. The reactions that make up phase 1 drug metabolism are
catalyzed by a number of enzymes including, but not limited to, the following enzyme
families: CYP, monoamine oxidase (MAO) and FAD-containing mono-oxygenase
(FMO)125.
The CYP superfamily is one of the most relevant determinants of drug
metabolism in humans and is responsible for the metabolism and activation of a vast
number of xenobiotics, including many of the drugs used today126. CYP enzymes are
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hemoproteins that are able to reversibly catalyze oxidation and reduction reactions using
their heme group through the transfer of electrons127. The CYP enzymes are subclassified into families (1, 2, 3 and 4), sub-families and isoforms on the basis of their
shared amino acid structures. In addition to variations in their amino acid sequences,
CYP isoforms vary with respect to their catalytic activity and tissue localization126, 127.
CYP isoforms found in the hepatic parynchema are likely the most important enzymes
for determining the disposition of drugs used in clinical practice today126 (Figure 1.1a).
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Figure 1.1a Relative hepatic abundance of the cytochrome P450 enzymes (adapted from Xie et.al. 2009
Chapter 1, pg 4)125

Figure 1.1b Relative intestinal abundance of the cytochrome P450 enzymes (adapted from Paine et.al.
2006)128
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1.2.1. Cytochrome P450 3A
The CYP3A subfamily is a key mediator of drug metabolism and disposition in
humans129. Overall, its isoforms are highly concentrated in organs essential to first-pass
metabolism such as the liver and the intestinal tract and act as a barrier to the systemic
exposure of its orally-ingested substrates130. CYP3A accounts for 28% and 80% of the
human hepatic and intestinal CYP content respectively (Figure 1.1a, 1.1b) 125, 128. Three
functional enzymes have been indentified: CYP3A4, CYP3A5 and CYP3A7. CYP3A4
is the most abundant and comprehensively investigated of the CYP3A isoforms 131. It is
responsible for the metabolism of more than 50% of the drugs that are used in clinical
practice 132. It is also important for the inactivation of pollutants and environmental
chemicals known as xenobiotics as well as the metabolism of endogenous substances
such as steroids, sterols, fatty acids and bile acids132. CYP3A4 is localized to the liver,
intestinal tract and kidneys, with the highest expression in the liver 131. In the liver,
CYP3A4 is localized to the hepatocyte and biliary epithelium, while in the intestinal
tract, CYP3A4 is found at the villous tip of individual enterocytes with the highest
expression in the jejunum and ileum131, 133-135. CYP3A5 is similarly distributed, but to a
lesser degree. Many of the CYP3A4 substrates are shared substrates of CYP3A5 due to
their similar amino acid sequences (>85% shared)136. It is often impossible to distinguish
between the contributions of either enzyme to a specific substrate's disposition. CYP3A7
is present only in the fetal liver and plays a minimal role in drug metabolism125.
The expression of CYP3A4 is highly variable. It is inducible by a wide selection
of compounds including drugs and endogenous substances; however, its inter-individual
variability may also be independent of inducers. Studies by Rogers et.al. (2003)137 and
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Floyd et.al. (2003)138 have found up to a 10-fold variation in inter-individual clearance of
CYP3A substrates in healthy subjects, while other groups cite variation as high as 20fold139. Different factors influence CYP3A4 expression to a varying degree. This
includes inducers and inhibitors such as a wide selection of drugs and endogenous
compounds. Signaling pathways, in particular the nuclear receptor superfamily136, 140, 141
as well as sex, age, disease states and the presence or absence of inflammation are also
important for determining its activity142.

1.2.2. Regulation of CYP3A4
Complex signaling pathways mediated by nuclear receptors (NR) and other
transcription factors appear to play an important role in the regulation of CYP3A4.
Constitutive transcriptional regulation is mediated through CCAAT-enhancer binding
proteins-α and - β, hepatocyte nuclear receptor (HNF)-1α, -3γ, and -4α143 while inducible
transcriptional regulation is mediated through ligand-induced activation of the pregnane
X receptor (PXR), the constitutive androstane receptor (CAR), the farnesoid X receptor
(FXR)144, the liver X receptor (LXR), the vitamin D receptor (VDR) and the peroxisome
proliferator-activated receptor, (PPARα)136. Specifically, in the case of PXR and CAR,
the ligand-activated nuclear receptors migrate to the nucleus, bind to response elements
on CYP3A4 and increase mRNA transcription significantly145.
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1.2.3 Role of Age, Sex and Genetics in CYP3A4 Variability
The role of age as a contributor to CYP3A4 variability is controversial. Several
animal studies have described an age-dependent effect on CYP expression146. The
evidence for a similar effect in humans is less clear and studies have been contradictory.
One study by Sotaniemi et.al. (1996) showed that the metabolism of the CYP3A4-probe
drug, lignocaine was significantly less in individuals older than 65 years of age compared
to a healthy young cohort (ages less than 25 years)147; however, other groups have not
been able to demonstrate a similar finding using other modalities for assessing CYP3A4
activity such as the C14 erythromycin breath test148. Furthermore, age-related declines in
hepatic CYP3A4 content are not consistently shown149, 150.
Sex appears to be a determinant of CYP3A4 expression. Wolbold et.al. (2003)
published an analysis in 94 surgical liver samples, evaluating the CYP3A4 content as
well as the expression of P-gp, PXR and CAR. Higher CYP3A4 expression was seen in
the women compared to the men, with a 50% increase in the CYP3A-mediated
metabolism of verapamil151. This has been supported by other human studies using
endogenous probes of CYP3A4 activity as well as in studies evaluating the
pharmacokinetics of CYP3A4 substrates 152, 153. The reasons for sex-specific differences
in CYP3A4 expression and/or activity are unclear. The role of estrogen in the activation
of CYP3A4 pathways has been evaluated in a limited fashion. Estradiol (E2) may
interact with regulators of CYP3A4 such as PXR or CAR154, 155. However, with respect
to PXR, E2 only occupies a small portion of the receptor, making binding weak and
estradiol-induced PXR activation negligible154. Furthermore, the E2-mediated
repression of another CYP3A4 activator, FXR has been observed in vitro, with
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downstream consequences for FXR target genes (bile salt export pump, BSEP)156, 157.
This has not been directly evaluated with respect to CYP3A4. At present, the
mechanisms for sex-specific differences in CYP3A4 activity and expression as well as
the role and degree of impact of estrogen on CYP3A4 are not known.
Genetic variability is also essential to CYP3A4 expression and in turn activity.
To investigate this, Ozdemir et.al. (2000) conducted a systematic review of 13 healthyvolunteer studies and 3 patient-volunteer studies158. They assessed the inter- and intraindividual differences in the disposition of different CYP3A4 substrates based on genetic
variability. They concluded that 90% of inter-individual variability in CYP3A4 activity
is genetically determined in healthy individuals. This was reported to be less of a factor
in patient populations. No allelic variants were identified in this study; however, it
prompted further investigation into the contribution of genetic variation in CYP3A4
activity.
A variant within CYP3A4 intron 6 (C>T, rs35599367), CYP3A4*22 has been
associated with diminished CYP3A4 mRNA expression in cultured cells. It also
accounted for a small fraction of the variability in mRNA expression in a cohort of
healthy human livers159. Otherwise, no common CYP3A4 genotypes have been identified
that explain the variability in CYP3A4 expression160. It has thus been hypothesized by
Lamba et.al. (2010) that CYP3A4 expression may be related to genetic variation in the
transcription factors regulating CYP3A4, because its activity and protein expression is
highly correlated with its mRNA expression, as shown in previous studies161-164. Lamba
et.al. (2010) found that variation in CYP3A4 mRNA expression was related to genetic
variation in the following nuclear transcription regulators: pregnane X receptor (PXR),

26

hepatic nuclear factor 3β (HNF3β, FOXA2), hepatic nuclear factor 4α (HNF4α), and
hepatic nuclear factor 3𝛾 (HNF3γ, FOX A3) as well as to the MDR1 polymorphism
3435C>T161. They concluded that SNPs in these factors contributed to up to 24.3% of
the variation seen in CYP3A4 expression. Similarly, another group showed that SNPs in
VDR, another transcriptional regulator of CYP3A4 influenced the activity of intestinal
CYP3A4 161, 165.

1.2.4. Epigenetic Modification of CYP3A4 Expression
"Epigenetics" refers to "the heritable changes in gene expression that are not
coded in the DNA sequence itself."166 Epigenetic mechanisms such as histone
modification by acetylation or methylation, DNA methylation and RNA-mediated gene
silencing by non-coding RNAs, all play a significant part in, most-often, silencing DNA
transcription.
DNA methylation is the system most-studied in the regulation of drug
metabolizing genes.167 Peng et.al. reported that 90% of the "identified epigenetic
regulation" in genes involved in drug metabolism pertains to DNA methylation168.
However, in the case of CYP3A4, it is the post-transcriptional changes mediated through
non-coding RNAs such as various microRNAs (miRNAs) that appear to be the most
impactful on its expression. As examples, the binding of miRNA-27b and -206 to the 3'
untranslated region (UTR) of CYP3A4 results in a decrease in CYP3A4 mRNA levels169,
170

. Epigenetic mechanisms mediated through alterations in the expression of NRs such

as PXR and VDR also contribute to the variability in CYP3A4 expression169, 171.
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1.2.5. The Impact of Disease on CYP3A4
Several non-hepatic diseases appear to affect hepatic CYP3A4 expression and
activity. Patients with chronic kidney disease (CKD) are exposed to a wide number of
CYP3A-metabolized drugs. Down-regulation of hepatic CYP3A has been documented in
this patient population in human studies as well as in in vivo models172, 173. Velenosi
et.al. (2014) suggested that changes in CYP3A activity in CKD may be due to changes in
"NR binding and histone acetylation"174. Similarly, down-regulation of CYP3A has been
documented in individuals with non-alcoholic fatty liver disease (NAFLD). Woolsey
et.al. (2015) demonstrated that individuals with biopsy-proven non-alcoholic
steatohepatitis had a near 3-fold increase in midazolam (CYP3A4 probe drug) plasma
concentrations versus healthy controls175. This was validated by quantifying the plasma
concentrations of the CYP3A-endogenous probe, 4β-hydroxycholesterol (4β-OHC). The
plasma concentration of 4β-OHC was significantly lower in the NAFLD population.
Decreased CYP3A4 expression and activity were also demonstrated using in vivo murine
and in vitro cell models by the same group175.
Other animal models of inflammation such as lipopolysaccharide-exposed mice
demonstrate down-regulation of hepatic CYP3a11 mRNA (equivalent to human
CYP3A4)176. Similarly, the 3% dextran sulfate sodium (DSS) mouse model of colitis
shows reduced CYP3a11 expression which is reversed with pre-treatment with
metronidazole177. In acute inflammation, such as with surgery or infection, CYP3A4
activity is diminished 178, 179. Several mechanisms by which inflammation alters
CYP3A4 activity have been posited and are outlined by Aitken et.al (2006)123. Increases
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in oxidative stress and inflammatory cytokines as well as changes in NR signaling are
highlighted as important.
The impact of IBD on CYP3A4 activity is less clear and has not been extensively
studied. A study in 21 subjects with CD, versus 10 with UC and 26 healthy volunteers
found a significant reduction in the 4β-hydroxycholesterol plasma concentrations of the
individuals with CD, suggesting a total body decrease in CYP3A4 activity in this
cohort180. Conversely, a case-control study in a small pediatric CD population evaluating
CYP3A4 mRNA expression in non-inflamed duodenal pinch biopsies found an increase
in CYP3A4 expression181. Ultimately, further work is needed to clarify the impact of CD
on CYP3A4-mediated metabolism as this may impact non-IBD drugs prescribed to CD
patients as well as commonly used CYP3A4 substrates such as the glucocorticoids
prednisone and budesonide.

1.2.6. Important Drug-Drug and Food-Drug Interactions and CYP3A4
Interactions with other compounds, either prescribed drugs, food stuffs or herbal
medicines taken at a patient's own discretion, influence CYP3A4 activity and likely
account for a significant portion of the inter-individual variability seen within patient
populations182. A list of CYP3A4 substrates, inhibitors and inducers are included in
Table 1.3. Substances interact with CYP3A4 either to enhance or impair its catalytic
activity or to serve as a substrate for CYP3A4-induced metabolism. This is the basis for
many drug-drug or food-drug interactions that may lead to varying degrees of patient
toxicity or loss of drug efficacy. For example, the co-administration of ketoconazole, a
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potent inhibitor of CYP3A4, with terfenadine, a non-sedating anti-histamine approved for
the treatment of allergic rhinitis, led to reports of a deadly drug-drug interaction mediated
through changes in CYP3A4 metabolism183.

In addition to its effects as an anti-

histamine, terfenadine is also a cardiac potassium channel blocker with low systemic
bioavailability due to extensive metabolism by CYP3A4. Unfortunately, ketoconazolemediated inhibition of CYP3A4 activity led to increased plasma concentrations of
terfenadine and, in past, has precipitated fatal ventricular arrhythmias184. Similarly, the
reduced systemic exposure and lack of efficacy of various CYP3A4 substrates such as
benzodiazepines when co-administered with CYP3A4 inducers such as carbamazepine or
of tacrolimus when co-administered with rifampin illustrates the importance of CYP3A4
to clinically relevant drug-drug interactions185, 186.
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Table 1.3: Selected CYP3A4 substrates, inducers and inhibitors (adapted from
United States Food and Drug Administration – Drug development and drug
interactions)
Substrates
Tyrosine kinase
inhibitor:
Imantinib
Dasatinib
Benzodiazepines:
Midazolam
Triazolam
Alprazolam
Glucocorticoids:
Budesonide Prednisone

Inducers
Rifamycin antibiotics:
Rifampin
Rifabutin
Anticonvulsants:
Carbamazepine
Phenytoin
Primidone
Phenobarbital
Other:
Hypericum perforatum
(St.John’s wort)

Inhibitors
Tyrosine kinase inhibitor:
Imantinib
Azole antifungals:
Ketoconazole
Itraconazole
Fluconazole
Macrolide antibiotics:
Erythromycin
Troleandomycin
Clarithromycin

Non-sedating
antihistamines:
Terfenadine
Astemizole)

Non-dihydropyridine
calcium channel blockers:
Verapamil
Diltiazem

Immunosuppressive
agents:
Tacrolimus
Cyclosporine
Sirolimus

Proton pump inhibitor:
Omeprazole

HIV protease
inhibitors:
Saquinavir
Indinavir
Nelfinavir
Ritonavir
HMG-COA reductase
inhibitor:
Simvastatin
Atorvastatin
Lovastatin
Non-dihydropyridine
calcium channel
blockers:
Verapamil
Diltiazem

Other:
Grapefruit juice
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Other non-traditional medicines, such as Hypericum perforatum also known as St.
John's wort, interact with CYP3A4 and have important consequences for other
concomitantly administered CYP3A4 substrates. St. John's wort, a commonly used
herbal therapy for treatment of depression, is a potent inducer of CYP3A4 metabolism
via PXR187. A number of interactions with CYP3A4 substrates have been identified and
reported125, 188.
Lastly, aspects of an individual's diet likely play an important role in interindividual CYP3A4 variability. Bailey et.al. (1998) discovered that grapefruit juice is an
inhibitor of CYP3A4 metabolism189. This group and others have demonstrated
significant increases in the bioavailability of orally administered drugs such as felodipine,
cyclosporine and midazolam when administered concurrently with grapefruit juice190-192 .

1.2.7. Quantifying CYP3A-Mediated Metabolism In Vivo
Given the breadth of CYP3A substrates and the potential for numerous drug
interactions, several techniques are available for evaluating CYP3A activity in vivo using
a variety of "probe" substances. A probe substance is defined as a compound whose
pharmacokinetics are determined by a single elimination process and from which a
enzyme's catalytic activity can be infered125. Criteria for a valid probe are outlined in a
review by P. Watkins in a 1994 review invited by Pharmacogenetics193. In vivo
measures of CYP3A4 catalytic activity include the assessment of midazolam or quinine
pharmacokinetics, the C14-erythromycin breath test, and the measurement of endogenous
metabolites such as 4βOHC in plasma or 6β-hydroxycortisol (6βHC) in urine131.
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Certain limitations exist for each of these modalities: conflicting reports regarding
the accuracy of urinary 6βHC concentrations for estimating CYP3A activity exist; C14erythromycin breath testing is only useful for the estimation of hepatic (not intestinal)
CYP3A activity and requires the administration of a radiolabeled carbon193.
Currently, the assessment of midazolam pharmacokinetics appears to satisfy all
the tenants of a CYP3A probe drug outlined by Watkins193. Midazolam is rapidly
oxidized by CYP3A4 to its 1- and 4-hydroxymidazolam metabolites, detectable in blood
by liquid chromatography-tandem mass spectrometry (LC-MS/MS)194, 195. It can be
administered intravenously and orally to capture the contribution of hepatic and intestinal
CYP3A activity131. Furthermore, studies have validated the substitution of midazolam
microdosing (in comparison to standard dosing) for the evaluation of hepatic and
intestinal CYP3A activity196, 197. This eliminates concerns around a subject's exposure to
the sedative and amnestic properties of midazolam.
The cholesterol metabolite, 4βOHC has also been proposed as a biomarker of
CYP3A activity. Cholesterol undergoes transformation to form oxysterols, of which
4βOHC appears to be the product of CYP3A-mediated oxidation198. Plasma
concentrations of 4βOHC appear to correlate with CYP3A activity: patients exposed to
increasingly potent CYP3A inducers had similarly matched increases in their 4βOHC
plasma concentrations199. Furthermore, in vitro data support a mechanistic role for
CYP3A in the formation of 4βOHC versus other metabolites198. The utility of plasma
concentrations of 4βOHC for evaluating CYP3A activity may be limited by its relatively
slow rate of elimination and in conditions where cholesterol concentrations may be
altered.
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1.3

Nuclear Receptors
CYP3A4 expression and activity are regulated by the NRs, FXR and PXR. Both

of these NRs are implicated in CD and UC pathogenesis. Disease-dependent changes in
FXR and PXR activity may have important consequences for drug metabolism sequences
in general and CYP3A4-mediated metabolism specifically. This section will provide an
overview of IBD-related changes in PXR and FXR activity as well as the link to IBD
pathogenesis.

1.3.1 Nuclear Receptors: a Brief Overview
NRs are a group of transcription factors that share a common structure: a ligandbinding domain at the C-terminus and a DNA-binding domain at the N-terminus. NRs
regulate the transcription of genes that are important to the development of, metabolism
and disease processes occurring within humans 200, 201. They are activated by lipophilic
substrates binding to a ligand-binding domain. Substrates include endogenous hormones,
vitamins A and D, and xenobiotics as well metabolic intermediates such as fatty acids,
bile acids and sterols201. The binding of a ligand to the ligand-binding domain permits the
dissociation of a bound co-repressor202 (Figure 1.2). Subsequent recruitment of a coactivator allows NRs to bind to specific DNA sequences in the regulatory domain of
target genes and regulate their transcription.
To date, more than 48 members of the NR family have been identified 200. This is
including, but not limited to, FXR, PXR, LXR and the glucocorticoid receptor (GR).
Many NRs have an identified ligand, while others are termed "orphan receptors" with no
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recognized ligand. PXR and FXR are important to drug metabolism and transport
pathways and are increasingly recognized as being important to IBD pathogenesis.
Herein, PXR and FXR will be discussed in greater detail.
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A

B

C

Figure 1.2 Model of nuclear receptor molecular structure as well as signaling sequence.
A represents the inactive cytoplasmic state bound to a corepressor. B represents binding
of the ligand, loss of the corepressor, and recruitment of a coactivator as well as the
heterodimerization with another nuclear receptor. There is translocation to the nucleus
(C) and binding of the nuclear receptor complex DNA-binding domains to the target gene
to induce transcription. Activation domain, AD; hinge region, HR; ligand-binding
domain, LBD; DNA-binding domain, DBD; corepressor, CoR; coactivator, CoA; nuclear
receptor, NR.
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1.3.2 Pregnane X Receptor
PXR (gene NR1I2), also known as the steroid and xenobiotic-sensing NR plays
an important role in the "detoxification" of the human body203. Similar to CYP3A4, it is
abundantly expressed in the liver and intestine 204. It is activated by a variety of
endogenous and exogenous compounds and in turn heterodimerizes with the retinoid X
receptor (RXR) to up-regulate the transcription of target genes that code for proteins
necessary for the degradation and clearance of toxins from the body 203.
PXR is activated by a number of different ligands including, but not limited to
rifaximin205, lithocholic (LCA) and deoxycholic acid (DCA) 206 in humans and
pregnenolone 16-carbonitrile (PCN) 207 in rodents, from which its name is derived. PXR
regulates the expression of a variety of genes including, but not limited to the following:
UDP-glucuronosyltransferases (UGT) 208, glutathione-S-transferases (GST) 209,
sulfotransferases (SULT)210 as well as drug efflux transporters from the ATP-binding
cassette (ABC) exporter families including P-gp (gene MDR1) and the multidrug
resistance proteins 2 and 3 (MRP2, MRP3). It also regulates members of the solute
carrier organic anion transporter superfamily like organic anion transporter
(OATP)1B1211 . Most important to the discussion at hand, is the PXR-mediated
regulation of CYP3A4 212. This relationship has been confirmed using in vivo murine
models, whereby disruption of the PXR gene impedes CYP3A4 activation via established
PXR ligands206, 213. In humans, CYP3A4 mRNA expression as well as the protein's
activity are increased in response to known PXR activators; it is felt that most drugs that
induce CYP3A4 are acting via PXR203.
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1.3.3 Farnesoid X Receptor
FXR (gene symbol NR1H4) is a NR that acts as a sensor of intracellular bile acid
concentrations within the liver and intestine and plays a key role in the regulation of the
enterohepatic circulation 214, 215. Activation of FXR by bile acids leads to significant
changes in bile acid homeostasis as well as in the transcription of genes responsible for
bile acid synthesis 214. Similarly to PXR, FXR binds in tandem with RXRα to response
elements within the promoter regions of target genes. This leads to the up-regulation of
bile acid export systems in the ileum (organic solute transporter, OST- α/β) and liver
(BSEP) and down-regulates the expression of bile acid import systems (apical sodiumbile acid transporter, ASBT, ileum; sodium-taurocholate co-transporting polypeptide,
NTCP, liver) 216-220. Bile acid-induced activation of FXR has also been found to reduce
the transcription of genes encoding bile acid synthesis enzymes such as CYP7A1 (via the
small heterodimer partner, an orphan nuclear receptor) thus reducing bile acid synthesis
221

. Other target genes of FXR include CYP3A4 and PXR144, 222. Gnerre et.al.(2004)144

demonstrated an increase in CYP3A4 mRNA in HepG2 cells in response to the FXRspecific agonist, GW4064. A gel-mobility shift assay was used to highlight the capacity
of FXR to bind to a 345-base pair sequence FXR-responsive unit within the CYP3A4 gene
and confirmed the importance of this binding by introducing various mutations into
different binding sites144. They subsequently confirmed the PXR-independent nature of
FXR-mediated CYP3A4 activation by showing that GW4064 administration in PXR null
mice did induce the mRNA expression of murine Cyp3a11, while GW4064 did not
increase Cyp3A11 mRNA expression in FXR null mice. Similarly, Jung et.al. (2006)
confirmed the FXR-mediated regulation of PXR222. Wild type mice fed with GW4064 or
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cholic acid (CA) had a robust induction of PXR detected by changes in PXR and SHP
mRNA that was abolished when repeated in FXR null mice. Furthermore, FXR binding
sites were detected in the murine PXR gene.
In addition to using detectable changes in the mRNA expression of downstream
gene targets, in vivo changes in FXR activity can be estimated by plasma concentrations
of the ileal hormone, fibroblast growth factor (FGF) 19 in humans and its murine
ortholog, FGF15223-225. FXR is found in small and large bowel enterocytes. It induces
the expression of FGF19 which in turn represses the transcription of CYP7A1 and
inhibits bile acid synthesis226. Its plasma concentrations are affected by loss of viable
ileal epithelium.

1.3.4 A Role for Bile Acids in Differential Nuclear Receptor Signaling in
IBD
PXR and FXR are activated by bile acids, though not all bile acids exert equal
effects. As previously stated, PXR is most robustly activated by free or conjugated LCA
and DCA, while FXR is most robustly activated by free or conjugated CDCA and CA.
There is limited data describing the pattern of bile acids in IBD; however, Duboc et.al.
(2013) used LC-MS/MS technology to evaluate plasma and fecal bile acids in IBD
subjects as well as healthy controls. They detected fundamental differences in fecal bile
acids and linked these apparent disease-dependent changes to alterations in the gut
microbial profile227. Similarly, Gnewuch et.al. (2009) described differences in the ratio
of primary to secondary bile acids using LC-MS/MS in subjects with UC versus non-IBD
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controls228. Authors hypothesized that this finding was likely due to described IBDdependent differences in the gut microbial profile leading to differential de-hydroxylation
of primary bile acids. Differences in bile acid patterns may be an underappreciated
determinant of NR signaling in CD; however, this has not been yet explored.

1.3.5 Nuclear Receptors and a Role in IBD Pathogenesis
The role of NRs in CD and UC pathogenesis and, as a consequence, therapeutics
has come under intense scrutiny within the last two decades. This is unsurprising given
their pervasive role as master regulators of a number of biological processes. As
discussed in earlier sections, NRs are important to drug metabolism sequences,
specifically to the regulation of CYP3A4-mediated metabolism. In the following section,
the current evidence for NR involvement in IBD susceptibility will be presented.

1.3.5.1

The Role of PXR in IBD:

PXR is down-regulated in the setting of CD and UC, independent of active
inflammation210. This finding was revealed in 2004, when Langmann et.al. demonstrated
a concomitant reduction in the intestinal mRNA expression of PXR and its downstream
targets such as UGT, GST, and MDR1, key genes involved in the detoxification and
processing of xenobiotics in subjects with CD and UC. Moreover, using three distinct
intestinal model cell lines, they showed that TNF-α exposure blocked the PXR-mediated
expression of CYP3A4 and MDR1 in LS174T cells. A subsequent study by Shah et.al.
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(2007) highlighted a protective role for PXR in the setting of an inflammatory insult.
Ligand-induced activation of PXR in a DSS-mouse model of colitis showed symptomatic
and histological improvement in the study animals211. Though without established
certainty, PXR-mediated amelioration of colitis has been hypothesized to occur through
several different pathways including: the up-regulation of efflux transporter proteins such
as P-gp or the suppression of the NFκB pathway.
As previously discussed, PXR is important to xenobiotic metabolism and upregulates the expression of several exporter proteins203, 210. Intestinal efflux transporters
such as P-gp contribute to the integrity of the epithelial barrier by increasing the export of
toxic environmental substances and bacterial toxins from within the enterocyte 210. This
impedes the exposure of the host immune system to "foreign" antigen and reduces the
risk of activating the host inflammatory cascade. A correlation between intestinal
inflammation and a reduction in P-gp expression has been shown in a cohort of
individuals with inflammatory gastrointestinal diseases including IBD142.
Secondly, PXR-mediated suppression of NFkB proteins and in turn its target
genes has been convincingly demonstrated in mouse models of colitis 211, 229. Shah et.al.
(2007) were able to show that the administration of the PXR ligand, (PCN) caused a
significant reduction in the colonic mRNA expression of NFκB target genes, TNF-α,
iNOS, IL-1β, IL-10. This was confirmed in in vitro studies using HCT116 colon cancer
cells.211
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1.3.5.2

Genetic variation in PXR and its Influence on IBD

There is much interest in, not only the role of PXR in IBD pathogenesis, but in the
link between IBD susceptibility and genetic variation in PXR (NR1I2). To date, no
consensus has been reached regarding variations in the PXR gene and their association
with IBD susceptibility. Of the existing studies, results remain conflicting. In 2006,
Dring et.al. reported that the SNPs, -23585 and -24381 in PXR were predictive of
susceptibility to both UC, CD and IBD overall in an Irish cohort of 422 IBD patients and
350 matched controls230. They hypothesized that these SNPs, which have also been
associated with a decrease in CYP3A4 activity, confirm a PXR-mediated contribution to
the pathogenesis of IBD231.
However, in the same year, Ho et.al. (2006) carried out a similar study in a
Scottish cohort of 725 IBD patients and 328 controls and refuted the findings of the Irish
study232. They were unable to show an association between 5 different SNPs in PXR or
in a variety of constructed haplotypes. They concluded that the positive findings of the
study by Dring et.al. (2006) were reflective of genetic heterozygosity amongst controls,
unclear population stratification and type 1 error.
In 2007, Martinez et.al. were able to reproduce the data reported in the study by
Dring et.al. (2006) to a limited extent in a Spanish cohort of 696 IBD patients and 550
controls233. They reported that the SNP, -23585, while not more common in IBD overall,
was found more frequently in the subphenotype of UC-pancolitis. Carriers of the T/T
genotype also had a different distribution of P-gp compared to non-carriers.
Subsequently, Glas et.al. (2011) carried out the largest genetic analysis in NR1/2
in a cohort of over 2800 individuals, over 1300 of which had IBD234. They analyzed 8
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SNPs, including -23585 and 24381, as well as several haplotypes. They found a weak
association between the SNP 8055 and UC and more notably a haplotype consisting of
multiple SNPs, including -23585 and -24381 that was associated with CD susceptibility
in a sub-cohort of patients. They concluded that further investigation is needed to clearly
define the relationship between PXR variation and the functional role of PXR in IBD.

1.3.5.3

PXR as a Target for IBD Therapy: Rifaximin Studies In Vivo

The activation of PXR activation by a variety of ligands has been shown to be an
effective treatment of inflammation in mouse models of colitis 211, 229, 235. These studies
have also demonstrated that the beneficial effects are mediated through the downregulation of NFkB target genes. Studies by Cheng et.al. (2010)235 and Ma et.al.
(2007)236 used PXR-humanized and PXR null mice to show the protective effect that
PXR agonists, such as the rifamycins, have on inflammatory changes in the intestine
induced in a DSS model of IBD. The rifamycin antibiotics include rifaximin and
rifampicin, with the former stimulating intestinal PXR target genes alone due to its poor
absorbability and low systemic bioavailability and the latter stimulating both intestinal
and hepatic PXR target genes 236. Some success in CD and UC patients has been seen in
short, open-label trials involving small cohorts of patients 2, 237-241 as well as in slightly
larger blinded and randomized studies 242. The largest study to date in CD (n=402)
showed that at the end of a 12-week treatment period, 62% of CD patients who received
an 800-mg dose of extended release rifaximin were in remission, compared with 43% of
patients who received placebo, a result that reached statistical significance 243. To date,
this has not been applied to clinical practice.
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1.3.5.4

The Role of FXR in IBD

It has been shown that bile acid-induced activation of FXR plays a role in
regulating several genes that protect against intestinal inflammation, increased intestinal
permeability and bacterial overgrowth 8, 244, 245. Limited data suggest that FXR activity is
repressed in CD180, 246, 247. While, FXR deficiency in mice and humans is not associated
with the development of a spontaneous colitis, FXR deficiency appears to portend a more
severe disease phenotype in the setting of a primary insult244, 248. These concepts will be
discussed herein.
Researchers have highlighted that FXR-regulated pathways are important to
intestinal integrity. Raimondi et.al. (2008) demonstrated that bile acids modulate
intestinal paracellular permeability: CA, chenodeoxycholic acid (CDCA), DCA increased
intestinal permeability, DCA- and CDCA- induced phosphorylation of the epidermal
growth factor receptor, occludin dephosphorylation, and occludin redistribution, all key
components of intestinal permeability249. Stojancevic et.al. (2012) and Luettig et.al.
(2015) showed FXR regulates other proteins, such as keratin-13 and claudin-1 and
claudin-2 involved in maintenance of the intestinal barrier250, 251.
Vavassori et.al. (2009) investigated the role of FXR activation in the regulation of
inflammatory responses in a murine model of colitis244. At baseline, it was noted that
increased cellular infiltrate and collagen deposition as well as increased expression of
inflammatory genes (TNFα, IFNγ, IL-1β) were seen in FXR-null mice in comparison to
wild type mice. Acute and chronic colitis were then induced in wild type and FXR-null
mice using rectal administration of trinitrobenzenesulfonic acid (TNBS) in 40% ethanol.
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Colitis was prevented in 60% of the wild type mice receiving synthetic chenodeoxycholic
acid (INT-747) and a reduction in the transcription of pro-inflammatory genes was seen.
No effect was seen in FXR-null mice, demonstrating the role of FXR in the intestinal
immune response .
A complimentary study by Gadaleta et.al. (2011), linked FXR agonism to
improvements in intestinal permeability in vivo and in vitro. It was further demonstrated
that FXR agonism counteracts proinflammatory cytokine expression and secretion by
enterocytes8. In wild type mice, INT747 treatment induced FXR target genes in both
ileum (small heterodimer partner, SHP) and colon (Fgf15). FXR null-mice expressed
very low levels of SHP and Fgf15 at baseline and with INT747 administration. In wild
type mice treated with 2.5% DSS, INT747 reduced wt loss, improved rectal bleeding
scores, and prevented colonic shortening. At baseline, chemically-induced colitis was
associated with complete disruption of the epithelial layer and acute inflammatory
infiltrates in wild type and FXR-null mice. INT747-treated wild type mice showed less
intestinal morphological alteration and decreased inflammatory infiltrates and less goblet
cell loss. INT747 had no effect in FXR-null mice. Measures of increased permeability
were markedly elevated in wild type and FXR-null mice after induction of colitis, though
this was abolished in INT747-treated wild type mice. Furthermore, in DSS-treated wild
type mice, INT747 significantly decreased colonic mRNA expression of proinflammatory genes IL-1β, IL-6 and macrophage attractant protein (Mcp)-1. Also,
antimicrobial proteins, iNOS and cathelicidin in the colon and angiogenin 1 (Ang1) in the
ileum, were significantly induced by INT747 in wild type but not FXR-null mice. It was
concluded that FXR normalizes chemically-induced pro-inflammatory gene expression
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and reduces inflammatory infiltrates in the intestine. It also it induces the expression of
several antibacterial defense genes.
Moreover, Nijmeijer et.al. (2011) evaluated the converse: is FXR activation
repressed in the setting of chronic colitis246? MRNA expression of FXR and its target
gene, SHP were analyzed in ileal and colonic samples taken from IBD and healthy
subjects. FXR activation in the ileum was found to be reduced in subjects with CD
colitis, while no difference was seen in subjects with UC versus healthy subjects.
Subsequent studies by Lenicek et.al. (2011) and Iwamoto et.al. (2013) support the
findings of Nijmeijer et.al. (2011) using the FXR activity surrogate marker, FGF19180, 247.
Ultimately, these studies highlight the potential importance of FXR to IBD
pathogenesis. FXR activation contributes to the maintenance of intestinal epithelial
integrity as well as down-regulates the expression of certain pro-inflammatory genes.
This correlates with reduced intestinal inflammation in mouse models of colitis and
human subjects with IBD.

1.3.5.5

Genetic Variation in FXR and its Influence on IBD

Furthermore, it should be mentioned that genetic variation in FXR has been linked
to IBD pathogenesis. A study by Attinkara et.al. (2012) evaluated the association
between IBD and 5 variants (2 common, 3 rare) of the FXR (NR1H4) gene214. They
found that one of the rare variants (rs3863377) was less common in the IBD population
versus the healthy controls. It was proposed that this variant confers a protective effect
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against the disease. The rare variant, FXR-1G>T (rs56163822) was more prevalent in the
IBD group. Our group demonstrated that this variant is associated with reduced
activation of downstream FXR gene targets252. Nijmeijer et.al. (2011) did not find any
FXR polymorphisms associated with the CD or UC susceptibility246. Genetic variation in
FXR and the link to UC and CD remains poorly defined.

1.3.5.6

FXR as a Target for IBD Therapy

Success has been seen with the use of obeticholic acid (INT-747), a semisynthetic and potent ligand of FXR in chronic liver diseases. A recent randomized
controlled study in the New England Journal of Medicine revealed the utility of
obeticholic acid for patients with primary biliary cholangitis (PBC)253. Phase 2 trials in
diabetic subjects with NAFLD have shown promise with reduced liver inflammation and
fibrosis seen over the short term254.

In vitro and in vivo models of FXR agonism

demonstrated down-regulation of stellate cell activity with reduced collagen deposition
and up-regulation of SHP 255, 256. As stated above, INT-747 has also been used with
success in animal and in vitro models of colitis 8, 244. This has not been evaluated in
human subjects with CD or UC.

1.4

Summary
CD is an important disease due to its high prevalence, debilitating symptoms,

associated complications and incurability. Patients are exposed to a high burden of
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medications in addition to other treatments they may be receiving for co-morbid illnesses.
CD pathogenesis is complex and multi-factorial with overlapping roles for the immune
system, the human genome and the environment in the onset of disease. Though
substantial advances have been made in the last two decades regarding our understanding
of its pathophysiology, we are still unable to prevent its onset, predict those at imminent
risk or select the most efficacious treatment for affected individuals. Disease severity
based on patient demographic data or previous disease behavior often dictates the most
appropriate therapy, but does not necessarily predict drug response. Small and large
molecule drugs have found varying degrees of success in the management of CD;
however, one of the unfortunate, overarching themes in CD therapeutics is a lack of interindividual predictability of drug exposure and drug response.
Significant overlap is seen in CD pathogenesis and drug metabolism pathways.
CYP3A4-mediated metabolism is one of the most important systems for the processing of
xenobiotics including human drugs. Its activity is highly variable between individuals
and, in the setting of other acute and chronic inflammatory illnesses, may be associated
with additional variation in function. Its intestinal location and PXR- and FXR-mediated
regulation make its expression and activity plausible targets for CD-induced changes;
however, CD-related alterations in drug metabolism, as a whole, are largely unexplored.
Experts in the field recognize that our inability to predict drug response in both CD and
UC and to personalize therapies for patients is a huge deficiency in a field dependent on
long-term drug use. Furthermore, CD-related changes in CYP3A4 activity may have
important consequences for additional treatments patients receive for non-CD-related
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diseases. Ultimately, a better and more complete understanding of drug metabolism
sequences in CD is needed.
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2

HYPOTHESES & AIMS
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2.1

Hypothesis
The interplay between genes, nuclear receptors (NR), cellular transporters,

metabolizing enzymes and the gut microbial profile affect drug metabolism pathways and
ultimately drug disposition in humans. The cytochrome P450 (CYP) family in general
and CYP3A4 specifically play a principal role in an individual's systemic exposure to a
drug. CD is a primary intestinal illness where variation in the aforementioned factors
forms the basis of a still-incompletely defined pathophysiology.
We believe the presence of CD will negatively affect CYP3A4 expression and
activity in such patients and that genetic variation in key NRs, such as the farnesoid X
receptor (FXR) regulating CYP3A4 may have important consequences for disease
severity and are an indirect determinant of drug response.

2.2

Aim 1:

a) To assess the impact of CD on the activity of intestinal and hepatic CYP3A4 using
exogenous and endogenous in vivo probes.
b) To propose a molecular mechanism by which detectable changes in CD-specific
CYP3A4 activity occur.
The activity of the enzyme, CYP3A4, is subject to significant inter-individual
variation. Diet, concomitant drug exposures, age, sex, genetic variation, and NR
regulation are a short, but incomplete, list of factors that may alter its activity1-6. Acute
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and, to a certain extent, chronic inflammatory states appear to affect CYP3A4 activity7, 8.
Any changes in the activity of CYP3A4, a key enzyme involved in phase 1 drug
metabolism, are thought to have important consequences for the disposition of substrates
in vivo. Little is known regarding the in vivo influence of CD on this protein. Given that
the intestine, in addition to the liver, is the site of highest expression of CYP3A4, one
could assume a primary, inflammatory intestinal illness may have a substantial impact on
CYP3A4 activity.
We hypothesize that CD negatively impacts CYP3A4 activity in vivo,
specifically in the intestinal compartment and such changes are due to a CD-specific
effect on the activity of the NR, pregnane X receptor (PXR).

2.3

Aim 2:

To evaluate the impact of CD on the intestinal expression of CYP3A4 compared to a
healthy population.
A hallmark of CD is disruption of the intestinal mucosal layer9, 10. The intestinal
mucosa consists of the following: the epithelium, made up of enterocytes as well as
goblet, paneth and neuroendocrine cells; the lamina propria, home to a variety of immune
cells; and the muscularis mucosae11, 12. The onset of CD induces disruption of the
epithelial cell tight junctions, epithelial cell apoptosis, expansion of the lamina propria
with pro-inflammatory cells and recruitment of pro-fibrotic fibroblasts13-15. As
previously discussed, CYP3A4 is predominantly expressed in the liver and intestine, with
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the highest expression of intestinal CYP3A4 on the enterocytes found at the villous tip of
the small intestine16, a prime target of the inflammatory lesions of CD. It likely acts in
concert with the enterocyte-bound xenobiotic exporter P-glycoprotein (P-gp) to limit the
oral bioavailability of several shared substrates17.
Thus, we hypothesize that individuals with CD have reduced intestinal
expression of CYP3A4.

2.4

AIM 3:

To explore the role of genetic variation in FXR, a key regulator of CYP3A4
metabolism, and its impact on CD severity, a surrogate marker of drug metabolism
and response.
Genetic variation in key CYP3A4 transcriptional regulators, such as FXR and
PXR may have important consequences for the function of the NR protein product and
ultimately CYP3A4 expression and activity. Defects in key functions carried out by FXR
are closely linked to CD pathophysiology and genetic variation may further impair these
pathways and portend a more severe CD phenotype18-20.
We hypothesize that the FXR -1G>T polymorphism confers a greater risk of
severe CD phenotype and is associated with a reduction in the downstream FXR
target, fibroblast growth factor (FGF) 19 and an expansion of the total bile acid
pool.
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EVALUATION OF CYP3A4 ACTIVITY IN
CROHN'S DISEASE
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3.1

Introduction
Inflammatory bowel disease (IBD) is a disease of chronic intestinal inflammation

punctuated by episodes of active disease and quiescent remission.

IBD can be

differentiated into ulcerative colitis (UC) and Crohn's disease (CD), which can follow
markedly different clinical courses: UC affects the mucosal layer of the large intestine
while CD causes transmural inflammatory lesions that may affect any part of the
intestinal tract1. The treatment of IBD focuses on effecting and maintaining remission at
the level of the intestine as well as inducing symptomatic response. CD therapeutic
options have significantly improved over the past decade. Immunosuppressants such as
azathioprine, methotrexate and glucocorticoids as well as biologic treatments such as
infliximab, adalimumab, vedolizumab and ustekinumab are important therapies for the
optimal treatment of CD.
The Cytochrome P450 (CYP) 3A subfamily of CYP enzymes is a key mediator of
drug metabolism and disposition in humans.

Three functional enzymes have been

indentified: CYP3A4, CYP3A5 and CYP3A7. CYP3A4 is thought to be involved in the
disposition of approximately 40-50% of drugs in clinical use, including many used to
treat CD or UC2, 3. Specifically, CYP3A4 has been shown capable of metabolizing
glucocorticoids used in CD, such as prednisone and budesonide3, 4. Based on limited
budesonide pharmacokinetic (Pk) data from patients with CD as well as Pk data from
healthy populations demonstrates that budesonide exposure after oral administration is
highly variable3, 5, 6. This variability may be due to inter-individual differences in total
CYP3A4 activity and may account for differences seen in clinical outcomes amongst CD
patients treated with budesonide7, 8.
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CYP3A4 is the most thoroughly investigated of the CYP3A isoforms2. CYP3A4
is expressed predominantly in the liver and intestinal tract2.

In the intestinal tract,

CYP3A4 is found at the villous tip of individual enterocytes and aids in the catabolism of
specific drug substrates9. The expression of CYP3A4 mRNA decreases longitudinally
along the intestinal tract, from small intestine to colon, with the highest expression in the
jejunum and ileum10,

11

. The interplay between intestinal CYP3A4 and intestinally-

expressed importers and exporters is considered to be of particular relevance to intestinal
drug metabolism and transport and to significantly impact drug exposure and response.
Intestinal CYP3A4 may act in concert with other transporters, such as Pglycoprotein (P-gp), and play a key role in first-pass metabolism in addition to the role
played by hepatic CYP3A412. P-gp bound to the cell membrane of enterocytes may
regulate the exposure of specific drugs to metabolism by CYP3A4 via an active "counter
transport" mechanism13, 14. The influence of diseases such as infection and more chronic
conditions such as cancer, organ transplantation and liver disease on in vivo CYP3A4
activity have been well-documented in the literature15-20. Interestingly, to our knowledge,
in vivo human CYP3A4 activity has only been reported in one other study in the setting
of IBD.

This study limited its evaluation of CYP3A4 activity to single-point

determination of 4β-hydroxycholesterol (4βOHC) plasma concentrations21.
Moreover, the mechanisms by which disease-dependent changes in CYP3A4
activity occur are not clearly defined.

One existing hypothesis is that circulating

inflammatory cytokines such as interleukin (IL)-1, tumor necrosis factor (TNF)-α or
interferon (IFN)-γ interfere with the transcription of CYP3A4 mRNA; however, data are
limited to animal models and results have been conflicting20,

22

.

Interestingly, key
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regulators of CYP3A4 activity, the nuclear receptors (NR), farnesoid X receptor (FXR)
and pregnane X receptor (PXR) are both down-regulated in IBD and are thought to
contribute to the pathogenesis of the disease21, 23, 24. Bile acids are important endogenous
ligands of PXR and FXR, though not all bile acids are created equal25, 26. Secondary bile
acids, lithocholic acid (LCA) and deoxycholic acid (DCA) are potent activators of PXR
and the primary bile acid, chenodeoxycholic acid (CDCA) is a potent activator of FXR.
The composition of the bile acid pool is highly dependent on the gut microbial profile27,
28

. Studies have demonstrated a loss of microbial diversity in the intestinal tract of those

with IBD, particularly amongst the Firmicutes and Bacteroidetes phyla, key phyla
involved in the processing of bile acids (deconjugation, dehydroxylation)27-29; thus, one
could surmise that changes in NR activation due to changes in the bile acid pool may
result in differential CYP3A4 activity.
Accordingly, we sought to assess the in vivo activity of CYP3A4 in CD using
well-known in vivo probes midazolam30 and 4βOHC31 and to investigate the role of
differential PXR activation on CYP3A4 activity in vitro.
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3.2

Materials & Methods

3.2.1 All Subjects
This study was conducted in two parts: in the first part, a detailed Pk analysis of
oral and intravenous midazolam metabolism was carried out in 8 patients with CD to
evaluate the in vivo activity of CYP3A4 in CD. In the second part, a cross sectional
study in an independent cohort of patients with CD (n=74) and non-CD controls (n=74)
was carried out to evaluate the in vivo activity of CYP3A4 using the endogenous
biomarker 4βOHC in plasma. Written, informed consent was obtained from each patient.
Both parts of the study received approval by the Western University Health Sciences
Research Ethics Board (104914, 105930).

3.2.1.1

Subjects Included in the Pharmacokinetic Study

Patient recruitment took place from March 2014 to September 2014. Eligible
subjects were 18 years of age or older with a history of CD who were starting on or
currently taking the oral medication, budesonide. Subjects receiving concurrent medical
treatment for their CD (n= 8) were eligible for this study. Subjects were excluded from
the study for the following reasons: having a hypersensitivity to budesonide; having a
hypersensitivity to midazolam; having a serum creatinine concentration greater than 1.7
mg per deciliter; being pregnant or breastfeeding; having a pre-existing liver disease
(examples include primary sclerosing cholangitis, autoimmune hepatitis, alcoholic liver
disease, viral hepatitis, cirrhosis); taking other, concurrent benzodiazepines; being
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unwilling to comply with the study protocol; having an estimated survival of less than
one year; abusing or misusing alcohol; being an active smoker; receiving on-going
therapy or treatment in the last 3 months with drugs known to be potent CYP3A
inhibitors or inducers. These are as follows: macrolide antibiotics, ‘azole’ antifungals,
nefazodone, verapamil, diltiazem, cyclosporine A, antiretrovirals, carbamazepine,
phenytoin, lamotrigine, rifampin, rifabutin, dexamethasone, St. John’s Wort, bosentan.
Subjects were screened for eligibility 4 weeks prior to enrollment. Body weight and
routine blood tests (blood count, biochemistries, liver enzymes and creatinine) were
measured for each patient. All female subjects were screened for pregnancy with a urine
pregnancy test. At baseline, demographic data, including age, sex, year of CD diagnosis,
disease distribution, and current medications were collected from each patient. Clinical
parameters to assess for disease activity (Harvey-Bradshaw Index), and subjective
response to budesonide, including efficacy and toxicity were noted.
Subjects were instructed to avoid citrus fruit products for one week prior to their
study day due to the inhibitory effect on CYP3A4 activity. They were also instructed to
avoid alcohol or caffeine one day prior to their study day. Subjects were instructed to
take nothing by mouth the morning of their study day. At the commencement of each
study day (time 0), subjects were administered an oral dose of budesonide (3-9mg). The
dose of budesonide was chosen based on the standard practice of care carried out at
London Health Sciences Centre (LHSC) for inducing remission in individuals with CD.
Subjects were also given a prepared 100µg dose of oral midazolam. At the 8-hour time
interval, subjects were given a prepared 50µg dose of intravenous (IV) midazolam. The
dose of oral and IV midazolam were selected based on previous studies conducted to
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assess the in vivo activity of CYP3A4 and P-gp.30,

32, 33

Blood samples were collected

from each subject at 19 pre-specified time points measured in hours (0, 0.25, 0.5, 1, 2, 3,
4, 5, 6, 7, 8, 8.08, 8.25, 8.5, 9, 9.5, 10, 11, 12). Samples were spun down using a
centrifuge and plasma was extracted and stored at -80◦C.

3.2.1.2

Subjects Included in the Cross Sectional Study

A cross sectional cohort was derived from patients being seen as part of the
Personalized Medicine Program at Western University, London, Canada as well as
healthy individuals being seen for colorectal screening consultation between March 2013
and March 2017. Each subject provided two blood samples for analysis. Subjects from
the CD arm had a histopathological diagnosis. CD subjects were excluded if there was
missing information pertaining to their CD medical history. Individuals were included in
the control arm if there was no history of cardiovascular, neurological, pulmonary, renal,
hepatic, malignant or auto-immune disease. Controls were required to be never-smokers,
to consume less than 5 alcoholic beverages weekly and to have had no prior history of
surgical intervention pertaining to the cardiovascular, neurological, pulmonary, renal,
hepatic, or intestinal systems. All subjects were required to be 18 years of age or older
and to not be taking a concomitant CYP3A4 agonist or antagonist (macrolide antibiotics,
‘azole’ antifungals, nefazodone, verapamil, diltiazem, cyclosporine A, antiretrovirals,
carbamazepine, phenytoin, lamotrigine, rifampin, rifabutin, dexamethasone, St. John’s
Wort, bosentan).

85

Data collected from the CD cohort included age, weight, sex, smoking history,
CD phenotype, activity (assessed by the HBI34), disease duration, medication use and
history of surgical resections or hospitalizations. Data collected from the control cohort
included age, weight, sex, smoking history and alcohol consumption, medical and/or
surgical history and any prescription or non-prescription drug use.

3.2.2 Clinical Study Objectives and Outcomes:
The objective of this study was to test the hypothesis that CYP3A4 activity is
decreased in CD. The primary endpoint was the midazolam AUC0-∞ in individuals with
CD compared to reported healthy cohorts.

Secondary outcomes included the intestinal

and hepatic extraction ratios for midazolam as well as other Pk parameters outlined in the
following section. Pk parameters were also assessed for budesonide and the contribution
of CYP3A4 to inter-individual differences in budesonide AUC0-∞ was evaluated. Other
endpoints included the 4βOHC plasma concentrations in an independent of cohort of CD
patients compared to non-CD controls as a means of confirming or refuting the primary
outcome. Any detectable differences in the bile acid pools of the controls versus the CD
population were also assessed.

3.2.3 Pharmacokinetic Analysis
Pk analysis was performed by the non-compartmental method. Pk parameters
were calculated based on its concentration-time curve. Collected parameters included the
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following: maximum plasma drug concentration (Cmax); time to the maximum plasma
drug concentration (tmax); total drug exposure estimated by the area of under the plasma
concentration-time curve (AUC0-∞); the drug half-life (t1/2); oral bioavailability (F);
systemic (CLs) and oral drug clearance (CL/F). Estimates of CYP3A4-mediated hepatic
and intestinal extraction ratios were calculated.
Cmax and tmax were obtained by visual inspection. The AUC0-∞ for each patient
was calculated using the trapezoidal rule (numerical integration) to the last measured time
point and extrapolated to infinity using the terminal elimination rate constant (ke),
estimated by log-linear regression of last 4-6 data points on the concentration-time curve.
The t1/2 was obtained by dividing the constant 0.693 by ke. Oral clearance was calculated
as the ratio of the oral dose divided by the oral AUC0-∞. F was calculated by dividing the
product of the oral AUC0-∞ and IV dose by the product of the IV AUC0-∞ and oral dose.
CYP3A4-mediated extraction in the liver and intestine were estimated by the hepatic and
gut extraction ratios (Eh and Egi), where Eh = CLs/Qh, plasma and Egi = 1-[F/(1-Eh)]. Qh,
plasma

represented the liver plasma flow and was equal to (1-hematocrit) x Qh, blood. Qh, blood

or liver blood flow was assumed to be 25.7ml/min per kg of body weight.

3.2.4 Quantification of Midazolam Plasma Concentrations
Midazolam plasma concentrations were determined by LC-MS/MS using a
previously described method by Gong et.al. (2012) Supplemental Data32. The lowest
limit of quantification was 0.025 ng/mL.
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3.2.5 Quantification of Budesonide Plasma Concentrations
For measuring budesonide, a five hundred microlitre plasma sample was acidified
using 50µl 4% formic acid (diluted in water) containing the internal standard, d6budesonide (10 µl, 500ng/ml in methanol; Toronto Research Chemicals, Toronto, ON).
Standards made with drug free plasma were similarly spiked with budesonide internal
standard as described above. Protein was precipitated from samples and standards with
the addition of 500 µl of 30% ethanol in water and incubation at 4◦C for 15 minutes.
Precipitated proteins were pelleted by centrifugation at 14000g at 4◦C for 10 minutes.
Supernatants were applied to OASIS HLB 96-well plates (5mg/well, 30 µm particle size,
Waters, Milford, MA) pre-treated with 1ml of methanol and water each. Wells were
washed with 1ml of 20% methanol and eluted using 0.5ml of 100% methanol. The eluate
was dried with heat (70C) and reconstituted using the mobile phase (150µl of
acetonitrile/5mM ammonium acetate in water [25%/75%]). One hundred microlitres of
sample was injected into the liquid chromatograph (Agilent 1200, San Jose, CA).
Analytes were separated using reverse phase chromatography on a Thermo
Hypersil Gold C18 Column (50 x 5mm; 5µm) using gradient elution with Mobile Phase
A (5mM ammonium acetate in water) and Mobile B phase (acetonitrile) over minutes: 1
minute of 75:25 (A:B), from 75:25 to 20:80 (A:B) over 5 minutes, back to 25:75 (A:B)
over 1 minute then held for 1 minute. The retention time for budesonide and d6budesonide is 4.5 minutes.
Mass detection occurred on a Thermo TSQ Vantage triple quadrupole mass
spectrometer, set in positive mode, with a quantitative and qualitative mass transition
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measured for budesonide (431.2 →147.1 m/z). The standard curve was linear over 0 to
10ng/ml concentration range.

3.2.6 Quantification of 4β-hydroxycholesterol Plasma Concentrations
Plasma concentrations of 4βOHC were determined by LC-MS/MS following
sterol isolation by saponification and enhancement of the analyte product by picolinic
acid derivatization as described by Honda et.al. (2009)35 and Woolsey et.al. (2016)36. A
4βOHC-standard curve from 0 to 200ng/ml was created in Krebs-Henseleit Bicarbonate
buffer. Fifty microlitres of subject plasma and 100µl of standard were spiked with 1µl of
1mg/ml internal standard (d7-4βOHC) obtained from Avanti Polar Lipids (Alabaster,
Alabama) .

Each aliquot was saponified in 500µl of 1M ethanolic potassium hydroxide

at 37◦C for one hour followed by the addition of 150µl of water. Sterols were twice
extracted into hexane and further isolated by the evaporation of the hexane layers to
dryness. Following this, 250µl of a derivatization mixture (2-methyl-6-nitrobenzoic acid,
4-dimethylaminopyridine, picolinic acid, pyridine, triethylamine) was added to each
sterol extract and incubated at 80◦C for one hour. Hexane (1ml) was added to each aliquot
and, following centrifugation at 14,000 rpm, the supernatant was collected and
evaporated to dryness at 80◦C. Following re-constitution in acetonitrile and sodium
chloride, a 20µl-aliquot was injected into the LC-MS/MS system. An Agilent C18
Zorbax Eclipse Plus column (100 x 2.1mm, 1.8µm) was used with mobile phases of 0.1%
formic acid in water and 50:50 acetonitrile in methanol with 0.1% formic acid. The
retention times for d7-4βOHC and 4βOHC were 8 minutes and 8.1 minutes respectively
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with each analyte detected in positive mode ( mass transitions of 642.4>146.5m/z, d74βOHC and 635.4> 146.5m/z, 4βOHC). The lower limit of detection of plasma 4βOHC
was 2.5ng/ml.

3.2.7 Quantification of Bile Acid Plasma Concentrations
Plasma stored at -80◦C was used for quantification of 12 bile acids (cholic acid,
CA; chenodeoxycholic acid, CDCA; deoxycholic acid, DCA; glycocholic acid, GCA;
glycochenodeoxycholic acid, GCDCA; glycodeoxycholic acid, GDCA; lithocholic acid,
LCA; taurocholic acid, TCA; taurodeoxycholic acid, TDCA; taurolithicholic acid, TLCA;
tauroursodeoxycholic acid, TUDCA; and ursodeoxycholic acid, UDCA) using high
performance liquid chromatography/mass spectrometry (LC-MS/MS). Taurocholic acidd5 (TCA-D5) was used as an internal standard (I.S). A standard curve of 1nM to 40µM
was generated. Patient samples were homogenized by vortexing for 15 minutes at 4 °C
@1400 RPM and incubated at -20°C for 20 minutes. Samples were centrifuged at
maximum speed at 4°C for 30 minutes. Finally, 100µL of supernatant was transferred to
vials and 80µL was injected into the LC-MS/MS system.
A two-dimensional LC system was used (Agilent HILIC plus column (4.6*50)
3.5µm followed by Phenomenex 00B-4462-Y0 Kinetex 2.6u C18 100A (3.0*50)). A
gradient elution technique was employed using the Agilent 1290 system. Mobile phase A
consisted of 2mM ammonium acetate (pH 4.15) with 10% acetonitrile. Mobile phase B
consisted of acetonitrile: isopropyl-alcohol with water. The columns' temperatures were
maintained at 60°C. Samples were eluted at a flow rate of 0.6ml/min to 1.4ml/min (0.1-
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12 minutes). Before injection of the subsequent sample, columns were cleaned with
100% mobile phase B for one minute and returned to a linear equilibrium for 7 minutes
for a total run of 20 minutes for each sample. Mass detection occurred on a TSQQuantum Ultra mass spectrometer equipped with HESI source and operated in negative
mode (4500 v spray voltage, 350°C vaporizing temperature, 45 sheath gas pressure, 15
auxiliary gas pressure and 350 °C capillary temperature).

3.2.8 In vitro CYP3A4 reporter activity
Human hepatocarcinoma (HepG2) cells, obtained from Cedarlane (Burlington,
Ontario) were cultured in DMEM (VWR, Radnor, Pennsylvania) supplemented with 10%
fetal bovine serum, penicillin and streptomycin. Cell viability in the setting of bile acid
exposure was assessed using the CellTiter-Glo Luminescent Cell Viability Assay
purchased from Promega Corporation (Madison, Wisconsin) at serial concentrations and
time points. Cells were then cultured in 12-well plates to 80% confluency in 3 days.
DNA was transiently transfected by lipofection method. The ratio of plasmid used was
0.5µg of CYP3A4-XREM-Luc, 0.5µg of hPXR-pEF. Additionally, 0.5µg of renilla
plasmid (pRL-CMV, Promega, Madison Wisconsin, USA) was co-transfected as an
internal standard of transfection efficiency. Plasmids, CYP3A4-XREM-Luc and hPXRpEF were previously prepared as described by Tirona et.al. (2003)37. A corresponding
"control" model was generated, with 0.5µg of pGL3 basic (Promega, Madison
Wisconsin, USA) and pEF (Invitrogen, Carlsbad California, USA) control vectors and
0.5 µg of pRL-CMV as a transfection a control. Cells were treated with one of the
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following: a pool of bile acids (25µM) representative of CD disease states (active CD,
inactive CD) as well as that of a healthy individual; 0.1% DMSO in Optimem; or 10µl of
one of GDCA, DCA or LCA. Cohort-specific bile acid pools were derived from subject
data presented in Table 3.7 and 3.8. Cells were incubated for 24 hours, washed with
phosphate buffered saline and lysed with passive lysis buffer. Using the Promega
Corporation Dual Luciferase Reporter Assay System (Madison, Wisconsin USA),
luciferase activity was measured by Glomax 20/20 Luminometer (Promega, Madison
Wisconsin, USA) and normalized by dividing the relative light units by the Renilla
luciferase activity (firefly:renilla luciferase ratio, F/R ratio). The fold-change in
luciferase activity was then estimated by dividing the F/R ratio for each cell group by the
control (pGL3 basic or pEF control vector). Each experiment was performed in triplicate
and repeated 2-3 times.

3.2.9 Statistical Analyses
All statistical analyses were carried out in Graphpad Prism and SPSS. For the
midazolam Pk analysis, data are presented as the arithmetic mean with standard
deviations.

Linear regression analysis was used to assess the possible relationship

between the Pk values of budesonide and midazolam.

A one-way ANOVA with

Student's t-test and Bonferroni post hoc test were used to compare 4βOHC plasma
concentrations between CD (active, inactive disease, n=74) and control groups (n=74). A
p-value ≤0.05 was considered significant. A multiple linear regression analysis was used
to further evaluate the relationship between presence or absence of CD, other covariates
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and the inter-individual variation in 4βOHC plasma concentrations (natural logtransformed). Other covariates assessed included the following: sex, age, weight, and
disease activity. Mean plasma concentrations for the 12 aforementioned bile acids were
compared between the control group and the CD group (sub-divided by disease activity)
using a Student's t-test. A p-value ≤0.05 was considered significant. Similarly, for the in
vitro experiments, a one-way ANOVA with Student's t-test identified any significant
differences between cell groups. A p-value ≤0.05 was considered significant.
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3.3

Results

3.3.1 Subjects
Seven females and one male completed the midazolam Pk study protocol (n=8).
The demographic data and clinical characteristics for each subject are presented in Table
3.1. There were no adverse events. All subjects were on budesonide therapy for a
minimum of 1 month prior to entry into the study.

All subjects had not received

treatment with a CYP3A4-inhibiting or -inducing drug in at least 1 year (with the
exception of budesonide). Seventy-four subjects with CD and 71 controls were included
in an independent cohort to evaluate in vivo CYP3A4 activity using the endogenous
probe, 4βOHC. Table 3.2 summarizes the demographic data as well as the clinical
parameters for both populations
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Table 3.1: Demographics (Pk Analysis)
Patient

Age
(yrs)

Sex

Wt
(kg)

Ds
Type

Ds
Location

Surgery

Additional
Medications
(oral)

Bude
dose, mg
(Duration
of tx,
months)
9 (3)

HBI
preBude

HBI
on
Bude

1

61

F

78.3

CD

ileal

N

Lansoprazole

9

1

2

70

F

70.1

CD

ileal

N

Rabeprazole,
Paroxetine,
Trazadone

6 (3.5)

7

1

3

28

F

75.0

CD

ileal

N

Pantoprazole,

9 (4)

10

9

4

62

F

57.4

CD

ileocolonic

N

Salofalk

3 (2)

9

0

5

25

F

70.0

CD

ileal

N

Cipralex

9 (4)

12

8

6

27

M

76.6

CD

ileal

N

Nil

9 (3)

5

0

7

41

F

69.0

CD

Ileocolonic

N

Synthroid,
methotrexate
(SC)

3 (6)

10

2

8

45

F

104.0

CD

Ileal

N

Metoprolol,
cipralex,
lansoprazole,
methotrexate
(SC)

6 (1.5)

8

0

Disease, Ds; years, yrs; Budesonide, Bude; Harvey Bradshaw Index of disease activity, HBI; Crohn's
disease, CD; subcutaneous, SC; treatment, tx
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Table 3.2: Demographics (Cross-sectional Study)
Variables

Crohn's disease
(n = 74)

Age, years (mean, range)
Female sex (%)
Weight, kg (mean ± std)
CD location
Ileal (%)
Colonic (%)
Ileo-colonic (%)
Disease duration, years (mean ±
std)
Disease activity (%)
Smoking history (%)
Current medications
5-ASA (%)
Glucocorticoid (%)
MTX (%)
Thiopurine (%)
Anti-TNF (%)
Combination therapy
(%)
Surgery (%)
Hospitalizations (mean ± std)

38.46 (18-72)
43 (58.1)
79.25 ± 17.88

Healthy
Volunteer
(n = 71)
45.3 (19-71)
43 (60.6)
81.65 ± 19.33

32 (43.2)
6 (8.1)
36 (48.6)
6.79 ± 7.90

-

30 (40.5)
17 (23.0)
0 (0.0%)
25 (21.6%)
10 (8.6%)
62 (53.4%)
64 (55.2%)
42 (36.2%)

0 (0)
0 (0)
-

0 (0)
0.41 ± 0.93

0 (0)
-

Kilograms, kg; standard deviation, std; inflammatory bowel disease, IBD; Crohn's disease, CD; ulcerative
colitis, UC; tumor necrosis factor, TNF; 5-aminosalicylate, 5-ASA; methotrexate, MTX
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3.3.2 Pharmacokinetic Assessment
The Pk parameters for budesonide, IV and oral midazolam are presented in Table
3.3. Budesonide values are standardized to a 1mg-dose. Mean plasma concentrationtime curves for budesonide, IV and oral midazolam are shown in Figure 3.1. Budesonide
plasma concentration-time curves for individual subjects are shown in Figure 3.2. Panel
A illustrates the budesonide plasma concentration-time curves standardized to a 1mgdose and panel B illustrates the budesonide plasma concentration-time curves colourcoded by dose. There was significant inter-patient variability in budesonide exposure
(Figure 3.2) (coefficient of variation = 0.626; p<0.001).
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95.1
5.5

25.2

46.5
3.0

2.37
322.2
0.40
0.12
0.54

5.3

129.2
2.6

3.29
317.2
0.57
0.16
0.32

3.7

180.7
1.9

0.26
7630.8
7.1

1.90
483.0
0.07
0.02
0.93

42.9

32.1
2.0

0.29±0.17
32347.5±12617.6
3.5±1.7

437.9±218.6
0.31±0.22
0.11±0.06
0.64±0.25

Mean ± s.d.

245.0
1.5
8.6

2.19
480.0
0.10
0.04
0.90

0.44
5653.4
3.6

Subject Subject
7
8

139.4
1.6
0.7

1.29
525.6
0.18
0.10
0.80

0.05
178140.2

Subject
6

69.0
3.7
3.6
0.57
899.3
0.27
0.21
0.66

0.20
10174.4
2.8

117.1±71.8
2.7±1.3

14.3
5.05
206.7
0.67
0.12
0.23

0.51
4465.0
1.9

2.73±1.67

13.05±14.4

5.20
268.9
0.26
0.06
0.73
0.09
39841.5
2.2

Subject Subject Subject Subject Subject
1
2
3
4
5

Table 3.3: Pharmacokinetic parameters in a cohort of Crohn's disease patients (n= 8)
Parameter
Midazolam
CLs (ml/min)
t1/2 (h) (po)
Cmax
(ng/ml)(iv)
Cmax
(ng/ml)(po)
CLs/F (ml/min)
F
EH
EGI

Budesonide
0.41
6839.6
3.8

Cmax (ng/ml)*
0.39
CL/F (ml/min)
6034.7
t1/2 (h)
3.2
*normalized to a 1mg-dose

Intravenous, iv; systemic clearance, CLs; half-life, t1/2; maximum concentration, Cmax; oral bioavailability, F; oral clearance, CL/F; hepatic
extraction ratio, EH; intestinal extraction ratio, EGI; standard deviation, s.d.
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A
20

PO Midazolam

IV Midazolam
15

2
10
1
5

0

Mean Midazolam
Concentration (ng/ml)
Post IV Dose

Mean Midazolam
Concentration (ng/ml)
Post PO Dose

3

0
0

2

4

6

8

10

12

Time (hr)

B
PO Budesonide

Budesonide Concentration
(ng/ml) / dose (mg)

0.5

0.4

0.3

0.2

0.1

0.0
0

2

4

6

8

10

12

Time (hr)

Figure 3.1 Mean intravenous midazolam (50µg-dose) (A), oral midazolam (100µg-dose)
(A), and budesonide (standardized to a 1mg-dose) (B) plasma concentrations versus time
(hours) for subjects with Crohn’s disease (N= 8); error bars represent the standard
deviation upper limit. Oral, PO; intravenous, IV; hour, hr.
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Budesonide Plasma Concentration (ng/ml per 1 mg dose)

A.

0.6

p< 0.0001
Subject 1
Subject 2
Subject 3

0.4

Subject 4
Subject 5
Subject 6

0.2

Subject 7
Subject 8
0.0
0

5

10
Time (hr)

Budesonide Plasma Concentration (ng/ml)

B.

4
Subject 4
Subject 6
3

3mg

Subject 7
Subject 2

2

6mg

Subject 8
Subject 1
Subject 3

1

9mg

Subject 5
0
0

5

10
Time (hrs)

Figure 3.2 Budesonide plasma concentrations (ng/ml) versus time (hours) for 8 subjects with
Crohn’s disease. Panel A shows values standardized to a 1-mg dose of budesonide received by
each subject. Panel B shows values separated by the dose of budesonide administered to each
subject (light grey notched line = 3mg; solid black line = 6mg; dark grey dotted line = 9mg).
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An individual's exposure to a drug is represented by the area-under-concentrationvs.-time curve extrapolated to infinity (AUC0-∞). The mean oral AUC0-∞ of budesonide
and midazolam were 2.02ng/ml*hr ± 1.25 and 4.57ng/ml*hr ± 2.08 respectively (Table
3.4 & 3.5). Mean oral clearance (CL/F) was 32,347.5ml/min ± 12,617.6 (budesonide),
and 437.9ml/min ± 218.6 (midazolam). The systemic clearance (Cls) of midazolam was
117.1ml/min ± 71.8 (Table 3.3).
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Table 3.4: Comparison of the pharmacokinetic parameters of oral budesonide in a cohort of
subjects with Crohn's disease to healthy populations¥
Study

Current
study
Dilger et.al.
2007
Ufer et.al.
2008
Seidegard
et.al. 2000
¥

Population

N

BUDE
po
dose
(mg)

Cmax
(ng/ml)

Tmax
(hr)

AUC po
(ng/ml*hr)

AUC po
(ng/ml*hr)

T1/2
(hr)

CD

8

1

0.27

3.38

2.02

2.02

3.5

Healthy

12

3

1.00

4.5

4.88

1.62*

2.6

Healthy

18

9

2.03

5.47

11.82

1.31*

3.4

Healthy

8

3

0.39^

4.87

4.51^

1.50^*

4.9

All date are presented as previously published, with the exception of values indicated by "*"

*

Data values are normalized to a 1mg oral dose of budesonide by dividing the AUC po value by the
reported dose in mg.
^ Data are converted from nmol to ng
Crohn's disease, CD; N, number; budesonide, BUDE; oral, PO; maximum concentration, Cmax; time to
maximum concentration, Tmax; area under the concentration time curve, AUC
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Study

Healthy

CD

30

21

8

N

100

75

100

MID
po
dose
(µg)

100

-

50

MID iv
dose
(µg)

0.37

0.31

2.73

Cmax
(ng/ml)

0.56

0.8

0.53

Tmax
(hr)

1.02

0.68

4.57

AUC po
(ng/ml*hr
)

1.02

*0.91

4.57

AUC po
(ng/ml*hr)

1491

2133

437

CLs/F
(ml/
min)

340

-

117

CLs
ml/
min)

-

-

0.64

EGI

-

-

0.11

EH

-

0.22

-

0.31

F

Cohort

Healthy

-

0.23

-

0.44

0.2

-

0.53

0.43

0.33

-

439

0.61

0.36

0.86

1880

428

0.47

0.30

0.86

*0.87

2050

383

0.43

0.19

0.57

0.026

-

1182

0.44

0.62

0.47

0.5

8.13

-

370

0.30

-

0.5

-

1413

385

100

9.99

-

-

2200

23

1000

20.2

-

-

Healthy

300
0

1000

-

-

1

16
400
0

NR

-

3

Healthy
21

1000

NR

16

Healthy
20

200
0

2000

Healthy

Healthy

30

Healthy

500
0

Data values are normalized to a 100-µg oral dose of midazolam by dividing the AUC po value by the reported dose in µg and multiplying it by 100µg

All date are presented as previously published, with the exception of values indicated by "*"

Current
Study
Eap et.
al. 2004
Lappin
et. al.
2006
Gong et.
al. 2012
Hohman
et. al.
2015
Hohman
et. al.
2015
Dresser
et.
al.2003
Thummel
et.
al.1996
Xie et. al.
2005

0.011
9

Table 3.5: Comparison of the pharmacokinetic parameters of oral and intravenous midazolam in a cohort of subjects with
Crohn's disease to healthy populations¥

¥
*

Crohn's disease, CD; N, number; midazolam, MID; oral, PO; maximum concentration, Cmax; time to maximum concentration, Tmax; area under the
concentration time curve, AUC; not reported, "-"; intestinal extraction ratio, EGI; hepatic extraction ratio, EH
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3.3.3 Comparison between drugs
The mean hepatic and intestinal extraction ratios for midazolam representing the
proportion of CYP3A4 activity occurring were 0.11 ± 0.06 and 0.64 ± 0.25 respectively
(Figure 3.3a, b). The mean oral bioavailability (F) of midazolam was 31% ± 22% (Figure
3.3c). There was no significant relationship between budesonide exposure (AUC0-∞) and
the oral clearance or exposures of midazolam (Figure 3.4).
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A

1.0

Hepatic Extraction Ratio

0.8

0.6

0.4

0.2

0.0
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7
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B
1.0

Intestinal Extraction Ratio
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0.0
1

2

3

4

5
Subjects

C

100

Oral bioavailability (F) (%)

80

60

40

20

0
1

2

3

4

5
Subjects

Figure 3.3. Hepatic (A), intestinal (B) extraction ratios and oral bioavailability (C)
separated by subject. The mean value is presented following the final individual subject
value.
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Budesonide AUC0-∞ (ng/ml*hr) normalized to 1 mg dose

A.

p= 0.55
Rs= 0.23

4

3

2

1

0

0

2

4

6

8

10

800

1000

Midazolam Oral AUC0-∞ (ng/ml*hr)

Budesonide AUC0=∞ (ng/ml*hr) normalized to 1mg dose

B.

p= 0.37
Rs = 0.13

4

3

2

1

0

0

200

400

600

Midazolam Oral Clearance (ml/min)

Figure 3.4 Correlation between budesonide exposure (AUC0-∞; normalized to a 1mgdose) and oral midazolam exposure (AUC0-∞, ng/ml*hr) (panel A), oral midazolam oral
clearance (Cls/F, ml/min) (panel B) using the Spearman correlation coefficient (Rs).
AUC, area under the curve.
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3.3.4 4β-hydroxycholesterol Plasma Concentrations Are Decreased in
Crohn's disease
A second cohort of subjects with CD (n=74) provided a blood sample for the
quantification of 4βOHC in plasma as did a cohort of non-CD controls (n=71) to estimate
CYP3A4 activity in vivo. The 4βOHC plasma concentrations were significantly lower in
the total CD population compared to the non-CD controls (CD= 18.68ng/ml±13.02ng/ml,
non-CD= 58.14ng/ml±61.76ng/ml, p≤0.0001) (Figure 3.5) on bivariate analysis or when
adjusting for the covariates, age, sex, and disease activity (Table 3.6). The multiple
linear regression analysis accounted for 33.6% of the inter-individual variation in 4βOHC
plasma concentrations. No significant difference was seen in 4βOHC plasma
concentrations between CD subjects stratified by disease activity (inactive CD=
19.75ng/ml±13.34ng/ml, active CD= 17.11ng/ml±12.60ng/ml, p=0.99) (Figure 3.5).

107

Table 3.6. Multiple linear regression model for the effect on Ln-transformed
4βOHC plasma concentrations for the total population (n = 145)
β-coefficients
2.721
0.548
0.130
0.000
-0.832
-0.200

Standard error
0.447
0.151
0.005
0.004
0.162
0.197

P-value
≤0.0001
≤0.0001
0.008
0.92
≤0.0001
0.31

300

200

100

***

**

C
D
e
ct
iv
In
a

e
tiv
Ac

O
N
C

C

O
LS

D

0

TR

4β-hydroxycholesterol (ng/mL)

Variable
Intercept
Sex
Age
Weight
Crohn's disease
Disease activity

Figure 3.5 The mean 4βOHC plasma concentrations for subjects with active and inactive
Crohn's disease (CD) as well as non-CD controls. Median values (thick horizontal line),
25th and 75th percentile values (box outline), minimum and maximum values (whiskers),
and outlier values (circles). 4β-hydroxycholesterol, 4βOHC.
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3.3.5 Plasma Bile Acid Profiles Differ Between Individuals with and
without Crohn's Disease
Plasma bile acid profiles consisting of 12 bile acids were determined for all
subjects (n=145). Tables 3.7 and 3.8 summarize the plasma bile acid profiles as whole
concentrations and as a percentage of the total bile acid pool respectively.
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Bile acid (ng/mL)
CA
TCA
GCA
CDCA
GCDCA
DCA
TDCA
GDCA
LCA
TLCA
UDCA
TUDCA

Inactive CD (n=44)
176.6
43.9
276.3
519.3
1984
368.3
253.8
2523
114.6
8.3
331.4
0.7487

Active CD (n=30)
184.6
44.7
256.5
472.3
2730
274.9
176.8
3587
86.8
17.5
434.7
0.8586

Table 3.7: Bile acid profiles presented as concentrations (ng/mL)
Control (n=71)
200.6
47.8
71.5
342.8
1705.3
202.2
106.8
473.2
96.5
11.1
175.8
1.7

*Comparison of control to active and inactive CD

p-value*
ns
<0.01
<0.001
ns
<0.001
ns
ns
<0.001
<0.001
ns
ns
ns

Crohn's disease, CD; cholic acid, CA; chenodeoxycholic acid, CDCA; deoxycholic acid, DCA; glycocholic acid, GCA; glycochenodeoxycholic acid, GCDCA; glycodeoxycholic acid,
GDCA; lithocholic acid, LCA; taurocholic acid, TCA; taurodeoxycholic acid, TDCA; taurolithicholic acid, TLCA; tauroursodeoxycholic acid, TUDCA; and ursodeoxycholic acid, UDCA;
not significant, ns.
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Plasma Bile acids
CDCA
G-CDCA
Total
CA
G-CA
T-CA
Total
DCA
G-DCA
T-DCA
Total
LCA
T-LCA
Total
UDCA
T-UDCA
Total

Control
(n=71)
4.87%
47.11%
51.98%
4.87%
1.08%
3.01%
8.96%
5.44%
14.46%
3.20%
23.10%
6.49%
1.33%
7.82%
6.97%
0.08%
7.05%

Inactive CD
(n=44)
6.75%
33.11%
39.86%
2.61%
4.79%
1.31%
8.71%
5.74%
32.00%
3.97%
41.71%
3.50%
0.09%
3.59%
6.17%
0.02%
6.19%

Active CD
(n=30)
8.76%
37.02%
45.78%
2.84%
4.98%
0.90%
8.72%
3.19%
31.32%
2.19%
36.70%
1.46%
0.38%
1.84%
6.91%
0.03%
6.94%

ns
ns

<0.001
ns

ns
<0.001
ns

ns
<0.001
<0.01

ns
<0.001

p-value*

Table 3.8: Bile acid profiles presented as a percentage of the total bile acid pool by group

Primary Bile
acids plus
conjugates

Secondary bile
acids plus
conjugates

Tertiary bile
acids plus
conjugates
*Comparison of control to active and inactive CD

Crohn's disease, CD; cholic acid, CA; chenodeoxycholic acid, CDCA; deoxycholic acid, DCA; glycocholic acid, GCA; glycochenodeoxycholic acid, GCDCA; glycodeoxycholic acid,
GDCA; lithocholic acid, LCA; taurocholic acid, TCA; taurodeoxycholic acid, TDCA; taurolithicholic acid, TLCA; tauroursodeoxycholic acid, TUDCA; and ursodeoxycholic acid, UDCA;
not significant, ns.
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Subjects with CD had a higher ratio of conjugated to unconjugated bile acids compared to
controls (active CD= 5.9; inactive CD= 6.9; control= 3.0, Figure 3.6). Significant
differences in the composition of the bile acid pool were seen based on presence or
absence of CD. Differences in the percent composition of GCDCA, GCA, TCA, GDCA,
LCA were most significant (Figure 3.7). CDCA and DCA were different between
controls and CD subjects with active disease. There was no difference in UDCA, TDCA,
CA.
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The ratio of the plasma concentration of conjugated to unconjugated bile

acids stratified by cohort (control, active CD, inactive CD). The 95%CI is represented by
the vertical T-line. *, p<0.05; **, p<0.01; ***, p<0.001. Crohn's disease, CD.
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Figure 3.7 Bile acid profiles. The mean individual bile acid profiles expressed as mean
concentrations in ng/ml and as a percentage of the total bile acid pool, stratified by cohort
(control, active CD, inactive CD). The 95%CI is represented by the vertical T-line. *, p<0.05;
**, p<0.01; ***, p<0.001. Crohn's disease, CD; cholic acid, CA; chenodeoxycholic acid, CDCA;
deoxycholic acid, DCA; glycocholic acid, GCA; glycochenodeoxycholic acid, GCDCA;
glycodeoxycholic acid, GDCA; lithocholic acid, LCA; taurocholic acid, TCA; taurodeoxycholic
acid, TDCA; taurolithicholic acid, TLCA; tauroursodeoxycholic acid, TUDCA; and
ursodeoxycholic acid, UDCA.
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3.3.6 Activation of PXR by Individual Bile Acids and Cohort-Specific Bile
Acid Profiles
To explore the impact of CD-dependent alterations in the plasma bile acid profile
on PXR-mediated CYP3A4 activity, a transient transfection and dual luciferase assay
were used. We found that luciferase activity (a surrogate of CYP3A4 activity) was
markedly elevated in cells exposed to known PXR activators, DCA (12-fold), GDCA
(10-fold) or LCA (23-fold) (Figure 3.8). These data are in agreement with other reports
of bile acid-induced activation of PXR38, 39. Conversely, no difference was seen in the
luciferase activity amongst the transfected cells exposed to the cohort-specific bile acid
pools (Figure 3.8).
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PXR-CYP3A4 (n=3)
DCA 10uM
+
control

LCA 10uM
GDCA 10uM
Active CD
Inactive CD

Healthy volunteer

40

30

20
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0

DMSO 0.1%
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Figure 3.8

Effect of known bile acid PXR agonists and patient-derived bile acid

profiles on CYP3A4-pGL3 basic reporter activity in HepG2 cells co-transfected with
hPXR. One of DCA, LCA, GDCA (10µM) a bile acid pool (25µM) representative of
inactive or active CD or a healthy population were incubated with cells for 24 hours. All
experiments were completed in triplicate and repeated 3 times. Error bars indicate the
95% confidence interval.
Deoxycholic acid, DCA; lithocholic acid, LCA; glycol-deoxycholic acid, GDCA; Crohn's
disease, CD; dimethyl sulfoxide, DMSO; pregnane X receptor, PXR; cytochrome p450,
CYP; hepatocarcinoma, Hep;
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3.4

Discussion
CYP3A4 is considered to be one of the most clinically-relevant determinants of

drug metabolism and exposure today. Although there is a significant amount of data in
terms of CYP3A4 activity in vivo in human subjects, nearly all such studies have been
conducted in healthy volunteers. In disease conditions, such as CD, remarkably little is
known with regards to the extent of CYP3A4 activity. In this study, we evaluated
subjects with active CD on stable doses of the glucocorticoid drug, budesonide, where
pharmacokinetic analysis of an exogenous probe substrate of CYP3A4 was utilized to
better delineate the difference in hepatic versus intestinal CYP3A4 activity. We were
also able to evaluate the impact of CYP3A4 activity on budesonide exposure, a known
CYP3A4 substrate.

Furthermore, we were able to validate our findings of reduced

CYP3A4 activity in CD in an independent cohort of CD patients as well as explore a
possible mechanism for this difference. To our knowledge, this is the first study to assess
CYP3A4 activity in a CD population using both in vivo probes midazolam and 4βOHC.
Of high clinical relevance, is the near 5-fold higher AUC0-∞ for oral midazolam
in our patient Pk population compared to what has been reported in healthy populations
(Figure 3.9b, Table 3.5)30, 32, 40, 41. This suggests that total CYP3A4 activity is profoundly
reduced in CD compared to healthy individuals. Interestingly, the decrease in CYP3A4
activity cannot necessarily be attributed to a reduction in intestinal CYP3A4 activity as
one might suspect in a primary intestinal illness.

A higher degree of midazolam

extraction and subsequently CYP3A4 activity occurred in the gut (Egi= 0.64 ± 0.25)
compared to the liver (Eh= 0.11 ± 0.06) (Figure 3.3a, b). And while, to date, the degree
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of extraction in the liver versus the intestine has been reported at varying levels, the
degree of difference seen between the liver and gut extraction in our CD population has
not been seen in healthy populations33, 41-43.

One potential limitation of our Pk study

might be the absence of a control population. However, in comparison to a cohort of
healthy volunteers who participated in a previous study conducted in our laboratory

32

using the same midazolam microdose-based phenotyping approach for CYP3A4 and the
same LC-MS/MS assay used in the current study, we observed a marked reduction in our
CD subjects (Figure 3.9b, Table 3.5).
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In this study, we note that subjects with CD have a comparable exposure to
budesonide, a known substrate of CYP3A4, to what has been reported in studies of
healthy individuals when standardized to the same dose (Figure 3.9a, Table 3.4)3,

5, 44

.

We also see that budesonide exposure is highly variable in subjects with CD (Figure 3.2);
consistent with what has been shown in healthy populations as well as in a single adult
CD population

3, 6

. This may account for the some of the variability seen in response to

budesonide treatment. Based on our data, CYP3A4 activity accounts for only a small
fraction of the variability in budesonide exposure. This suggests that there are other
factors determining budesonide exposure in CD and that CYP3A4 may not have a
significant impact on its disposition in this population; however, our sample size may be
too small to draw any firm conclusions.
Moreover, we independently confirm a reduction in CYP3A4 activity in CD using
the CYP3A4-in vivo probe, 4βOHC. The evaluation of hepatic CYP3A activity using
this endogenous marker has been well-documented31. CYP3A4 and 3A5 regulate the
production of 4βOHC and it is useful for the evaluation of CYP3A induction by specific
drugs. The plasma concentration of 4βOHC is significantly lower in the CD population
compared to a control population (Figure 3.5). The effect of CD presence on CYP3A4
activity remains even when age, sex, weight and disease activity (assessed by HBI) are
taken into account (Table 3.6). Of note, some groups endorse the use of the ratio of the
plasma concentrations of 4βOHC to cholesterol31,

45, 46

. In some populations, plasma

concentrations of cholesterol may differ based on treatment, which may impact the ability
to form 4βOHC from its parent compound.

Though, plasma cholesterol was not

measured in our population, no subjects included in our study were being treated for
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dyslipidemia. This may have minimized confounding in our population, though does not
entirely eliminate it. Furthermore, some groups suggest there is only a weak correlation
between midazolam Pk parameters (total and liver CYP3A4 activity) and 4βOHC plasma
concentrations.47 However, this may be partially explained by the fact that 4βOHC is a
substrate of both CYP3A4 and 3A5, while midazolam is only a substrate of CYP3A431.
Moreover, 4βOHC has a long half-life (1-3weeks) and therefore cannot be used to assess
rapid fluctuations in CYP3A activity.31,

47

It has been concluded that 4βOHC may be

most useful for assessing constitutive CYP3A4 activity. Midazolam Pk parameters are
considered the gold standard for assessing CYP3A4 activity in vivo31. Despite, these
possible limitations, we are able to show, using both modalities, that CYP3A4 activity is
reduced in CD.
Reduced hepatic CYP3A4 activity in the setting of systemic or non-hepatic
inflammation has been reported, although our study is the first to demonstrate such an
effect in CD using multiple CYP3A4-phenotyping modalities. In vitro and in vivo animal
studies both conclusively show that in the setting of acute non-hepatic inflammation,
hepatic CYP3A4 expression is down-regulated.22 Studies in humans show an increase in
the plasma drug concentrations of CYP3A4 substrates in the setting of acute
inflammation48. The effect of chronic inflammation on CYP3A4 activity and expression
in humans is not well defined and there is a paucity of literature on this subject. One
small study did assess CYP3A4 activity in IBD. Iwamoto et.al. (2013) evaluated singlepoint 4β-OHC plasma concentrations in subjects with IBD as well as healthy
volunteers21. They found a significant reduction in the 4β-OHC plasma concentrations of
their CD cohort compared to a cohort of healthy controls; however, their sample size was
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small (21 CD patients, 26 controls), limiting the generalizability of their findings. They
also did not account for CD disease activity in their analysis nor any other factors that
may have confounded CYP3A4 activity. It has been suggested that hepatic CYP3A4 is
down-regulated due to the effects of IL-1𝛽, IL-6, TNF-α, and IFN-α and 𝛾20, 22; however,

in our cross-sectional cohort, no difference is seen in the CYP3A4 activity of CD subjects
with and without active disease, suggesting an alternate mechanism for this reduced
activity.
We tested the hypothesis that changes in bile acid-mediated activation of PXR
account for detectable differences in CYP3A4 activity in CD using a HepG2 cell model.
We show that there are differences in the bile acid profiles of CD (active and inactive)
and non-CD cohorts (Table 3.7, 3.8; Figure 3.7). These data provide a more detailed
analysis of bile acid pool composition in CD; however, they re-iterate principles already
established in the literature49, 50. Specifically, that individuals with IBD have a different
pattern of bile acids compared to healthy controls, perhaps due to documented changes in
the presence of bile acid-modifying gut bacteria29,

50

. We then applied these cohort-

specific bile acid pools to a HepG2 cell model and evaluated the effect of bile acidinduced PXR on CYP3A4 activity. Our findings confirm that glycine-conjugated and
unconjugated DCA as well as LCA are potent PXR agonists. Conversely, we did not find
an appreciable difference in the activation of CYP3A4 based on exposure to our cohortspecific bile acid pools (Figure 3.8). The reasons for this may be multi-factorial: 1)
plasma bile acid composition is a relatively dilute compared to what is seen in the liver
and bile51; thus small differences in individual bile acid concentrations in plasma may
under-represent the ultimate impact of these changes in the liver or bile on downstream
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target pathways 2) other bile acid-activated NRs, such as FXR, with impact on CYP3A4
activity, may need to be accounted for. Ultimately, more studies are needed.
In summary, this is the first study in CD populations evaluating CYP3A4 activity
using dual in vivo probes. CYP3A4 activity is lower in the setting of CD based on
midazolam Pk and single point-4βOHC plasma concentration measurements.
Interestingly, this effect is mainly due to a reduction in hepatic CYP3A4 activity based
on the midazolam data. Our findings suggest that a disease-dependent reduction in
CYP3A4 needs to be taken into consideration when prescribing substrate drugs such as
certain HMG-CoA reductase inhibitors, benzodiapines or oral anticoagulants to a CD
population. The molecular mechanisms responsible for these findings remain to be
explored.
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4.1

Introduction
The intestinal mucosa plays a vital role in human health: it is the key interface for

the absorption of nutrients including electrolytes and water as well as an effective barrier
against host exposure to environmental pathogens and toxins. It is composed of a
monolayer of columnar epithelial cells known as enterocytes, as well as goblet cells,
paneth cells and enteroendocrine cells. Cells are arranged in villi, superimposed over the
lamina propria and inferiorly bound by the muscularis mucosae1, 2. The enterocytes,
overlaying the lamina propria, are tightly joined by a series of junctional proteins (tight
junctions, adherens junctions, desmosomes) and are arranged in a folded pattern,
producing crypts and villi on a cytoskeleton framework3. The lamina propria, the
bedrock of the epithelium, houses a number of different cell types that carry out a host of
important functions for maintaining the integrity of the mucosal layer and its
immunological role in barrier function. Fibroblasts, lymphocytes, plasma cells,
granulocytes, macrophages and dendritic cells form part of the rich cellular fabric of the
lamina propria amidst an extensive vascular network4.
An extension of the barrier function of the intestine is its contribution to first-pass
metabolism. It is well established that an individual's exposure to an orally-dosed
medication may differ considerably from their exposure to its intravenously-dosed
counterpart5. The concept of first-pass metabolism refers to the extensive processing
applied to orally-dosed drugs in the hepatic parenchyma and now, increasingly
recognized, in the gut mucosa that limits the delivery of active drug to the systemic
circulation6, 7. The cytochrome P450 enzyme (CYP) 3A4 is an integral part of the "firstpass" phenomenon in humans given its abundance in both liver and intestinal tissue. It
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accounts for up to 40% and 80% of their respective CYP burdens and is involved in the
metabolism of up to 50% of drugs used in clinical practice8-10. Within the intestine,
CYP3A4 is localized to enterocytes found at the tips of villi and is expressed in highest
concentrations within the jejunum and ileum7, 11. Intestinal CYP3A4 may act in a
coordinated manner with key xenobiotic exporters, such as P-glycoprotein (P-gp), a
member of the ATP-binding cassette protein (ABC) superfamily12. This idea is
reinforced by the findings of multiple shared substrates and inhibitors as well as colocalization within villous tip-enterocytes. P-gp bound to the cell membrane of
enterocytes may regulate the exposure of specific drugs to metabolism by CYP3A4. It is
thought that P-gp reduces the concentration of a drug within the enterocyte by actively
moving the drug back into the intestinal lumen across the plasma membrane. This limits
the saturation of intestinal CYP3A4 and leads to more effective and complete metabolism
of drugs13.
The impact of chronic liver and kidney disease on the expression of hepatic
CYP3A4 has been evaluated and reductions in CYP3A4 expression are observed14-16.
Similarly, research pertaining to P-gp reveals that there is over-expression of P-gp and
the gene by which it is coded, MDR1, in a multitude of cancers17, 18. The effect of a
primary intestinal illness on the intestinal expression of CYP3A4 and P-gp has only been
explored in a limited capacity 19-25.

Crohn's disease (CD) is a primary, chronic illness of

the intestinal tract that produces transmural, discontinuous inflammatory lesions along
the gut's longitudinal access. It is often confined to the small and large intestines, but can
be found anywhere from the oral cavity to the most distal colon26. Hallmarks of CD
include disruption of the epithelial cell tight junctions, epithelial cell apoptosis, expansion
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of the lamina propria with pro-inflammatory cells and the recruitment and activation of
pro-fibrotic fibroblasts27-29. Such changes in barrier function lead to the trademark
clinical profile of CD including abdominal pain, profuse diarrhea, intestinal stricturing
and fistulization. Disruption of the intestinal mucosa may also have important
implications for epithelial-based processes such as phase 1 and 2 drug metabolism and
drug transport. Specifically, the loss of mucosal surface area may result in the loss of
intestinally-expressed CYP3A4 and P-gp protein. The impact of CD on the protein
expression of both CYP3A4 and P-gp has not been well-evaluated, particularly in an
adult population.
The aim of this study was to evaluate the intestinal expression of CYP3A4 and Pgp at two intestinal sites in adult patients with CD compared to non-CD controls.
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4.2

Materials & Methods

4.2.1 Subjects
The study protocol was approved by the University of Western Ontario Health
Sciences Research Ethics Board (13067) and was carried out in accordance with the
Declaration of Helsinki. Written and informed consent was obtained from all
participants. Twenty three subjects with CD and 37 non-CD controls were recruited from
a single centre in London, Ontario between August 2009 and December 2014. Eligible
CD subjects were 18 years of age or older with a history of CD confirmed by previous
histopathologic examination. Eligible controls were 18 years of age or older with no
clinical history of gastrointestinal pathology. Subjects in either group taking CYP3A4 or
P-gp agonists or antagonists (with the exception of budesonide) were excluded. Clinical
data pertaining to CD subject age, sex, weight, smoking history, medication history and
drug response, diagnosis, disease location, disease activity were collected. Demographic
data were collected for each non-CD control. All participant data is summarized in Table
4.1.

4.2.2 Study Objectives and Outcomes
The objective of this study was to test the hypothesis that individuals with CD
have reduced expression of intestinal CYP3A4 and P-gp protein relative to a healthy
population. The primary endpoints were the density ratios of ileal CYP3A4 and P-gp
protein to villin in subjects with CD compared to non-CD controls. Secondary endpoints
included the density ratios of colonic CYP3A4 and P-gp protein to villin in CD versus
non-CD cohorts, as well as the relative densities of ileal and colonic CYP3A4 and P-g
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protein stratified by one of age, sex, or CD activity (by Harvey Bradshaw Index, HBI)
respectively for the CD cohort as well as by age and sex in the non-CD cohort.

4.2.3 Tissue Collection
Tissues samples from the terminal ileum and ascending colon were obtained from
all subjects at the time of colonoscopy. Tissue sampling from the CD cohort was
obtained exclusively from non-inflamed areas (based on endoscopic examination) in the
presence or absence of active disease. All tissue samples were immediately frozen on dry
ice after excision and stored at -80ºC until further use.

4.2.4 Protein Quantification:
Total protein was isolated from the ileal and colonic tissue samples and quantified
using bovine serum albumin as an internal standard. Twenty micrograms of isolated
protein was separated on a 4-12% tris-acetate gel and transferred to a nitrocellulose
membrane. P-gp-expressing caco2 cells and human liver samples were used as controls
for P-gp and CYP3A4 respectively. Blots were blocked overnight at 4ºC in 10% non-fat
dried milk in Tris buffer containing 1% Tween 20. Blots were incubated with the
primary antibody, 3H8 directed against CYP3A4 (Thermoscientific, Rockford IL, USA;
dilution 1:500) and C219 directed against P-gp (Covance, Dedham MA, USA; dilution:
1:500) respectively. Villin (CWWB1) was used as the internal standard (Santa Cruz
Biotechnology; dilution 1:500). Horse radish peroxidase conjugate-labeled goat antimouse IgG was used as a secondary antibody (dilution 1:10,000). Detection was
achieved by chemiluminescence with enhanced chemiluminescence western blot
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detecting reagents (GE Healthcare, Chicago Illinois, USA). Quantification by
densiometry was performed using Image J software. Relative CYP3A4 and P-gp protein
expression were represented as the ratios of densities of the target protein to villin.

4.2.5 Statistical Analysis:
All statistical analyses were carried out in Graphpad Prism and SPSS. The
distribution of the protein expression data was assessed using the D'Agostino & Pearson
omnibus normality test. The Mann-Whitney test was used to assess any statistically
significant differences in protein expression between two groups, while the KruskalWallis test was used to assess any statistically significant differences in protein
expression between three or more groups. Dunn's multiple comparison test was used to
conduct a post-hoc analysis of data evaluated by the Kruskal-Wallis test. A linear
regression analysis was used to assess the relationship between one of sex or age and the
relative densities of ileal and colonic CYP3A4 and P-gp respectively in both CD and nonCD cohorts. A multiple linear regression model was to evaluate the effect of multiple
covariates (age, sex, disease presence, disease activity) on inter-individual variation in
ileal and colonic CYP3A4 and P-gp relative densities.
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4.3

Results:

4.3.1 The effect of disease presence and activity on intestinal CYP3A4
protein expression
Demographic data are presented in Table 4.1. The expression of intestinal
CYP3A4 protein is presented as the density of CYP3A4 protein on Western Blot relative
to the density of villin (Figure 4.1 and 4.2). The protein expression patterns of CYP3A4
relative to villin in ileum and ascending colon are presented for CD and non-CD
populations in Figure 4.3. CYP3A4 expression in both the CD cohort and the controls
mirrored physiological patterns previously reported in healthy individuals: CYP3A4
content was higher in the ileum than in the colon (CD, p<0.0001; control, p<0.0001).
Ileal CYP3A4 expression was decreased in CD compared to controls (CD, 0.40±0.35;
control, 0.72±0.33; p<0.01) (Figure 4.3). Similarly, colonic CYP3A4 expression was
decreased in CD compared to controls (CD, 0.08±0.08; controls, 0.37±0.34; p<0.0001)
(Figure 4.1). Significant inter-individual variation was observed in ileal (CD, 39-fold;
control, 93-fold) and colonic (CD, 49-fold; control, 67-fold) CYP3A4 expression.
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Table 4.1: Demographics
Variables

CD
(n=23)

Non-CD Controls
(n=37)

Age, years (mean, range)
Female sex (%)
Smoking history (%)
Disease location
Ileal disease (%)
Ileo-colonic disease (%)
Colonic disease (%)
Active disease (%)*
Previous resection (%)
Duration of disease
Medication use
Glucocorticoids
5-aminosalicylates
Azathioprine
Methotrexate
Biologics

48.87 (22-80)
16 (69.6)
6 (26.1)

63.77 (27-85)
()
0 (0.0)

11 (47.8)
9 (39.1)
3 (13.1)
9(39.1)
4 (17.4)
10.71±8.54
38 (95.0)
19 (82.6)
0 (0)
11 (47.8)
14 (60.9)
11 (47.8)

-

Crohn's disease, CD
*Disease activity is based on the Harvey-Bradshaw Index for individuals with CD;
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Figure 4.1 Intestinal expression of CYP3A4 and P-gp by Western blot for 21 of 23 CD
participants (ileal data for subject 6 is not included in this figure nor data for subjects 22
and 23). Cytochrome P450 3A4, CYP3A4; P-glycoprotein, P-gp; Crohn's disease, CD; +,
positive control.
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Figure 4.2 Intestinal expression of CYP3A4 and P-gp by Western blot for 37 non-CD
controls (data for subjects 28 and 32 are not included in this figure). Cytochrome P450
3A4, CYP3A4; P-glycoprotein, P-gp; +, positive control.
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Relative CYP3A4 Protein Expression

2.0

**

***

1.5

1.0

0.5

0.0
CD

Control
Ileum

CD

Control

Ascending colon

Figure 4.3 The relative protein expression of CYP3A4 to villin in the ileum and
ascending colon of individuals with (n=23) and without (n=37) CD. Per the box plot,
mean values (thick horizontal line), 25th and 75th percentile values (box outline),
minimum and maximum values (whiskers), and outlier values (circles). ***, p <0.0001,
**, p<0.01. Cytochrome, CYP; Crohn's disease, CD.
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Neither, disease location nor disease activity, assessed by the Harvey-Bradshaw Index
(HBI), accounted for any appreciable difference in ileal or colonic CYP3A4 expression in
the CD cohort. Multiple linear regression was performed on the relative densities of ileal
and colonic CYP3A4, adjusting for age, sex, weight, disease presence, and disease
activity (Table 4.2 and 4.3). Disease presence had a persistently significant and negative
impact on the relative expression of both ileal and colonic CYP3A4 protein.
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Table 4.2: Multiple linear regression model for the effect on relative densities of ileal
CYP3A4 for the total population (n = 60)
Variable
Intercept
Sex
Age
Crohn's disease
Disease activity

β-coefficients
0.740
-0.034
0.000
-0.279
-0.001

Standard error
0.277
0.110
0.004
0.131
0.180

P-value
0.011
0.762
0.991
0.048
0.995

Table 4.3: Multiple linear regression model for the effect on relative densities of
colonic CYP3A4 for the total population (n = 60)
Variable
Intercept
Sex
Age
Crohn's disease
Disease activity

β-coefficients
0.596
-0.091
-0.002
-0.279
-0.062

Standard error
0.206
0.008
0.003
0.106
0.143

P-value
0.006
0.309
0.392
0.012
0.669
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4.3.2 The Effect of Age and Sex on Intestinal CYP3A4 Expression
CYP3A4 expression varied significantly with age in both the CD and control
cohorts (Figure 4.4). Ileal CYP3A4 expression decreased with advancing age in the
control cohort (Figure 4.4a); however, this was not observed in the corresponding colonic
samples (Figure 4.4b). Conversely in the CD cohort, ileal CYP3A4 expression increased
with age (Figure 4.4c). This was not seen in the CD ascending colon samples (Figure
4.4d). Sex did not have significant impact on CYP3A4 expression in either cohort at
either intestinal location.
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Figure 4.4 The influence of age on the relative densities of ileal and colonic CYP3A4
protein in control (Panel A and B) and CD (Panel C and D) populations. The solid line
represents the linear regression. Cytochrome P450, CYP; Spearman correlation, R;
Crohn's disease, CD; non-significant, ns.
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4.3.3 The Effect of Disease Presence and Activity on Intestinal P-Gp
Protein Expression
The expression of intestinal P-gp protein is presented as the density of P-gp
protein on Western Blot relative to the density of villin (Figure 4.1 and 4.2). The protein
expression patterns of P-gp relative to villin in ileum and ascending colon are presented
for CD and non-CD populations in Figure 4.5. No difference was seen in the relative
ileal P-gp expression in CD compared to controls (CD, 0.095±0.10; control, 0.11±0.09;
p=ns) (Figure 4.3). Conversely, the relative colonic P-gp expression was decreased in
CD compared to controls (CD, 0.026±0.029; controls, 0.17±0.21; p<0.01) (Figure 4.3).
Significant inter-individual variation was observed in ileal (CD, 18-fold; control, 13-fold)
and colonic (CD, 22-fold; control, 207-fold) P-gp expression.

Relative P-gp protein expression
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Figure 4.5 The relative protein expression of P-gp to villin in the ileum and ascending
colon of individuals with (n=23) and without (n=37) CD. Per the box plot, mean values
(thick horizontal line), 25th and 75th percentile values (box outline), minimum and
maximum values (whiskers), and outlier values (circles). **, p<0.01. P-glycoprotein, Pgp; Crohn's disease, CD.
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Similar to CYP3A4 expression, neither disease location nor disease activity, assessed by
HBI, affected P-gp expression in the ileum or ascending colon of the CD cohort.
Multiple linear regression was performed on the relative densities of ileal and colonic Pgp, adjusting for age, sex, weight, disease presence, and disease activity (Table 4.4 and
4.5). Disease presence had a persistently significant and negative impact on the relative
expression of colonic P-gp protein (Table 4.5), but not in the ileum (Table 4.4).
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Table 4.4: Multiple linear regression model for the effect on relative densities of ileal
P-gp for the total population (n = 60)
Variable
Intercept
Sex
Age
Crohn's disease
Disease activity

β-coefficients
0.186
-0.052
-0.001
-0.002
-0.032

Standard error
0.073
0.031
0.001
0.036
0.047

P-value
0.015
0.099
0.479
0.947
0.497

Table 4.5: Multiple linear regression model for the effect on relative densities of
colonic P-gp for the total population (n = 60)
Variable
Intercept
Sex
Age
Crohn's disease
Disease activity

β-coefficients
0.360
0.043
-0.004
-0.179
-0.037

Standard error
0.113
0.047
0.002
0.055
0.071

P-value
0.003
0.368
0.028
0.002
0.602
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4.3.4 The Effect of Age and Sex on Intestinal P-Gp Expression
Colonic P-gp expression varied significantly with age in both the CD and control
cohorts (Figure 4.6). Colonic P-gp expression decreased with advancing age in the CD
and control cohorts (Figure 4.6b, d). This remained significant based on the multiple
linear regression analysis (Table 4.5). Conversely, this was not observed in the
corresponding ileal samples (Figure 4.6a, c). Sex did not have significant impact on Pgp expression in either cohort at either intestinal location.

149

Control Cohort: Ileum
(p=ns, R2 =0.04)

Control Cohort: Ascending colon
(p<0.01, R2 =0.21)

B

0.5

Relative P-gp protein expression

Relative P-gp protein expression

A
0.4

0.3

0.2

0.1

0.0
0

80

60

40

20

1.0

0.8

0.6

0.4

0.2

0.0

100

0

20

Relative P-gp protein expression

Relative P-gp protein expression

0.3

0.2

0.1

0.0
20

40

100

CD Cohort: Ascending colon
(p<0.05, R2 =0.18)

D

0.4

0

80

Age

CD Cohort: Ileum
(p=ns, R2 =0.08)

C

60

40

Age

60

Age

80

0.15

0.10

0.05

0.00
0

20

60

40

80

Age

Figure 4.6 The influence of age on the relative densities of ileal and colonic P-gp protein
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4.4

Discussion:
The intestine is essential for nutrient absorption, host defense and plays a key role

in drug metabolism in concert with the liver. The interplay of numerous factors likely
contributes to inter-individual variation in drug exposure and response. Key phase 1 drug
metabolism enzyme, CYP3A4 has been proposed to act in a synchronized manner with
xenobiotic exporter, P-gp to significantly affect the oral bioavailability of numerous
shared substrates. This theory is further supported by their co-localization in enterocytes.
Disease-dependent decreases in hepatic CYP3A4 activity and expression are
observed in a myriad of chronic hepatic and non-hepatic diseases14-16, 30. Similarly, the
endothelial expression of P-gp at the blood-brain barrier is noted to be decreased in
Alzheimer's disease31, 32. The impact of disease on the intestinal fractions of the highly
abundant and relevant CYP3A4 and P-gp has only been evaluated in a limited capacity.
Specifically, studies assessing the impact of a chronic, primary intestinal illness on
intestinal CYP3A4 expression are few. Data are mainly derived from pediatric
populations and are contradictory.
Two small studies in pediatric patients with celiac disease and inflammatory
bowel disease (IBD, either CD or ulcerative colitis, UC) showed a decrease and an
increase in duodenal CYP3A4 mRNA expression respectively19, 20. Similarly, a more
recent study in a pediatric CD population showed a relative reduction in ileal CYP3A4
mRNA compared with CYP3A4 mRNA taken from non-inflamed duodenal biopsies21. In
an adult population of individuals with UC, decreased CYP3A4 mRNA expression was
seen in rectal samples taken from inflamed tissue22.
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The effect of an inflammatory bowel disease on P-gp expression has received
more attention, with a large focus on ulcerative colitis (UC). Of 4 studies identified to
date evaluating the mRNA and/or protein expression of P-gp (gene MDR1), reductions in
the colonic expression of P-gp protein or MDR1 mRNA are documented predominantly
in UC patients with active disease23-25, 33.
Our study is the first to evaluate the concomitant protein expression of intestinal
CYP3A4 and P-gp in a CD population. We demonstrate a significant reduction in ileal
and colonic CYP3A4 as well as colonic P-gp expression in subjects with CD compared to
those without. Based on our findings, one could hypothesize that alterations in the
intestinal expression of important drug disposition regulators may account for a portion
of the heterogeneity seen in CD-oral drug response.
A limitation of our study is the absence of further experimentation to confirm the
mechanism by which CYP3A4 and P-gp protein are decreased in the setting of CD.
Other studies have shown a decrease in mRNA, suggesting that the change is reflective of
changes in gene expression19, 21; however, further study is needed to evaluate the
contribution of other factors such as RNA polymerase recruitment, histone acetylation
and methylation, the binding of transcription factors as well as a diverse range of possible
epigenetic modifications.
Our data re-enforce the principal that age and disease appear to affect CYP3A4
expression, but highlight the specific impact on intestinal CYP3A4 rather than on hepatic
CYP3A4. We show that CD independently and negatively affects CYP3A4 expression in
the ileum and colon. Moreover, we show that CYP3A4 varies with age. Our data
support an age-related decline in ileal CYP3A4 expression in our control cohort. The
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literature, though inconsistently, demonstrates a similar decrease in hepatic and total
body CYP3A4 with age34-36. Interestingly, we see an increase in ileal CYP3A4
expression with age in our CD cohort. The reasons for this remain unexplained.
Colonic P-gp expression declined with age in both the CD and non-CD cohorts.
The effect of age on intestinal P-gp expression is not well-studied. Decreases in the
endothelial expression of P-gp at the blood-brain barrier are documented in Alzheimer's
disease31, 32. It is unclear if this is secondary to the aging process or related to
pathophysiologic changes of the disease.
There are several hypotheses to explain the decrease in hepatic CYP3A4 activity
and/or expression seen in disease states such as acute infection, cancer, liver and kidney
disease. It is has been proposed that during an acute inflammatory process, hepatic
CYP3A4 is down-regulated due to the effects of IL-1𝛽, IL-6, TNF-α, and IFN-α and 𝛾37,
38

. Intestinal CYP3A4 may likewise be down-regulated. Other theories pertain to

disease-dependent changes in the activation of nuclear receptor (NR) such as the
farnesoid X receptor or the pregnane X receptor. These transcription factors and master
regulators of homeostasis control transcription of CYP3A4 and are increasingly shown to
be relevant to and changed in those affected by IBD24, 39-42. This may have important
consequences for intestinal CYP3A4 expression. Specific to intestinal CYP3A4,
disruption of the intestinal mucosa by the discontinuous, transmural inflammatory
changes of CD may also be a contributor to altered CYP3A4 expression; however, our
data do not support differential CYP3A4 protein expression based on CD activity or
location.
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Overall, reasons for the molecular changes in the intestinal epithelium of CD
patients may extend beyond the presence or absence of active inflammation and may be
due to the inherent changes in the host's physiology that predispose them to this
condition. Here, we see that CYP3A4 protein expression is appreciably different in the
setting of endoscopically normal intestinal tissue irrespective of disease activity.
Langmann et. al. (2004) showed that MDR1 mRNA coding for P-gp was reduced to the
same degree in inflamed and non-inflamed UC colonic samples 24. It was proposed that
that loss of P-gp function may be an initiating factor pre-disposing to the development of
chronic intestinal inflammation, rather than being a consequence of it. P-gp is colocalized in the enterocyte with CYP3A4; it is concentrated at the enterocyte brush
border with CYP3A4 found below in the cytoplasmic endoplasmic reticulum. CYP3A4
and P-gp share many substrates, inducers and inhibitors7. They are hypothesized to act in
a coordinated manner in the determination of the disposition of their shared endogenous
and exogenous substrates, playing a key role in detoxification and intestinal barrier
function43, 44. Therefore, one could surmise that changes in CYP3A4 expression (similar
to P-gp) could predispose to CD rather than be a downstream effect of its presence.
Further studies are needed to explore these theories.
In conclusion, these data emphasize the loss of expression of CYP3A4 and P-gp
in the CD gastro-intestinal tract. This appears to be independent of disease activity and
location, highlighting a possible role for CYP3A4 and P-gp in CD pathogenesis and
disease predisposition. Replication of this study, as well as assessment of protein
activity, in a larger patient population would be useful in further elucidating the impact of
altered enzyme expression on drug response in CD as well as disease pathogenesis.
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5
GENETIC VARIATION IN CYP3A4-REGULATOR
FXR PREDICTS SEVERITY OUTCOMES IN CROHN'S
DISEASE
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5.1

Introduction
Crohn's disease (CD) is an autoimmune inflammatory bowel disease defined by

remitting and relapsing episodes of intestinal inflammation1.
complex.

CD pathogenesis is

Dysregulation of the host immune response in the setting of specific

environmental and genetic factors are hypothesized to serve as disease precursors1-5. A
key component of this inappropriate immune response is the disruption of the mucus
layer, loss of epithelial tight junctions and increased intestinal permeability and thereby
an increase in the intestinal immune system's exposure to bacteria, resulting in an
immune response via its innate and adaptive arms2-4. Furthermore, there is a shift in
production from anti-inflammatory proteins to pro-inflammatory cytokines through the
activation of nuclear transcription factors such as nuclear factor κB (NFκB)6. Early in its
course, CD is remitting and relapsing, with periods of activity punctuated by debilitating
symptoms of abdominal pain, diarrhea, and weight loss as well as biochemical and
endoscopic findings of inflammation. As the disease progresses over time, permanent
damage to the intestinal structure may result, leading to an irreversible impairment of
intestinal function, significant morbidity and long-term disability. Disease severity is
marked by the need for and time to surgery, failure of multiple medical therapies, need
for hospitalization and the presence of complications such as fistulas or strictures7.
Many studies have attempted to link genetic variation in key genes associated
with inflammation, xenobiotic metabolism and transport as well as gene regulators of
such pathways to CD susceptibility. Several single nucleotide polymorphisms (SNPs) in
the multi-drug resistance-1 (MDR1) gene, the pregnane X receptor (PXR, NR1I2) gene
and to a lesser extent the farnesoid x receptor (FXR, NR1H4) gene have been evaluated
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and some linked to IBD susceptibility with varying degrees of success 8-14; however, none
have emerged as a clinically translatable marker of IBD presence, drug response or
disease severity.
There is now an increasing appreciation of the bile acid-sensing nuclear receptor,
FXR, as the master regulator of bile acid homeostasis and transport pathways, intestinal
inflammation, intestinal permeability and response to bacterial overgrowth

6, 15, 16

. FXR

is also an important regulator of drug metabolism sequences, with the ability to activate
key cytochrome P450 (CYP) family isoform 3A4 directly and indirectly via the pregnane
X receptor17, 18. Interestingly, the expression and activity of CYP3A4 is altered in CD,
though this has not been conclusively linked to CD-related changes in FXR activity19, 20.
In vivo models confirm that in the absence of FXR activation, there is an expansion of the
bile acid pool and a more severe presentation of chemically-induced colitis, including
increased intestinal cellular infiltrate, collagen deposition and expression of inflammatory
genes. FXR activation modulates fibroblast growth factor (FGF) 19 expression, and
plasma FGF19 concentrations have been used as a surrogate marker of FXR activity 21, 22.
Moreover, FXR agonism in these same models improves intestinal permeability and
attenuates the production of pro-inflammatory cytokines such as IL-1β and TNFα via the
nuclear factor κB (NFκB) pathway6,

15

.

Defects in the epithelial barrier are well-

documented in CD and may contribute to disease onset and progression

4, 23, 24

. There is

data to support a decrease in FXR activity and expression in CD14, 25, 26.
Our group was the first to identify and demonstrate that a SNP adjacent to the
ATG start codon, in a sequence known as the Kozak consensus motif, in FXR (NR1H4), 1G>T, is linked to reduced transactivation of FXR gene targets27. Conservation of the
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Kozak consensus motif is necessary to ensure ribosomal binding to mRNA transcripts
and efficient protein translation28. Genetic variation in the Kozak motif is associated with
decreased protein translation28. Van Mil et.al. (2007) demonstrated that the FXR1-1G>T
SNP is associated with reduced FXR protein expression as well as decreased activation of
its down-stream targets, citing translational inefficiency as the underlying cause29. Thus,
despite being in a non-coding region of the FXR gene, the FXR-1G>T SNP may have
important functional consequences. Interestingly, SNPs in FXR tend to be rare, although
they have been documented in FXR-deficiency, which presents as a more severe form of
progressive familial intrahepatic cholestasis (PFIC), associated with coagualopathy,
jaundice and a rapid progression to liver failure

30, 31

. These data suggest major loss of

function mutations in FXR as contributors to CD are unlikely; however, partial loss of
function or expression of FXR due to changes in translational efficiency may contribute
to CD progression or severity. To date, the role of FXR-1G>T SNP has not been
evaluated in a CD population.
Accordingly, we hypothesize that changes in the intestinal barrier regulated
through reduced FXR expression among those who harbor the FXR-1G>T SNP are more
likely to exhibit a severe CD phenotype including a more rapid progression to surgery.
Alterations in FXR activity may in part be secondary to genetic variation in the FXR
gene. In this study, we demonstrate the impact of FXR-1G>T SNP on a CD population
in comparison to genetic variation in PXR and MDR1.
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5.2

Materials And Methods

5.2.1 Subjects
This study was conducted in two parts: in the first phase, a retrospective, single
centre, cohort study was carried out in 198 patients with CD, being seen as part of the
Personalized Medicine Program at Western University, London Canada between March
2013 and 2015.

The aim was to evaluate the utility of FXR-1G>T as a genomic

biomarker of severity in CD. In the second phase, a separate cohort of patients with CD
(n=188) were retrospectively screened for the FXR-1G>T genotype between November
2015 and June 2017 to validate the findings of the first phase.

The cohorts were then

pooled for further analysis (n= 386). In addition, all subjects were screened for MDR1
3435C>T and PXR -25385C>T. A subset of subjects underwent plasma FGF19 and
plasma bile acid profile determination. Subjects from each cohort provided written,
informed consent. Eligible subjects were more than 18 years of age. All subjects had a
histopathological diagnosis of CD. Subjects were excluded if information pertaining to
their medical history was unavailable or unknown or if they had a diagnosis of ulcerative
colitis. Each subject provided one blood sample. The study protocol was approved by
the Western University Health Sciences Research Ethics Board (15586).

5.2.2 Demographic and Covariate Data Abstraction
Data collected on subjects from both cohorts included age, sex, weight, smoking
history, medical history, duration of disease as well as CD medication exposures and
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responses (adverse drug reactions (ADRs), induction of remission, resistance or loss of
response). Data relevant to their CD diagnosis was also collected including disease
phenotype, disease activity (based on the clinical scoring index, Harvey-Bradshaw Index,
HBI) at the time of blood collection, hospitalizations, and history of and time to surgical
resection. This information was collected from patient records between the date of
diagnosis and the study end period (cohort 1, March 30, 2015 and cohort 2, June 1,
2017).

5.2.3 Genotypic Analysis
DNA was extracted from whole blood using a standard DNA extraction protocol
(MagNA Pure Compact System, Pleasanton California, USA). Allelic discrimination
using TaqMan assays and a 7500 RT-PCR System (Applied Biosystems, Carlsbad
California, USA) was used to determine the presence of the variant, FXR (NR1H4) 1G>T (rs56163822) in CD subjects with available DNA (n=386) as well as the variants,
MDR1 3435C>T (rs1045642) and PXR (NR1I2) -25385C>T (rs3814055). Genotyping
experiments included three positive controls and one negative control. Five percent of
samples were genotyped in duplicate. Congruency was seen amongst all duplicated
genotypes.
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5.2.4 Fibroblast Growth Factor 19 Quantification
Blood samples were drawn from study subjects and plasma was extracted by
centrifugation. A commercial enzyme-linked immunosorbent assay (ELISA) kit (FGF19
Quantikine ELISA kit, category no. DF1900; R&D Systems, Minneapolis, MN, US) was
used for the colorimetric detection and estimation of FGF19 plasma concentrations
following the manufacturer's instructions for subjects with available plasma samples who
underwent surgical intervention (n=137). All plasma aliquots as well as the standard
curve (0pg/ml-1000pg/ml) were assayed in duplicate.

5.2.5 Bile Acid Profile Determination
Plasma stored at -80◦C was used for quantification of 12 bile acids (cholic
acid, CA; chenodeoxycholic acid, CDCA; deoxycholic acid, DCA; glycocholic acid,
GCA; glycochenodeoxycholic acid, GCDCA; glycodeoxycholic acid, GDCA; lithocholic
acid, LCA; taurocholic acid, TCA; taurodeoxycholic acid, TDCA; taurolithicholic acid,
TLCA; tauroursodeoxycholic acid, TUDCA; and ursodeoxycholic acid, UDCA) using
high performance liquid chromatography/mass spectrometry (LC-MS/MS). Taurocholic
acid-d5 (TCA-D5) was used as an internal standard (I.S). A standard curve of 1nM to
40µM was generated. Patient samples were homogenized by vortexing for 15 minutes at
4 °C @1400 RPM and incubated at -20°C for 20 minutes. Samples were centrifuged at
maximum speed at 4°C for 30 minutes. Finally, 100µL of supernatant was transferred to
vials and 80µL was injected into the LC-MS/MS system.
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A two-dimensional LC system was used (Agilent HILIC plus column (4.6*50)
3.5µm followed by Phenomenex 00B-4462-Y0 Kinetex 2.6u C18 100A (3.0*50)). A
gradient elution technique was employed using the Agilent 1290 system. Mobile phase A
consisted of 2mM ammonium acetate (pH 4.15) with 10% acetonitrile. Mobile phase B
consisted of acetonitrile: isopropyl-alcohol with water. The columns' temperatures were
maintained at 60°C. Samples were eluted at a flow rate of 0.6ml/min to 1.4ml/min (0.112 minutes). Before injection of the subsequent sample, columns were cleaned with
100% mobile phase B for one minute and returned to a linear equilibrium for 7 minutes
for a total run of 20 minutes for each sample. Mass detection occurred on a TSQQuantum Ultra mass spectrometer equipped with HESI source and operated in negative
mode (4500 v spray voltage, 350°C vaporizing temperature, 45 sheath gas pressure, 15
auxiliary gas pressure and 350 °C capillary temperature).

5.2.6 Study Objectives and Outcomes
The objective of this study was to test the hypothesis that the FXR-1GT genotype
is a predictor of disease severity in CD. The primary endpoints were the rate of surgery
and time to surgery in subjects with an FXR-1GG genotype versus subjects with a -1GT
genotype. Secondary outcomes included other indicators of severity such as number of
flares, number of hospitalizations and number of failed medications all standardized to
per-year of CD diagnosis.

Other endpoints included determination of the plasma

concentration of FGF19 in these two genotypic populations suggesting a mechanism by
which FXR-1G>T is influencing intestinal barrier integrity. Moreover, we evaluated the
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rate of surgery, time to surgery, flares, hospitalizations and number of failed medications
amongst wild type and variant carriers of the MDR1 3435C>T (rs1045642) and PXR 25385C>T (rs3814055) as well as evaluated the plasma bile acid profile in subjects with
a the heterozygous variant genotype (FXR-1GT) versus sex-, age- and weight-matched
controls (FXR-1GG, wildtype).

5.2.7 Statistical Analysis
Statistical analysis was performed using Graphpad Prism, R, and SPSS statistical
software. Allele frequency distribution for the FXR -1G>T, MDR1 3435C>T and PXR
25385 genotypes were tested for Hardy-Weinberg equilibrium using a χ2 goodness-of-fit
test. A Cox proportional-hazards regression model with or without adjusting covariates
was used to assess the influence of FXR-1T, MDR1 3435T and PXR -25385T variant
carrier status on the time to first surgical resection for the total population, males and
females and hazard ratios (HR) were expressed with 95% confidence intervals (CI). Risk
of surgery associated with FXR-1T, MDR1 3435T and PXR -25385T variant carrier status
was evaluated using a logistic model with and without adjustment and are expressed as
odds ratios (OR) with 95%CI. Covariates that were considered included the following:
PXR-25385C>T genotype, MDR13435C>T genotype, exposure to combined therapy
with an immunosuppressant and biologic, any biologic, methotrexate, glucocorticoid or
thiopurine exposure, biologic failure32 (defined as development of an ADR requiring
cessation of the biologic; primary non-response: a lack of improvement in clinical
symptoms with induction therapy as defined by their treating physician; or loss of
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response: a recurrence in disease activity during maintenance therapy despite an adequate
response to induction dosing as defined by the treating physician), any drug failure,
hospitalizations, smoking history, duration of disease, pre-operative biologic exposure,
and time to biologic exposure. A final model was constructed for the total population as
well as stratified by sex, adjusting for FXR-1G>T genotype, age, weight and other,
aforementioned covariates.
To test the hypothesis of an association between the FXR -1G>T SNP and a
decrease in downstream products of the FXR gene, a Welch's t-test was used to compare
FGF-19 plasma concentrations between genotype groups (FXR -1G>T variant carriers
versus wild-type) within the surgical cohort (n=137). A p-value ≤0.05 was considered
significant.

A multiple linear regression analysis was used to further evaluate the

relationship between FXR-1T carrier status, other covariates and the inter-individual
variation in FGF-19 plasma concentrations (natural log-transformed) in participants who
underwent a surgical intervention. The analysis was performed for the total population as
well as stratified by sex. Other covariates assessed included the following: age, weight,
disease activity, and disease location. Lastly, mean plasma concentrations for the 12
previously referenced bile acids were compared between FXR-1G>T variant carriers
(FXR-1GT, n= 22) and age- and sex-matched wild type individuals (FXR-1GG) in a 2:1
ratio using a Student's t-test. A p-value ≤0.05 was considered significant.
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5.3

Results

5.3.1 Study Population
Baseline characteristics for all participants are presented in Table 5.1.

Five

hundred and eighty-seven individuals with a diagnosis of inflammatory bowel disease
(IBD) were screened at the time of visit to the Personalized Medicine Clinic. Individuals
with a diagnosis of UC were excluded (n=201).

Three hundred and eighty-six

participants with CD were included in the final analyses (cohort 1, n= 198; cohort 2, n=
188) of which 137 participants had undergone an intra-abdominal surgical intervention
for their CD. The rate of surgery increased with duration of diagnosis (1-year, 11.14%;
5-year, 23.32%; and 10 years after diagnosis, 29.53%). The most common indication for
surgery was stricturing disease (GG, n = 61; GT, n = 8) followed by fistulizing disease
(GG, n = 34; GT, n = 4). Surgical interventions included small bowel or ileocolic
resections with primary anastomosis and total colectomies with formation of an
ileostomy.

Table 5.2 summarizes the demographic data for subjects undergoing a

surgical intervention.

Table 5.3 summarizes the demographic data for subjects not

undergoing a surgical intervention.
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Table 5.1: Demographic Characteristics of Patients in Cohort 1 and Cohort 2
Variables
Age, years (mean, range)
Female sex (%)
Weight, kg (mean ± std)
Disease location
Ileal
Colonic
Ileo-colonic
Disease duration, years
(mean ± std)
Smoking history (%)
Biologic exposure (%)
Anti-TNF (%)
Anti-integrin (%)
Anti-IL12/23 (%)
Combination therapy (%)
Glucocorticoid exposure (%)
Immunomodulator
exposure
MTX (%)
Thiopurine (%)
Surgery (%)
Mean number of surgeries
(mean ± std)
Hospitalizations (mean ±
std)
FXR -1GT carrier status
(%)
FXR -1GG carrier status
(%)

Cohort 1
(n =198)
43.04 (18-85)
119 (60.1)
77.06 ± 18.43

Cohort 2
(n = 188)
41.55 (18-80)
115 (61.2)
76.64 ± 20.38

Total population
(n= 386)
42.31 (18-85)
234 (60.6)
76.81 ±19.42

75 (37.9)
36 (18.2)
87 (43.9)
9.63 ± 10.36

60 (31.9)
39 (20.7)
89 (47.3)
9.11 ± 10.01

135 (35.0)
75 (19.4)
176 (45.6)
9.37 ± 10.18

63 (31.8)
81(40.1)
81 (40.1)
0 (0)
0 (0)
68 (34.2)
157 (79.2)

36 (19.1)
102 (54.3)
93 (49.5)
13 (6.9)
10 (5.3)
83 (44.1)
105 (55.8)

99 (25.6)
183 (47.4)
136 (35.2)
13 (3.4)
10 (2.6)
151 (39.1)
262 (67.9)

50 (25.2)
131(66.1)
62 (31.3)
0.51 ± 0.99

39 (20.7)
122 (65.0)
75 (40.0)
0.67 ± 1.22

89 (23.1)
253 (65.5)
137 (35.5)
0.59 ± 1.11

0.92 ± 1.67

1.42 ± 2.64

1.17 ± 2.22

7 (3.5)

15 (8.0)

22 (5.7)

191 (96.4)

173 (92.0)

364 (94.3)

Kilograms, kg; standard deviation, std; Crohn's disease, CD; tumor necrosis factor, TNF; interleukin, IL; methotrexate,
MTX; farnesoid X receptor, FXR
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Table 5.2: Demographic Characteristics of CD Patients Undergoing Surgical
Intervention by FXR -1G>T Genotype
Variables
Age, years (mean, range)
Female sex (%)
Weight, kg (mean ± std)
Disease location
Ileal
Colonic
Ileo-colonic
Duration of disease, years
(mean ± std)
Smoking history (%)
Biologic exposure (%)
Anti-TNF (%)
Anti-integrin (%)
Anti-IL12/23 (%)
Pre-operative biologic
exposure (%)
Combination therapy (%)
Glucocorticoid exposure (%)
Immunomodulator exposure
MTX (%)
Thiopurine (%)
Number of surgeries (mean ±
std)
Time to first surgical
intervention, years (mean ±
std)
Hospitalizations (mean ± std)

FXR -1GG
n = 124
44.84 (19-85)
59 (47.6)
76.23 ± 17.46

FXR-1GT
n = 13
40.15(20-70)
12 (92.3)
71.09 ± 20.53

38 (30.6)
22 (17.7)
64 (51.6)
16.29 ± 12.10

1 (7.7)
1 (7.7)
11 (84.6)
14.67 ± 12.50

39 (31.4)
62 (50.0)
51 (41.1)
6 (4.8)
5 (4.0)
27 (21.8)

0 (0)
8 (61.54)
5 (38.46)
1 (7.69)
3 (23.08)
4(30.77)

43 (34.7)
104 (83.8)

3 (23.08)
13 (100)

32 (25.8)
79 (63.7)
1.60 ± 1.31

5 (38.46)
7 (53.85)
1.85 ± 1.07

5.99 ± 6.94

1.56 ± 2.08

2.31 ± 2.81

2.62 ± 1.85

Farnesoid X receptor, FXR; kilograms, kg; standard deviation, std; Crohn's disease, CD; tumor necrosis factor, TNF;
interleukin, IL; methotrexate, MTX
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Table 5.3: Demographic Characteristics of CD Patients Who Did Not Undergo
Surgical Intervention by FXR -1G>T Genotype
Variables
FXR -1GG
FXR-1GT
n =240
n=9
41.04 (18-80)
36.44(18-60)
Age, years (mean, range)
153 (63.8)
1 (11.1)
Female sex (%)
77.28 ± 20.31
88.41 ± 16.54
Weight, kg (mean ± std)
Disease location
90 (37.5)
2 (22.2)
Ileal
56 (23.3)
2 (22.2)
Colonic
94 (39.2)
5 (55.6)
Ileo-colonic
5.63 ± 6.66
5.92 ± 6.92
Duration of disease, years
(mean ± std)
37 (15.4)
3 (33.3)
Smoking history (%)
103 (42.9)
6 (66.7)
Biologic exposure (%)
94 (39.2)
6 (66.7)
Anti-TNF (%)
7 (2.9)
0 (0)
Anti-integrin (%)
2 (0.8)
0 (0)
Anti-IL12/23 (%)
30 (12.5)
2 (22.2)
Combination therapy (%)
187 (77.9)
6 (66.7)
Glucorticoid exposure (%)
Immunomodulator exposure
44 (18.3)
3 (33.3)
MTX (%)
159 (66.3)
5 (55.6)
Thiopurine (%)
0.57 ± 1.64
0±0
Hospitalizations (mean ± std)
Farnesoid X receptor, FXR; kilograms, kg; standard deviation, std; Crohn's disease, CD; tumor necrosis factor, TNF;
interleukin, IL; methotrexate, MTX

172

5.3.2 FXR-1G>T Predicts Surgery Risk and Early Progression to Surgery
Most Significantly in Women
All subjects underwent genotyping for the SNP FXR (NR1H4) -1G>T. The minor
allele (-1T) frequency was 2.8% in the total cohort. FXR-1G>T was in Hardy-Weinberg
equilibrium. Genotype frequencies classified by the presence or absence of surgery are
displayed in Figure 5.1. There was a strong association between carriers of the variant T
allele and surgical intervention (odds ratio, OR=2.78, 95%CI=1.16-6.69, p=0.02) (Figure
5.1a). However, this association did not remain (OR=2.21, 95%CI=0.65-7.50, p=0.20)
with adjustment for covariates such as age, sex, weight, smoking history, drug exposures,
hospitalizations, use of combination therapy or drug failures.
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Figure 5.1 Genotype frequency separated by the presence or absence of an intra-abdominal
surgical intervention related to the CD diagnosis for all subjects (A), female subjects (B), and
male subjects (C). Genotypes are expressed as a percentage of the total population of study
subjects undergoing surgery (n=137) or not undergoing surgery (n=249). *, p <0.05, **, p <0.01,
***, p <0.001. Crohn's disease, CD; farnesoid X receptor, FXR; number, n.
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FXR-1T variant carriers were more likely to go on to an early surgical
intervention compared to wild type individuals (combined cohorts, 5.99 years ± 6.94
versus 1.56 years ± 2.08; hazard ratio, HR=2.75, 95%CI=1.55-4.90, p < 0.001) (Figure
5.2).
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Figure 5.2 Time to first surgery following the diagnosis of CD stratified by FXR-1G>T
genotype expressed as wild type (GG) or variant (GT) for individuals in cohort 1 (A),
cohort 2 (B), and the combined cohorts (C). *, p <0.05, **, p <0.01, ***, p <0.001.
Crohn's disease, CD; farnesoid X receptor, FXR.
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FXR -1T remained significant (p=0.002) as an independent predictor of early progression
to surgical intervention in CD in a Cox proportional-hazards regression model with
adjusting covariates. Covariates included in the model were: age, sex, weight, smoking
history, number of drugs or biologics failed, hospitalizations, glucocorticoid, thiopurine
and methotrexate exposure, combination therapy (biologic with an immunomodulator)
and pre-operative biologic exposure. (Table 5.4, Figure 5.3).
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Table 5.4: Cox regression for the effects of covariates on time to surgical
intervention in a CD cohort (n = 386)
Covariate

Hazard Ratio

P-value

2.70
1.00
0.87
1.00
0.77
1.12
2.68

95% Confidence
interval
1.45 – 5.02
0.99 – 1.01
0.60 – 1.26
0.99 – 1.01
0.51 – 1.17
1.07 – 1.11
1.49 – 4.83

FXR-1T carrier status
Age (years)
Sex
Weight (kg)
Smoking history
Hospitalizations
Exposure to
glucocorticoids
Exposure to
methotrexate
Exposure to
thiopurines
Exposure to
combination therapy
Number of drugs
failed
Number of biologics
failed
Exposure to biologics
pre-operatively

0.79

0.49 – 1.25

0.31

0.87

0.58 – 1.31

0.51

1.12

0.68 – 1.83

0.67

0.69

0.53 – 0.89

0.004

1.76

1.22 – 2.53

0.003

2.10

1.33 – 3.30

0.001

0.002
0.80
0.47
0.48
0.22
<0.001
<0.001
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FXR -1T Carrier
Combination Therapy
Pre-operative Biologic
Biologic Failed
No. of Drugs Failed
Thiopurine Exposure
MTX Exposure
Glucocorticoid Exposure
No. of Hospitalizations
Smoking History
Weight
Sex
Age
0.125

0.25

0.5

Favours delayed surgery

1

2

4

8

Favours early surgery

Figure 5.3 HR estimates with the corresponding 95%CI for the evaluation of
demographic, medication exposures/responses and FXR-1G>T genotype and the impact
on time to first surgery. The HR estimate of each variable is marked with solid black
square. The 95%CI is represented by the horizontal T-line through the square. The
horizontal axis is plotted on a log scale. Hazard ratio, HR; confidence interval, CI;
farnesoid X receptor, FXR; number, No.; methotrexate, MTX.
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Most significantly, when data were stratified based on sex, the association
between carriers of the variant T allele and risk of surgical intervention and early
progression to surgical intervention was strongest and most striking in women on simple
linear regression analysis (risk of surgery, OR=27.46 95%CI=2.28-330.50, p=0.01;
progression to surgery, HR=9.08, 95%CI=4.72-17.48, p < 0.0001) (Figure 5.1b, Figure
5.4) and with adjustment for covariates (risk of surgery, OR= 23.65, 95%CI=1.83-304.74
p≤0.05; progression to surgery, HR=6.15, 95%CI=2.82-13.42, p < 0.0001) (Table 5.5).
Of the FXR-1GT carriers going on to surgery, 92.1% were women compared to the FXR1GG carriers (47.6%) (Table 5.2).

Conversely in men, FXR genotype was not

significantly associated with risk or time to surgery on simple linear regression analysis
(risk of surgery, OR=0.18, 95%CI=0.02-1.5, p=0.11; progression to surgery, HR=0.27,
95%CI= 0.04-1.94, p=0.19) or multiple linear regression analysis (risk of surgery,
OR=0.27, 95%CI=0.03-2.85, p=0.28; progression to surgery, HR=0.41, 95%CI=0.053.21, p=0.40).
Other indicators of severity evaluated included: number of drugs failed, number
of surgeries, hospitalizations, number of flares. There was no difference between FXR1G>T genotypes in any of these parameters of severity, even when adjusting for weight,
age, sex and disease duration.
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Figure 5.4 Time to first surgery following the diagnosis of CD stratified by FXR-1G>T
genotype expressed as wild type (GG) or variant (GT) and female sex in cohort 1 (A),
cohort 2 (B), and the combined cohorts (C). *, p <0.05, **, p <0.01, ***, p <0.001.
Crohn's disease, CD; farnesoid X receptor, FXR
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Table 5.5: Cox regression for the effects of covariates on time to surgical
intervention in a female CD cohort (n =234)
Covariate

Hazard Ratio

P-value

6.15
1.00
1.00
1.01
1.15
2.90

95% Confidence
interval
2.82 – 13.42
0.98 – 1.02
0.98 – 1.01
0.58 – 1.76
1.06 – 1.25
1.22 – 6.89

FXR-1T carrier status
Age (years)
Weight (kg)
Smoking history
Hospitalizations
Exposure to
glucocorticoids
Exposure to
methotrexate
Exposure to
thiopurines
Exposure to
combination therapy
Number of drugs
failed
Number of biologics
failed
Exposure to biologics
pre-operatively

0.95

0.52 – 1.73

0.86

1.05

0.61 – 1.82

0.86

1.41

0.70 – 2.83

0.34

0.61

0.43 – 0.88

0.008

1.87

1.15 – 3.02

0.011

1.24

0.68 – 2.26

0.47

<0.001
0.85
0.79
0.98
<0.001
0.016
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5.3.3 Genetic Variation in PXR and MDR1 is not Associated with a Severe
CD phenotype
Additionally, all subjects were screened for the SNPs, MDR1 3435C>T and PXR
-25385C>T. Minor allele frequencies were 53.7% and 40.2% respectively. Overall,
there was no significant association between either SNP and risk of (Figure 5.5) or time
to surgical intervention (Figure 5.6-5.8). In cohort 1, male carriers of PXR -25385T
progressed to surgery more quickly than wild type men (HR=3.95, 95%CI=1.54-10.15);
however, this was not confirmed in cohort 2 nor in analysis of the combined cohort.
Furthermore, there was no significant association between either SNP and other
indicators of CD severity (number of drugs failed, number of surgeries, hospitalizations)
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Figure 5.5 Genotype frequency for MDR1 3435C>T (panel 1) and PXR -25385C>T
(panel 2) separated by the presence or absence of an intra-abdominal surgical intervention
related to the CD diagnosis for all subjects (A), female subjects (B), and male subjects
(C). Genotypes are expressed as a percentage of the total population of study subjects
undergoing surgery (n=137) or not undergoing surgery (n=249). Multi-drug resistance
protein 1, MDR1; pregnane X receptor, PXR.
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Figure 5.6 Time to first surgery following the diagnosis of CD stratified by MDR1
3435C>T (panel 1) and PXR -25385C>T (panel 2) genotype expressed as wild type (CC)
or variant (CT or TT) for individuals in cohort 1 (A), cohort 2 (B), and the combined
cohorts (C). Multi-drug resistance protein 1, MDR1; pregnane X receptor, PXR; wild
type (WT).
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Figure 5.7 Time to first surgery following the diagnosis of CD stratified by MDR1
3435C>T genotype expressed as wild type (CC) or variant (CT or TT) for women in
cohort 1 (A), cohort 2 (B), and the combined cohorts (C) and for men in cohort 1 (D),
cohort 2(E) and the combined cohorts (F). Multi-drug resistance protein 1, MDR1; wild
type (WT).
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Figure 5.8 Time to first surgery following the diagnosis of CD stratified by PXR 25385C>T genotype expressed as wild type (CC) or variant (CT or TT) for women in
cohort 1 (A), cohort 2 (B), and the combined cohorts (C) and for men in cohort 1 (D),
cohort 2(E) and the combined cohorts (F). Pregnane X receptor, PXR; wild type (WT).
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5.3.4 FXR-1G>T is a Determinant of FGF19 Plasma Concentrations in
Women
Another objective of this study was to evaluate FGF19 plasma concentrations in
FXR-1G>T wild type and variant allele carriers. FGF19 plasma concentrations were
lower in FXR -1GT variant carriers, though this did not achieve statistical significance on
bivariate analysis (GG = 0.35pg/L±0.04pg/L; GT = 0.23pg/L ±0.05pg/L , p=0.215)
(Figure 5.9a) or multiple linear regression analysis (natural log transformed FGF19
plasma concentrations, Table 5.6). Furthermore, the multiple linear regression analysis
only accounted for 6.5% of the inter-individual variation in FGF19 plasma
concentrations.
Interestingly, when stratified by sex, women with an FXR-1GT genotype had a
two-fold lower FGF-19 plasma concentration (p≤0.05) compared to women with a wild
type genotype on univariate and multivariate analyses (Figure 5.9, Table 5.7). This was
not seen in the male population.
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Table 5.6 Multiple linear regression model for the effect on Ln-transformed FGF-19
plasma concentration for all subjects (n = 137, adjusted R2=0.065)
Variable
Intercept
FXR -1T carrier
status
Age
Female Sex
Weight
Small bowel
resection or disease

β-coefficients
-1.748
-0.476

Standard error
0.635
0.345

P-value
0.007
0.170

-0.002
0.317
0.006
-0.516

0.007
0.208
0.006
0.274

0.787
0.130
0.236
0.062

Table 5.7 Multiple linear regression model for the effect on Ln-transformed FGF-19
plasma concentration for females (n = 74)
Variable
Intercept
FXR -1T carrier
status
Age
Weight
Small bowel
resection or disease

β-coefficients
-1.287
-0.714

Standard error
0.738
0.367

P-value
0.086
0.050

-0.003
0.001
0.054

0.009
0.007
0.274

0.693
0.897
0.062
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Figure 5.9 The mean FGF-19 plasma concentrations stratified by FXR-1G>T genotype,
GG or GT for the total population (A) and for women (B).

Median values (thick

horizontal line), 25th and 75th percentile values (box outline), minimum and maximum
values (whiskers), and outlier values (circles). Fibroblast growth factor 19, FGF-19;
farnesoid X receptor, FXR.
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5.3.5 The Bile Acid Profile is not Significantly Altered in FXR-1GT
Carriers
Plasma bile acid profiles were constructed for all subjects who carried the variant
FXR-1T allele (n=22). Similarly, a plasma bile acid profile was generated for age-, sexand weight-matched wild type (FXR-1GG) subjects (n=40) (Table 5.8). There was no
significant difference in the total plasma bile acid pool, the ratio of primary to secondary
bile acids or the ratio of unconjugated to conjugated bile acids (Figure 5.10) based on
FXR-1G>T genotype. Furthermore, there was no significant difference in any of the
individual bile acids between FXR-1G>T genotypes, with the exception of GDCA
(Figure 5.11). FXR-1T carriers had an increased concentration of GDCA compared to
wild-type subjects (p= 0.003).
stratified by sex.

No difference was seen in bile acid profiles when
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Table 5.8: Bile acid profiles
Plasma Bile acids
CDCA
G-CDCA
Total
CA
G-CA
T-CA
Total
Secondary DCA
bile acids G-DCA
T-DCA
plus
conjugates Total
LCA
T-LCA
Total
Tertiary UDCA
bile acids T-UDCA
plus
Total
conjugates
Total bile acids
Primary
Bile acids
plus
conjugates

FXR-1GG (n=40)
ng/ml
%
8.5
436.3
2075.7
37.6
2522.0
56.1
103.6
2.2
277.1
5.0
39.2
1.3
419.9
8.5
168.2
4.1
1961.4
27.7
141.6
3.4
2271.2
35.2
108.6
3.2
12.8
0.2
121.4
3.4
354.5
6.7
1.9
0.1
356.4
6.8

FXR-1GT (n=22)
ng/ml
%
421.6
8.6
2665.3
48.8
3086.9
57.4
195.4
3.3
371.2
6.6
43.6
1.0
610.2
10.9
118.4
1.8
1335.9
15.0
131.2
2.5
1585.5
19.3
57.1
1.3
31.1
0.6
88.2
1.9
492.7
10.5
3.1
0.0
495.8
10.5

5681.1

5866.4

*Plasma bile acid are represented as a percentage of the total bile acid pool
Cholic acid, CA; chenodeoxycholic acid, CDCA; deoxycholic acid, DCA; glycocholic acid, GCA;
glycochenodeoxycholic acid, GCDCA; glycodeoxycholic acid, GDCA; lithocholic acid, LCA; taurocholic acid, TCA;
taurodeoxycholic acid, TDCA; taurolithicholic acid, TLCA; tauroursodeoxycholic acid, TUDCA; and ursodeoxycholic
acid, UDCA.
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Figure 5.10 The mean total plasma bile acid concentrations (ng/ml) (A), the ratio of
primary to secondary mean bile acid concentrations (B) and the ratio of mean
unconjugated to conjugated bile acids (C) stratified by FXR-1G>T genotype expressed as
wild type (GG) or variant (GT) for the total population of subjects with CD. The 95%CI
is represented by the vertical T-line. Crohn’s disease, CD; farnesoid X receptor, FXR;
bile acid, BA.
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Figure 5.11 The mean individual bile acid profiles expressed as mean concentrations in ng/ml
(A) and as a percentage of the total bile acid pool, stratified by FXR-1G>T genotype expressed as
wild type (GG) or variant (GT). The 95%CI is represented by the vertical T-line. Cholic acid,
CA; chenodeoxycholic acid, CDCA; deoxycholic acid, DCA; glycocholic acid, GCA;
glycochenodeoxycholic acid, GCDCA; glycodeoxycholic acid, GDCA; lithocholic acid, LCA;
taurocholic acid, TCA; taurodeoxycholic acid, TDCA; taurolithicholic acid, TLCA;
tauroursodeoxycholic acid, TUDCA; and ursodeoxycholic acid, UDCA.
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5.4

Discussion
FXR is an important determinant of intestinal barrier function, inflammatory

response and drug metabolism. In this study, we are able to demonstrate an important
role for a genetic variation adjacent to the ATG start codon of the bile acid sensing
nuclear receptor, FXR, as a predictor of CD progression to surgical intervention (Figure
5.2). Remarkably, FXR-1T variant carrier status remains an independent predictor of
time to first surgery even when other important factors are taken into account (Figure 5.3,
Table 5.4).
Most striking, is the discovery that women with a CD diagnosis carrying the FXR1GT genotype are most at-risk for progressing on to surgery (OR=27.46 95%CI=2.28330.50, p=0.01) and progressing on to surgery earlier in their disease course (HR=9.08,
95%CI=4.72-17.48, p < 0.0001) compared to men or women with the FXR-1GG
genotype. Sex-specific differences in CD are largely unexplored; there is a paucity of
data on how sex differences impact CD diagnosis and disease management.
Interestingly, many important sex-related differences have been identified in other,
common, chronic diseases such as coronary artery disease, rheumatologic autoimmune
diseases, and renal disease33. Despite these findings, disparity is seen in the management
of men and women who suffer these conditions. For example, despite better outcomes in
females, women with congestive heart failure receive fewer guideline-based treatments
and transplantations compared to men34. Similarly, despite a greater risk of stroke,
women are less likely to be anti-coagulated in the setting of atrial fibrillation compared to
men35. Such differences and potential disparities have not yet been addressed adequately
in CD. There are data to support a slightly higher incidence of CD in women across
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several populations.36-38 Oral contraception (OCP) use has been linked to the onset of
CD in a large prospective cohort study of American women as well as to the risk of CDrelated surgery in a Swedish registry.39, 40 These findings allude to the importance of a
female-specific factor to the susceptibility and severity of CD.

Our work further

highlights the need to consider sex-related differences in CD management.
Interestingly, estradiol (E2), a major female sex hormone and the dominant form
of estrogen present during a woman's reproductive years and the main form of estrogen
used in OCP, has been shown to inhibit FXR activity via the estrogen receptor (ER) α in
vivo and in vitro41,

42

.

Authors examining the relationship of OCP use to CD

susceptibility and severity were unable to explain the biological mechanisms for their
data39, 40. Our work suggests a plausible molecular mechanism for their findings. More
recent work by Goodman et.al. (2017), using a murine model of colitis, showed that ERα
loss-of-function resulted in protection from chemically-induced colitis in female mice,
directly linking E2-signaling to pathways of IBD. 43
Conversely, we found that the IBD-linked SNPs, MDR1 3435C>T and PXR 25385 are not predictive of CD severity. To date, there has been a lack of consensus
regarding the relationship between CD susceptibility and genetic variation in MDR1 and
PXR. Brinar et.al. (2013) and Juyal et.al. (2009) both indicated a link between MDR1
genetic variation and IBD, while a larger meta-analysis of existing studies refuted the
finding8,

44, 45

. Similarly, Dring et.al. (2006) concluded that PXR -25385C>T was a

significant predictor of IBD susceptibility9; however, more recent and larger genomic
association studies have failed to confirm these original findings10, 12. Our study confirms
a lack of association between polymorphisms in either of these genes and CD severity,
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while emphasizing the association and possible mechanism of the FXR gene. A strength
of our study is the replication of the primary objective (association of FXR-1GT genotype
with time to and risk of surgery) in a second cohort of patients recruited at a separate time
interval. During the second time period, IBD therapies had expanded to include a wider
range of biologic treatments, yet the association between FXR-1GT carrier status and risk
and time to surgery persisted.
Additionally, a statistically significant difference in the FXR downstream product,
FGF19 was seen between individuals with a variant versus wild type FXR-1G>T
genotype when assessed in female CD patients (Figure 5.9b, Table 5.7). An almost twofold increase is seen in the FGF19 plasma concentrations of women with a wild type
FXR-1G>T genotype compared to carriers of the variant allele. Our group has previously
shown in vitro and in vivo that the FXR -1G>T SNP is associated with reduced activation
of downstream products

27

. Data by Van Mil et.al. (2007) demonstrated a concomitant

decrease in FXR protein and several of its down-stream gene targets29. They concluded
that variation in the Kozak consensus motif of the FXR gene is associated with inefficient
protein translation, providing a plausible functional mechanism.

Interestingly, our

finding regarding the downstream FXR target, FGF19, does not extrapolate to the total
population, but is of particular relevance to women, highlighting the idea that a femalespecific factor(s), in addition to genetic variation in FXR, is influencing the function of
the FXR protein. A limitation of this data may be that FGF19 quantification was carried
out in individuals with small bowel disease who underwent a small bowel resection of
varying, non-quantifiable lengths.

This may have impacted FGF19 plasma

concentrations and may have confounded our findings.
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Conversely, we found that plasma bile acid concentrations, another downstream
product of FXR activity, are not increased in individuals with a FXR-1GT genotype. This
remained unchanged even with the stratification of bile acid profiles by FXR-1G>T
genotype and sex. This is in discordance with murine models of FXR deficiency where
FXR null mice had an increase in the total bile acid pool15. Due to the low FXR-1T allele
frequency, only a small subset of study subjects (FXR-1GT, n= 22; FXR1GG, n= 40)
underwent plasma bile acid quantification.

This may have impacted our ability to

demonstrate a significant difference between FXR-1G>T genotypes.
We note that two previous studies have evaluated polymorphisms in FXR and the
link to IBD13, 14. Nijmeijer et.al. (2011) did not find an association between FXR-1T
variant carrier status and IBD disease presence, location or disease type among 2355 IBD
patients. Similarly, Attinkara et.al. (2012) failed to show an association between FXR-1T
variant carrier status and IBD susceptibility in a cohort of 1138 individuals, half of whom
had an IBD diagnosis. However, no assessment was performed to evaluate the link
between FXR-1G>T and parameters of disease severity.
In conclusion, we outline important new data in a largely neglected area of CD
management: genetic variation in FXR has important clinical consequences, particularly
for women with CD. Screening female CD patients for FXR-1T variant carrier status
may be useful for identifying female patients at risk for early, poor outcomes. Female
carriers of the variant allele may benefit from earlier, more aggressive medical
management.

Further evaluation of sex-specific differences in CD management is

needed to better personalize therapy and avoid the perpetuation of any unidentified
disparities.
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6

DISCUSSION AND CONCLUSIONS
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6.1

Summary and Discussion

The overall findings discussed in this work are summarized in Figures 6.1 and 6.2.

Figure 6.1 The proposed effect of Crohn's disease on CYP3A4 drug metabolism. Total CYP3A4 activity is
decreased in CD. In health, secondary bile acids such as LCA are potent activators of PXR, a known
regulator of CYP3A4 activity. Bile acid-induced activation of PXR leads to the translocation of PXR to the
nucleus and binding of PXR to its response element contained within the CYP3A4 gene. This results in
downstream CYP3A4 expression and activity. Bile acid patterns are altered in CD. There is a greater
proportion of unconjugated bile acids as well as primary bile acids compared to individuals without CD
(Panel A). This may lead to reduced bile acid-induced activation of PXR, with a resultant decreased in
hepatic CYP3A4 activation. There is decreased expression of CYP3A4 protein in the intestine in CD
(Panel B). Crohn's disease, CD; cytochrome P450 3A4, CYP3A4; lithocholic acid, LCA; pregnane X
receptor, PXR.
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Figure 6.2 The proposed effect of genetic polymorphism FXR-1G>T on Crohn's disease. In health, FXR
expression regulates bile acid homeostasis by repressing bile acid synthesis. Production of the ileal
hormome, FGF-19 is a direct result of FXR activation and inhibits CYP7A1. FXR activation is also
important for attenuating the NFκB pathway and the downstream production of pro-inflammatory
cytokines as well as enhancing the integrity of the intestinal epithelial barrier (Panel A). In CD, FXR
activity is attenuated with documented reductions in FGF19 production, an expansion of the bile acid pool,
increased NFκB activity and disruption of the intestinal epithelial barrier (Panel B).
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Figure 6.2 (continued) The presence of the genetic polymorphism, FXR-1G>T is associated with
translational inefficiency of the FXR protein. We have documented that female carriers of the FXR-1GT
genotype with CD have a more severe CD phenotype. This suggests that genetic variation in FXR and
possibly the presence of estrogen further impair FXR activity in addition to changes already documented in
CD (panel C and D). Farnesoid X receptor, FXR; Crohn's disease, CD; fibroblast growth factor 19,
FGF19; cytochrome P450 7A1, CYP7A1; nuclear factor κB, NFκB;
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6.1.1 Chapter 3
The cytochrome p450 (CYP) 3A family is the cornerstone of drug metabolism
and drug disposition in humans1, 2. Of the 3A family, the 3A4 isoform is the most wellstudied and makes up the highest CYP content in the liver and intestine, key organs of
drug metabolism. CYP3A4 activity is highly variable between individuals due to a
myriad of patient-intrinsic (sex, age, genetics) and extrinsic (diet, medications) factors3-10.
The impact of disease on CYP3A4 activity is still incompletely defined. Given the
importance of CYP3A4 to the disposition of a wide range of clinically-important
substrates and its high concentration in the intestine, understanding the effect of Crohn's
disease (CD), an exceedingly prevalent, chronic, primary intestinal illness, on CYP3A4
activity is highly relevant. In Chapter 3, we aimed to assess the impact of CD on
CYP3A4 activity using two in vivo modalities in real-time (exogenous probe, midazolam
and endogenous probe 4β-hydroxycholesterol, 4βOHC) as well as to propose a molecular
mechanism for any detectable differences from non-CD controls. Due to the previously
documented effect of acute and non-CD chronic inflammatory states on CYP-mediated
metabolism, we hypothesized that CD would negatively impact CYP3A4 activity in vivo,
particularly intestinal CYP3A4. We posited that a decline in CYP3A4 activity would be
related to CD-specific changes in pregnane X receptor (PXR) signaling. In fact, we
observed that exposure to CYP3A4 substrate, midazolam, as represented by the oral area
under the concentration-time curve (AUCpo), was significantly increased in our CD
cohort compared to reports in healthy controls11-14; thus, we inferred there was a
reduction in CYP3A4 activity in CD. Moreover, the greatest reduction in midazolam
extraction by CYP3A4 appeared to be at the liver rather than the intestine. Similarly, we
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were able to confirm a reduction in CYP3A4 activity in an independent CD cohort
compared to non-CD controls using the endogenous biomarker, plasma 4βOHC.
However, we were unable to provide a plausible mechanism for differential CYP3A4
activity in CD. Despite detectable differences in plasma bile acids, known PXRCYP3A4 pathway inducers, in individuals with CD versus non-CD controls, we were
unable to show an appreciable impact on PXR-signaling and downstream activation of
CYP3A4 in vitro.
Ultimately, we were able to identify CD-specific changes to CYP3A4 activity in
vivo. Despite being a primary intestinal illness, there appeared to be more of an impact
on hepatic CYP3A4 activity based on oral and systemic midazolam pharmacokinetics. In
other conditions, inflammatory cytokines are posited to decrease CYP3A4 activity8, 15;
however, we did not see an appreciable difference between subjects with active and
inactive CD. This suggests changes in CYP3A4 activity in CD may be a precursor to
disease rather than a consequence of inflammation. Despite this observation, we were
unable to provide a sound mechanism to explain CD-specific changes in CYP3A4
activity. PXR is an important regulator of CYP3A4 activity that is also known to be
altered in CD16-18. It is activated by bile acids, such as lithocholic acid (LCA) and
deoxycholic acid (DCA)19, 20. We observed differences in the plasma bile acid profiles in
our CD cohort, perhaps due to alterations in the gut microbiome21. However, these
differences did not translate to differential PXR signaling or downstream CYP3A4
activity in an in vitro hepatocarcinoma (Hep) G2 model. Higher concentrations of bile
acids reflective of hepatic concentrations (rather than blood) may be needed to further
assess the impact of PXR on CYP3A4 activity in CD. All in all, our data demonstrate a
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CD-specific decrease in CYP3A4 activity across two separate CD cohorts. This may
have important implications for the disposition of CD-related and non-CD-related
CYP3A4 drug substrates used in this patient population. Though differences in PXR
signaling, due to changes in the plasma bile acid profile, did not account for differences
in CYP3A4 activity, bile acid concentrations reflective of hepatic concentrations as well
as the effect of other nuclear receptors, such as the farnesoid X receptor (FXR), may need
to be considered.

6.1.2 Chapter 4
The concept of first-pass metabolism is well-established. A selection of orallyingested substrates are subject to extensive processing within the intestinal tract as well
as in the liver. CYP3A4 and P-glycoprotein (P-gp) play an important in this process. It
is a long-held notion that CYP3A4 and P-gp, both concentrated within enterocytes at the
intestinal villous tip, act in a coordinated manner to limit drug and xenobiotic oral
bioavailability. According to Zhang and Benet (2001), this theory is built upon the
findings of a common intestinal location, shared substrates and the poor oral
bioavailability of such substrates1. Given that the inflammatory bowel disease (IBD), CD
introduces a transmural intestinal insult that disrupts the intestinal barrier function, one
could assume that this has important consequences for intestinally-expressed proteins
such as CYP3A4 and P-gp. Thus, in Chapter 4, we aimed to evaluate the intestinal
expression of CYP3A4 and P-gp protein in a cohort of individuals with and without CD.
We hypothesized that individuals with CD have reduced intestinal expression of
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CYP3A4 and P-gp. We observed a significant reduction in ileal and colonic CYP3A4
protein expression in subjects with CD compared to those without. Similarly, a reduction
in colonic P-gp protein expression was seen in the CD cohort. Age appeared to play a
role in CYP3A4 expression in both CD and non-CD cohorts, though with opposing
effects. Our data highlight important and novel findings pertaining to CD-dependent
changes in the intestinal barrier function, first-pass metabolism with consequences for
drug and xenobiotic exposure. Further studies are needed to explore the mechanisms of
these findings.

6.1.3 Chapter 5
Nuclear receptors (NR) are key regulators of development, metabolism and
disease in humans22, 23. Several NRs, such as PXR and FXR, play a detoxification role by
regulating the expression and activity of CYP3A4 and P-gp24. In vivo and in vitro models
have demonstrated a decrease in PXR and FXR signaling in IBD, with a concomitant
improvement in intestinal inflammatory lesions with PXR and FXR up-regulation18, 25-27.
Interestingly, knocking out PXR and FXR in murine models does not induce a
spontaneous colitis as is seen in the MDR1a -/- (codes for P-gp) murine model. Rather, it
facilitates the onset and increases the severity of an inflammatory condition, suggesting
that these NRs may contribute to, but are not wholly responsible for, IBD pathogenesis25.
Genetic variation in FXR has been linked to deficits in FXR expression as well as a
decrease in the activation of downstream targets28. In Chapter 5, we aimed to explore the
role of genetic variation in FXR, a key regulator of CYP3A4 metabolism, and its impact
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on CD severity. We hypothesized that the novel FXR -1G>T polymorphism confers a
greater risk of a severe CD phenotype and is associated with a reduction in the
downstream FXR target, fibroblast growth factor (FGF) 19 and an expansion of the total
bile acid pool. Indeed, we confirmed that the FXR-1GT genotype predicts surgery risk
and early progression to surgery most significantly in women. We also observed a
significant reduction in FGF19 plasma concentrations in female carriers of the FXR-1T
allele; however, no appreciable differences were seen in the plasma bile acid pool of the
FXR-1GT carriers. Our data highlight the importance of drug metabolism sequences to
IBD pathogenesis. Specifically, genetic variation in FXR, a key regulator of CYP3A4,
appears to have important consequences for outcomes of disease severity in CD,
indicating a role for more aggressive medical management in these individuals. Most
interestingly, our data point to a sex-specific difference in CD, whereby women with CD
are most adversely affected by genetic variation in FXR as it pertains to CD outcomes.
This has gone largely unexplored. Our data offer a basis for exploring sex-specific
differences in CD as they pertain to disease pathogenesis, outcomes and management.
Ultimately, NRs such as FXR may be a key overlapping factor that links drug
metabolism sequences and CD pathogenesis.

6.2

Implications
To date, there is limited data evaluating the effect of CD on major drug

metabolism pathways. Ours is the first data set to confirm a decrease in CYP3A4 activity
in CD using multiple modalities and to suggest that said decline may be driven by
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decreases in hepatic CYP3A4 activity, beyond the impact of CD on the intestinal
expression of CYP3A4. Neither across in vivo biomarkers of activity, nor in gene
expression, did we find that CD activity (defined by the Harvey-Bradshaw clinical index)
impacted on CYP3A4. This suggests that factors beyond inflammatory cytokines are
contributing to CD-specific changes in CYP3A4. One could even construe that changes
in CYP3A4 expression and/or activity may be an antecedent event in CD onset rather
than a byproduct of disease progression.
These findings also have important implications for CYP3A4 substrates used in
patients with CD. The glucocorticoids, prednisone and budesonide, are substrates of
CYP3A4 and are widely used for inducing disease remission in CD29-32. There is
significant inter-individual variation in CD patient response to prednisone and
budesonide33. Our data show that budesonide exposure is highly variable amongst
individuals with CD and mirror the variability seen in healthy volunteer populations34, 35.
Conversely, we did not observe a correlation between CYP3A4 activity and budesonide
oral bioavailability, suggesting that CYP3A4 activity did not contribute significantly to
budesonide variability in our population; however, our sample size may have been too
small to draw definitive conclusions. Additionally, there is little, if any, data evaluating
the impact of CD on an individual's exposure to non-CD-related CYP3A4 drug substrates
taken concomitantly for co-morbid illnesses. In a single study by Sanaee et.al. (2011),
the authors observed a marked increase in the plasma concentrations of CYP3A4substrate, verapamil compared to healthy volunteers36. Further study is needed to assess
the clinical impact of CD-related decreases in CYP3A4 activity.
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Moreover, we draw attention to the overlap between drug metabolism sequences
and CD pathogenesis. Nuclear receptors, such as PXR and FXR are important regulators
of drug metabolism. They influence human exposure to xenobiotics including clinicallyused drugs by regulating the activity and expression of proteins involved in the different
phases of drug metabolism; however, they are also increasingly recognized for their
importance in the mechanisms of CD pathophysiology18, 25, 26. In addition to contributing
to barrier function and limiting drug absorption through the regulation of CYP3A4, FXR
is important to the integrity of the intestinal epithelium37, 38. Our data demonstrate a
novel and important implication for genetic variation in FXR as it pertains to CD
outcomes. Specifically, novel polymorphism FXR-1G>T confers a greater risk of severe
CD phenotype (as represented by risk and time to CD-related surgery) in women with CD
and is associated with reduced expression of downstream FXR targets. These findings
are important to drug disposition and exposure in CD for two reasons: 1) they link drug
metabolism pathways to CD pathogenesis and suggest that derailments in the expression
of key enzymes and transporters may be a co-incident or antecedent event in IBD
pathogenesis rather than a consequence of disease presence 2) they identify an at-risk
group within the larger CD community who may benefit from more aggressive "topdown" CD medical management39. The latter reinforces concepts championed by experts
in the field of CD therapeutics: that our approach to CD management needs to be tailored
to the individual and that there needs to be a re-structuring of our current provincial
approach to CD drug access.
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6.3

Future Directions
The clinical relevance of CD-specific changes in CYP3A4 activity remains to be

determined. Given the prevalence of CD worldwide, the clinical consequences of its
impact on a major drug metabolism pathway is highly relevant to drug development and
patient safety. Observational studies and pharmacokinetic analyses are needed in CD
populations to evaluate the impact of derangements in CYP3A4 activity and expression
on drug exposure and drug response.
In addition, our data evaluated changes in the hepatic and intestinal activity of
CYP3A4 in CD as well as changes in the intestinal protein expression. Interestingly, in
the midazolam pharmacokinetic analysis, it was observed that the decline in CYP3A4
activity was primarily related to hepatic CYP3A4. There are no studies evaluating the
impact of CD on the hepatic expression of CYP3A4. Logistically, this may be a difficult
feat to accomplish in human studies, as the gold standard-liver biopsy would likely be
difficult to carry out in the setting of a non-hepatic disease. In its place, the use of
intravenous, exogenous, systemic probes in larger CD cohorts to assess CYP3A4 activity
may provide an adequate alternative to further explore this finding.
We also examined the role of bile-acid induced PXR signaling on CYP3A4
activity in vitro as a means for better understanding differential CYP3A4 activity in CD.
We observed CD-specific differences in the bile acid profiles of CD and non-CD
populations. Specifically, differences in the percent composition of potent PXR ligand,
LCA were noted between groups. However, despite this, no difference was observed in
CYP3A4 activity in an in vitro cell model with exposure to a disease-specific bile acid
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pool. Of note, other CD-specific differences observed in the bile acid pools included an
increase in glycine-conjugated deoxycholic acid (GDCA) and cholic acid (GCA) amongst
the CD population as well as a relative decline in taurine-conjugated cholic acid (TCA)
and glycine-conjugated chenodeoxycholic acid (GCDCA). Activation of PXR by GDCA
was noted and may have compensated for any declines in CYP3A4 activity due to
differences in LCA. In future, evaluating the effect of the CD-specific bile acid pool on
FXR activation may also shed light on disparate CYP3A4 activation in CD.
One of the most interesting findings to emerge from this work is that of a link
between drug metabolism pathways and FXR to disease severity in women with CD. We
have identified a novel genomic biomarker of disease severity in women with CD with
evidence of an impact on its downstream targets. Beyond the predictive value of FXR1G>T in women with CD for poor outcomes, we have identified an area in need of
further investigation pertaining to CD pathophysiology. Validation of our retrospective
study in an independent and external CD population would reinforce its utility as well as
the application of this genomic test to a prospective cohort of woman to further
characterize its impact on clinical outcomes. Furthermore, using molecular technologies
to better understand the relationship between FXR, estrogen and CD, concepts not
currently well-explored in CD, may offer additional insights into a complex disease.

6.4

Conclusions
The effect of CD on drug metabolism pathways has only been considered to a

limited extent, despite a significant overlap between metabolism sequences, CD
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mechanisms and disease location. The aim of this work was to systematically consider
the impact of CD on key phase 1 enzyme CYP3A4, including its activity, expression and
regulation. We were able to show that CYP3A4 activity and protein expression are
down-regulated in CD. We observed a significant reduction in hepatic CYP3A4 activity
in vivo, despite our initial hypotheses of CD having the greatest influence on intestinal
CYP3A4. We also identified a significant relationship between CYP3A4 regulator, FXR
and outcomes of disease severity in women with CD. We observed a reduction in
downstream targets of FXR in female carriers of the FXR-1T allele, highlighting an area
of future research in CD pathogenesis as it may pertain to women. As a whole, these
studies highlight the effect of CD on an important drug metabolism pathway and offer
new insights into the overlap between CD pathogenesis and drug metabolism sequences.
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Refresher for the Busy Clinical Gastroenterologist. 2: Capstone Academic Publisher; 2015

7.

Wilson A. H. pylori infection and associated diseases. Medical Mini Review Series in Gastroenterology and
Hepatology: Efficient Refresher for the Busy Clinical Gastroenterologist. 2: Capstone Academic Publisher; 2015

8.

Wilson A. Post-transplant lymphoproliferative disorders. Medical Mini Review Series in Gastroenterology and
Hepatology: Efficient Refresher for the Busy Clinical Gastroenterologist. 2: Capstone Academic Publisher; 2015

Letter
Published
1.

Wilson A, Jansen LE, Rose RV, Gregor JC, Ponich T, Chande N, Khanna R, Yan B, Jairath V, Khanna N, Sey M,
Beaton M, McIntosh K, Teft WA, Kim RB. Letter: predicting azathioprine-associated pancreatitis in IBD-phenotype or
genotype? Authors’ reply. Aliment Pharmacol Ther. 2018 Apr 1, 47. (7): p.1044-1045
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ABSTRACTS
Abstracts Presented
1.

Aze Wilson, Trimethylamine-N-oxide and inflammatory bowel disease: differential role of intestinal microbiota in
Crohn’s disease vs ulcerative colitis - Presenter at the “CAG/CCC Student Prize Paper Presentations”, 2015 Mar 1,
Canadian Association of Gastroenterology, LONDON, Canada

Posters Presented
1.

Aze Wilson, FXR-1G>T predicts deleterious outcomes in Crohn’s disease, 2018 Feb 16, European Congress of
Crohn’s and Colitis (ECCO), Wien, Austria

3.

Aze Wilson, HLADQA1*01/HLADRB1*07 is a major predictor of azathioprine-induced pancreatitis in inflammatory
bowel disease, 2018 Feb 10, Canadian Association of Gastroenterology, Toronto, Ontario, Canada

5.

Seana Nelson, Aze Wilson, Plasma biomarker may detect disease-dependent alterations in gut microbiota in IBD: a
pilot study, 2018 Feb 10, Canadian Association of Gastroenterology, Toronto, Ontario, Canada

7.

Aze Wilson, Trimethylamine-N-oxide and Inflammatory Bowel Disease: the differential role of the intestinal
microbiome, 2015 Oct, American College of Gastroenterology, LONDON, Hawaii, United States

9.

Aze Wilson, Trimethylamine-N-oxide and Inflammatory Bowel Disease: the differential role of the intestinal
microbiome, 2015 Apr, Western University, LONDON, Canada

11. Aze Wilson, Trimethylamine-N-oxide and Inflammatory Bowel Disease: the differential role of the intestinal
microbiome, 2015 Feb, Canadian Association of Gastroenterology, LONDON, Canada
13. Aze Wilsona and Pari Basharat, Transient elastography for monitoring of liver fibrosis in methotrexate-treated patients
with inflammatory disorders: Systematic
Review, 2013 May, Western University
15. Aze Wilson, Transient elastography for monitoring of liver fibrosis in methotrexate-treated patients with inflammatory
disorders: Systematic
Review, 2013 Feb, Canadian Association of Gastroenterology, Canada
17. Pari Basharat, Transient elastography for monitoring of liver fibrosis in methotrexate-treated patients with inflammatory
disorders: Systematic
Review, 2013, Canadian Association of Rheumatology, Canada
19. Aze Wilson, Pharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn’s disease, 2012
Oct, American College of Gastroenterology, Las Vegas, Nevada, United States
21. Aze Wilson, Pharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn’s disease, 2012
Feb, Canadian Association of Gastroenterology, Vancouver, British Columbia, Canada
23. Aze Wilson, The prevalence of Candida glabrata esophagitis in an endoscopy population: a 30-month review, 2012
Feb, Canadian Association of Gastroenterology, Canada
25. Aze Wilson, Patterns of Food Allergy in
Eosinophilic Esophagitis, 2011 Feb, Canadian Association of
Gastroenterology, Toronto, Ontario, Canada
27. Aze Wilson, Patterns of Food Allergy in
Canada
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PRESENTATIONS
Invited Lectures
1.

Invited Lecturer, Is my PPI killing me and other tough questions, Clinical Pharmacology, Presenters: Aze Wilson, 2018
Mar 21, London, Ontario, Canada

2.

Invited Lecturer, Biologics for inflammatory bowel disease: a focus on ustekinumab, Janssen, Presenters: Aze Wilson,
2017 Nov 15, London, Ontario, Canada

3.

Presenter, Personalized Medicine in Inflammatory Bowel Disease, Division of Clinical Pharmacology, Presenters: Aze
Wilson, 2016 Feb 4, LONDON, Canada

4.

Presenter, Pharmacogenomics in IBD, Division of Gastroenterology, Presenters: Aze Wilson, 2015 Nov 3, LONDON,
Canada

5.

Presenter, Trimethylamine-N-oxide and IBD: the differential role of the intestinal microbiome, Division of Clinical
Pharmacology, Presenters: Aze Wilson, 2014 Nov, LONDON, Canada

6.

Presenter, IBD: From bench to bedside - new understanding in the molecular biology of the disease, Division of
Gastroenterology, Presenters: Aze Wilson, 2014 Mar 4, LONDON, Canada

7.

Presenter, Methotrexate and Inflammatory Bowel Disease: Let’s Get Personal, Division of Clinical Pharmacology,
Presenters: Aze Wilson, 2013, LONDON, Canada

Student Presentation
1.

Presenter, Trimethylamine-N-oxide and inflammatory bowel disease: differential role of intestinal microbiota in Crohn’s
disease vs ulcerative colitis - Presenter at the “GI Topics in Research” course, Canadian Association of
Gastroenterology, Presenters: Aze Wilson, 2015 Feb 25, LONDON, Canada

2.

Presenter, Pharmacokinetic Profiles for Oral and Subcutaneous Methotrexate in Patients with Crohn’s Disease,
Canadian Association of Gastroenterology, Presenters: Aze Wilson, 2012 Feb 1, LONDON, Canada

Symposia
1.

Presenter, “Code Clues”: novel pharmacogenomic strategies for enhancing care in inflammatory bowel disease,
Ontario Research Fund, Presenters: Aze Wilson, 2017 Sep 27, Ontario, Canada

2.

Presenter, Drug Metabolism in Inflammatory Bowel Disease, Western University Clinician Investigator Program,
Presenters: Aze Wilson, 2016 Jan 4, LONDON, Canada

GI Rounds
1.

Presenter, Translational Research in IBD, GASTRO UWO, Presenters: Aze Wilson, 2017 Apr 11, London, Ontario,
Canada
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Grand Rounds
1.

Presenter, “Is my PPI killing me?" and other tough questions, Clinical Pharmacology UWO, Presenters: Aze Wilson,
2018 Mar 21, London, Ontario, Canada

2.

Presenter, From “An Excellent Adventure to a “Bogus Journey” and back again: A monoclonal antibody story, Clinical
Pharmacology UWO, Presenters: Aze Wilson, 2017 Jan 11, London, Ontario, Canada

3.

Presenter, Personalized Medicine In IBD, Clinical Pharmacology UWO, Presenters: Aze Wilson, 2016 Feb 3, London,
Ontario, Canada

4.

Presenter, TMAO: a novel biomarker for the identification of IBD, Clinical Pharmacology UWO, Presenters: Aze
Wilson, 2015 Jun 9, London, Ontario, Canada

PhD Seminar
1.

Presenter, Drug Response and Metabolism in IBD, Department of Physiology and Pharmacology, Presenters: Aze
Wilson, 2018 Apr 2, Canada

Research
1.

Presenter, Translational research and you: a clinical approach to basic science, LHSC Medicine Department,
Presenters: Aze Wilson, 2017 May 11, London, Ontario, Canada

Research PhD
1.

Presenter, FXR Activity predicts deleterious outcomes in Crohn’s Disease, Physiology Pharmacology UWO,
Presenters: Aze Wilson, 2017 Mar 28, London, Ontario, Canada

Resident IM Rounds
1.

Presenter, Evidence Based Approach to CD MX, LHSC Medicine Department, Presenters: Aze Wison, 2017 Feb 27,
London, Ontario, Canada
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TEACHING RESPONSIBILITIES
Postgraduate Medical Education
Courses
Consultant - Subspecialty Clinical Teaching Unit
2016 Feb 16 - 2016 Feb 21
2015 Sep 8 - 2015 Sep 15
2015 Jun 22 - 2015 Jun 28
2014 Sep 29 - 2014 Oct 5
2014 Jul 28 - 2014 Aug 4

Examiner - OSCE PGY1 or PGY4
2018 Feb 22

Host - Journal Club
2015 Sep 29

Clinical Pharmacology Evening Journal Club

Instructor - Academic Half Day Seminars
2016 Mar 22

Participant - Journal Club
2016 Feb 10
2016 Jan 21

Clinical Pharmacology Evening Journal Club

Judge DOM Resident Research Day
2018 May 11

Undergraduate Medical Education
Courses
Digestive System & Nutrition
2015 Sep 22

Small Group Activity

2012 Sep 11

Small Group Activity

Instructor - Clinical Methods - Year 1 Advanced Interviewing
2015 Nov 12

Instructor - Clinical Methods - Year 1 Primary Physical Skills Part 1
2017 Nov 2 - 2017 Dec 7
2016 Nov 3 - 2016 Dec 8
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2016 Feb 3
2015 Feb 11
2014 Dec 5
2014 Feb 14
2013 Nov 29

Instructor - Clinical Methods - Year 2 Gastroenterology
2017 Nov 15

London, Clinical Methods - Small Groups

2016 Nov - 2016 Nov 30

London, Clinical Methods - Small Groups

Supervisor / Examiner - OSCE Year 2 or Year 4
2018 Jan 11

Evaluating Year 4 Medical Student Clinical Exam Skills

2017 Feb 9

Evaluation Year 2 Medical Students at practice OSCE

2017 Jan 12

Evaluating Year 4 Medical Student Clinical Exam Skills

Teaching OSCE Year 2
2017 Nov 16
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SUPERVISION AND MENTORING
Mentorship
Resident Research
2017 - present

Seana Nelson PGY1, Supervisor
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